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Abstract 
The University of Manchester 
Ian Daryoush Kamaly-Asl 
MD 
Molecular, genetic, patient and surgical factors involved in the 
development and outcome of central nervous system tumours 
Prognostic factors come in a variety of forms and may be patient, tumour or 
environmental related. 
 
This thesis examines the interaction of prognostic factors for a variety of 
tumour types.  It particularly focuses on single nucleotide polymorphisms 
(SNPs) of the vascular endothelial growth factor (VEGF) gene. 
 
The first section on meningiomas describes the frequency of sex steroid 
receptors in meningiomas.  In this study, absence of progesterone receptors 
is associated with high tumour grade and male gender.  Tumours that are 
progesterone receptor negative have an odds ratio for recurrence of 5. 
 
Choroid plexus carcinomas are aggressive malignant tumours generally 
occurring in young children.  Gross total surgical resection has been shown 
to be a highly significant factor in tumour recurrence and survival.  This 
study describes a treatment paradigm of neoadjuvant ICE chemotherapy in 
these children which decreases the vascularity and increase the chance of a 
complete removal.  The operative blood loss with this regimen is reduced to 
0.22 blood volumes from 1.11 blood volumes without neoadjuvant 
chemotherapy. 
 
The VEGF gene is highly polymorphic and SNPs of the region have previously 
been shown to influence VEGF protein expression.  This study looks at 
cohorts of both adult gliomas and a variety of paediatric brain tumours; 
comparing them to controls.  There are several associations described 
between the development of certain tumours and specific SNP genotypes.  
In addition to this, certain genotypes and haplotypes have an influence on 
survival of adult grade 2 astrocytomas and paediatric medulloblastomas and 
ependymomas.  There are consistent themes to the prognostic genotypes 
throughout both the adult and the paediatric tumours. 
 
Prognostic factors come in a variety forms as described in this thesis.  It is 
vital to understand the complex interaction between factors to best utilise 
them for the benefit of patients. 
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Chapter 1 – Introduction 
 
Prognosticate: To forecast or predict (something future) from present 
indications or signs; prophesy. 
From Old Italian prognosticare, from Latin prognosticum (-con), from Ancient Greek προγνωστικόν (prognostikon), 
neutral of προγνωστικός (prognostikos) "foreknowing, prescient, prognostic", from prefix πρό- (pro-) + γνωστικός 
(gnostikos) "of or for knowing, good at knowing", from γιγνώσκω (gignosko) "to learn to know, to perceive, to 
mark, to learn". 
 
This thesis is an examination of various factors and their influence the 
development and outcome in central nervous system (CNS) tumours. 
The introduction will discuss the nature of prognostic factors in oncology, 
followed by an overview of the various CNS tumours involved in the thesis 
and then a more detailed review of angiogenesis and particularly vascular 
endothelial growth factor (VEGF) biology and its association with CNS 
tumours. 
 
1.1 Prognostic factors in oncology 
In the field of medicine and oncology in particular, the requirement for 
clinicians to provide an accurate prognosis for a condition is vital.  Along with 
diagnosis and treatment, prognosis is one of the three core elements of the 
art of medicine,2 and Hippocrates included prognosis as a principle concept 
of medicine.3  The aspiration is to be able to predict if and when a tumour 
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will recur and what the life expectancy of a patient with cancer will be with 
100% accuracy.  Obviously given the complex nature of the development 
and progression of tumours this is impossible, but on a daily basis there is a 
need for individual patients to have this information in its most accurate form 
in order for decisions on their management to be made. 
I will describe the various types of prognostic factors as well as the 
application of such factors.  I will then discuss validation of factors and the 
guidelines for the development of prognostic factors in medicine. 
 
1.1.1 Types of prognostic factors 
There are three commonly used groups of prognostic factors in oncology;  
tumour, patient and environment (Figure 1.1).2  There will be a complex 
interplay between factors in these different groups that will determine the 
outcome of the disease.  It is unusual in modern medicine to be truly able to 
assess the “natural history” of a disease and the factors that may have 
influence on that in the absence of any intervention whatsoever.  Therefore 
all the various factors may have different weighting of influence depending 
upon the treatments that the patient may receive.2  In the literature there is 
an attempt to differentiate these factors by referring to prognostic factors as 
those that have an influence on patient outcome and predictive factors that 
will determine response to treatment.4  Prognostic factors have some 
interplay with aetiological factors and there are many similarities in the 
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design and analysis of both types of studies but the prediction of outcomes 
is not synonymous with the explanation of the cause of a particular tumour.5 
 
Figure 1.1 – Interaction of prognostic factor types – Tumour, Patient and Environment. 
 
1.1.1.a Tumour related factors 
The most common and longest used of factors relate to the nature and 
extent of the tumour itself.  One of the primary and most useful factors is 
the phenotypic histological appearance of the tumour.  For non-central 
nervous system tumours the International Union against Cancer (UICC) TNM 
(tumour, nodes and metastasis) classifications relating to the extent of local 
and distant invasion of the tumour are widely used.6  Individual tumour 
biology has been recognised as important for many years as a marker of 
prognosis and response to treatment e.g. secretion of markers such as α-
fetoprotein or β-human chorionic gonadotrophin.  There has, though, been 
an explosion of studies describing biological and genetic factors in tumours 
Environment
TumourPatient
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as the techniques required for their identification have become more 
widespread and easily performed.1, 2, 4  Opening up this field has 
exponentially increased the complexity of interaction between prognostic 
factors for each tumour. 
1.1.1.b Patient related factors 
These can be split into those factors that may be related to the presence of 
the tumour e.g. age, gender and ethnicity and those that are independent of 
the tumour but may still have a significant impact on the disease course e.g. 
co-morbidities, performance status and immune status.  For central nervous 
system tumours it has been recognised for many years that age and 
performance status have an influence on outcome.7  Ethnicity has also been 
shown to have an influence via genetic differences in malignant glioma8 and 
gender may have an influence in survival for patients with medulloblastoma.9 
Somatic genetic changes within tumours are recognised to have an impact 
on outcome.  Alterations in chromosomes 1p and 19q in Oligodendrogliomas 
are associated with a significant improvement in the response to 
chemotherapy.10  Constitutional genetic makeup can also have an influence 
on the development and outcome of central nervous system tumours.  A 
good example of this is neurofibromatosis type 1 (NF1) patients who are at 
increased risk of developing optic pathway gliomas but their clinical course is 
more indolent than those tumours occurring outside the setting of NF1.11  
Furthermore genetic traits have the potential to act as disease modifiers and 
angiogenesis is good model for this with known differences in individual’s 
genetic expression of angiogenic factors at both constitutional and inducible 
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levels having the potential to affect the progression of tumours.12, 13  This 
will be discussed in more detail later in this chapter. 
1.1.1.c Environmental related factors 
Environmental factors are clearly related to the development of certain 
cancers e.g. smoking and lung cancer, ultraviolet light exposure and skin 
cancer.  In addition there are significant environmental factors that influence 
outcome of cancers.  These relate to organisational and social issues such as 
availability of treatments, specialist care and health care policy.14-16  Social 
deprivation has also been shown in several studies to have an influence on 
cancer outcomes.17-19 
 
1.1.2 Application of prognostic factors 
There are a variety of ways that prognostic factors are used and the 
applications are constantly increasing as research and knowledge of 
individual tumour types deepens.2 
By identifying prognostic factors we can further our knowledge of the biology 
of certain tumours and also the factor related outcomes in both treated and 
untreated patients. 
There are several ways that prognostic factors can be applied to patient 
care.  Patients and families cannot make informed decisions regarding 
potential benefits of treatments and interventions if they are not accurately 
informed of the outcomes if no treatments are given.  There may be the 
opportunity to either intensify or avoid treatments depending upon 
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prognostic factors.  The most appropriate follow up care and monitoring will 
be determined by factors influencing the chance of tumour recurrence.  
Lastly there is a vital role for educating and informing patients and care 
givers, particularly in the palliative phase of cancer care. 
There is a necessity for information on the spectrum of prognostic factors for 
an individual tumour to be more utilised in the conducting of research 
studies.  For the effect of an intervention to be validated there is a 
requirement in study design, conduct and analysis to account for other 
known prognostic factors.  Knowing that a prognosis is poor and response to 
other treatments limited can allow for appropriate recruitment into 
experimental/phase 1 and 2 studies. 
In a wider setting, prognostic factors can help plan healthcare resources and 
monitor for the effect of screening programmes.  They can be effectively 
used in the design and evaluation of clinical practice guidelines.  Patient 
health education can be informed and enhanced with appropriate 
information from prognostic factors.  Lastly as a greater understanding of 
the factors influencing prognosis for a particular tumour are known there will 
be better understanding of the apparent variation in clinical outcome. 
 
1.1.3 Guidelines for the development of prognostic factors 
There has been concern in the literature that the explosion of prognostic 
factors in oncology has led to studies that are badly designed, poorly 
analysed, poorly reported and subject to various types of bias.1, 4, 20-28 
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This problem has led to a variety of articles trying to standardise studies into 
prognostic factors.1, 4, 27, 29.  One of the issues with previous studies have 
been the difficulties with multiple testing.23  This is particularly problematic 
with the multiple variables that are generated with detailed genetic analysis.  
It is recognised that there is the potential need for adjusting the significance 
level for such multiple testing.  The most commonly used method being the 
Bonferonni correction where the standard level of cut off for significance is 
divided by the number of variables with the idea of reducing the chance of a 
type 1 error (where the null hypothesis is falsely rejected and a significant 
factor is found where it does not exist).  However, it is also recognised 
undertaking this correction, particularly in the context of a biologically or 
clinically relevant factor may lead to a type 2 error (where the null 
hypothesis is falsely accepted and a genuine prognostic factor is not shown 
to be significant).30 
Sample size to determine significance is difficult to ascertain in prognostic 
multivariable studies.5  A general rule of thumb is that for each candidate 
predictor studied there should be at least 10 outcome events, although one 
study showed that this may not be necessary in certain circumstances.31. 
For continuous variables there is a concern that cut off points which may not 
be appropriate are selected to optimise the significance of the variable.20 
In order to correct for low sample size there have been methods available 
for some time to address this with systematic reviews and meta-analysis of 
both published and individual patient data undertaken.32, 33  These methods 
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do have their own difficulties.  A study on microvessel density in non-small 
cell lung cancer found that when individual patient data was entered into a 
meta-analysis the significance of microvessel density as a prognostic factor 
was lost contradicting the findings of a previous meta-analysis on published 
data only.34 
Certain authors have outlined the different phases of studies in multivariable 
prognostic research.4, 5, 21 
Phase 1 is developmental studies, identifying potential prognostic factors and 
determining the weight of their effect.  Internal validation should be 
performed at this stage. 
Phase 2 involves further validation studies.  There are various forms of 
validation (essentially assessing whether the factor is predicting what it is 
designed to do) and various ways of testing it e.g. temporal validity where 
an already identified factor is retested on a later cohort of patients from the 
same institution.  The best form of validity for a factor to be universally 
useful is external validity where the factor is tested on a cohort of patients 
external to the initial study. 
Phase 3 involves impact studies looking at the utilisation of a factor in 
practice to see if it maintains its usefulness and relevance. 
In an attempt to standardise studies, The National Cancer Institute and 
European Organisation for Research and Treatment of cancer have published 
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reporting recommendations for tumour marker prognostic studies 
(REMARK)(Table 1.1).1 
 
  
 
INTRODUCTION 
1. State the marker examined, the study objectives, and any prespecified hypotheses. 
 
MATERIALS AND METHODS 
Patients 
2. Describe the characteristics (e.g., disease stage or co-morbidities) of the study patients, including their source 
and inclusion and exclusion criteria. 
3. Describe treatments received and how chosen (e.g., randomized or rule-based). 
Specimen characteristics 
4. Describe type of biological material used (including control samples) and methods of preservation and storage. 
Assay methods 
5. Specify the assay method used and provide (or reference) a detailed protocol, including specific reagents or kits 
used, quality control procedures, reproducibility assessments, quantitation methods, and scoring and reporting 
protocols. Specify whether and how assays were performed blinded to the study endpoint. 
Study design 
6. State the method of case selection, including whether prospective or retrospective and whether stratification or 
matching (e.g., by stage of disease or age) was used. Specify the time period from which cases were taken, the 
end of the follow-up period, and the median follow-up time. 
7. Precisely define all clinical endpoints examined. 
8. List all candidate variables initially examined or considered for inclusion in models. 
9. Give rationale for sample size; if the study was designed to detect a specified effect size, give the target power 
and effect size. 
Statistical analysis methods 
10. Specify all statistical methods, including details of any variable selection procedures and other model-building 
issues, how model assumptions were verified, and how missing data were handled. 
11. Clarify how marker values were handled in the analyses; if relevant, describe methods used for cut point 
determination. 
 
RESULTS 
Data 
12. Describe the flow of patients through the study, including the number of patients included in each stage of the 
analysis (a diagram may be helpful) and reasons for dropout. Specifically, both overall and for each subgroup 
extensively examined report the numbers of patients and the number of events. 
13. Report distributions of basic demographic characteristics (at least age and sex), standard (disease-specific) 
prognostic variables, and tumour marker, including numbers of missing values. 
Analysis and presentation 
14. Show the relation of the marker to standard prognostic variables. 
15. Present univariate analyses showing the relation between the marker and outcome, with the estimated effect 
(e.g., hazard ratio and survival probability).  Preferably provide similar analyses for all other variables being 
analyzed. For the effect of a tumour marker on a time-to-event outcome, a Kaplan – Meier plot is recommended. 
16. For key multivariable analyses, report estimated effects (e.g., hazard ratio) with confidence intervals for the 
marker and, at least for the final model, all other variables in the model. 
17. Among reported results, provide estimated effects with confidence intervals from an analysis in which the 
marker and standard prognostic variables are included, regardless of their statistical significance. 
18. If done, report results of further investigations, such as checking assumptions, sensitivity analyses, and 
internal validation. 
 
DISCUSSION 
19. Interpret the results in the context of the pre-specified hypotheses and other relevant studies; include a 
discussion of limitations of the study. 
20. Discuss implications for future research and clinical value. 
Table 1.1 – Summary of reporting recommendations for tumour marker prognostic studies 
(REMARK).1 
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1.2 Central nervous system tumours 
 
1.2.1 Meningiomas 
1.2.1.a Definition 
Meningiomas are tumours of meningothelial (arachnoidal) cell origin. 
Generally they are benign, slow growing tumours but there are a minority 
that are defined as atypical or anaplastic that are more aggressive lesions.35 
1.2.1.b Epidemiology 
After gliomas, meningiomas are the second most common primary central 
nervous system tumour.  They generally occur at an older age (peak 50-70 
years – median 65 years) and are more common in females (1.5 to 3 times).  
In autopsy series there is a prevalence of 2.7% of males and 6.2% of 
females over 80 years of age.35  Annual incidence is approximately 5.35 
(95% CI 5.28-5.42) per 100,000.36 
1.2.1.c Aetiology 
Most meningiomas are spontaneous but there is an association with ionising 
radiation.  This was first determined in the group of immigrants into 
Palestine in the 1950s where tinea capitis was regularly treated with ionising 
radiation.  There was a much higher incidence of meningiomas in this 
treated population with a delay in development of about 35 years.37 
In addition the incidence of meningiomas in the population of Hiroshima and 
Nagasaki was abnormally high with a similar delay in presentation.38  There 
is also an increased incidence of meningiomas post high dose therapeutic 
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cranial irradiation but with these doses the delay in presentation is only 
about five years.39 
1.2.1.c.i Progesterone and oestrogen receptors 
Given the increased incidence in post menopausal women and the 
observation of rapid growth of meningiomas in pregnancy (first documented 
by Harvey Cushing in 1929) there has been a longstanding link with sex 
steroids and meningiomas.40  Growth has also been shown to accelerate 
during the luteal phase of the menstrual cycle.41  Female preponderance is 
described in most series36 and a significant association between 
meningiomas and breast cancer has been reported.42  
It has been recognised for many years that some meningiomas do express 
sex steroid receptors.43-59  The overall findings of these studies are that 
generally a proportion of meningiomas express progesterone receptors but 
they rarely express oestrogen receptors.  Whilst this has been well 
documented in many series, the prognostic significance of the receptors has 
been less well studied. 
Several papers have shown association with grade 2 and 3 meningiomas and 
progesterone receptor negativity.57, 60 
A paper in 1995 was the first to show a correlation between steroid 
receptors and proliferative index using the MIB-1 antibody to Ki-67.  The 
tumours that were progesterone receptor negative had a significantly higher 
proliferative index (6.53% +/- 4.3%) compared to progesterone positive 
tumours (2.35% +/-2.12%).61  A further paper in 1997 confirmed this 
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finding of higher proliferative index in progesterone negative tumour 
spheroids and monolayer cultures.62 
Another paper in 1997 from 70 selected patients with a variety of grade 1 to 
3 meningiomas showed that absence of progesterone receptors, high mitotic 
index and higher tumour grade were significant factors for shorter disease 
free interval.  The significance of these factors was maintained in a 
multivariable Cox proportional hazards model but the relative contribution of 
each to the overall model was not indicated.  In this study they found, like 
others previously,47, 56 that males were more likely to be progesterone 
receptor negative, but gender in itself was not a significant prognostic factor 
for tumour recurrence. 
Papers from 2000 and 2007 showed that for grade 1 meningiomas, lack of 
expression of progesterone receptors was a significant prognostic indicator 
for higher tumour recurrence.63, 64  In the earlier paper there was a low 
incidence of atypical tumours with 60 being grade 1 out of an unselected 
series of 62 patients.63  In the second paper the cohort of 100 patients was 
very highly selected to be grade 1 tumours that had been completely 
excised.  In their series they had a very high recurrence rate for completely 
excised grade 1 tumours of 50%.64  In these grade 1 patients, they did find 
a significant correlation with mitoses per ten high powered field and both 
recurrence and progesterone receptor status. 
In 2006 a study of 239 patients with meningiomas found that progesterone 
receptor negative tumours were associated with an accumulation of 
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qualitative and quantitative karyotype abnormalities and an increasing 
potential for aggressive clinical behaviour, progression, and recurrence of 
these lesions.65 
Most recently a study on 31 meningioma patients found an association with 
progesterone receptor negativity and variations in gene expression using 
array analysis.66  This was particularly true for genes on the long are of 
chromosome 22 near the NF2 gene locus. 
1.2.1.d Molecular pathology 
Meningiomas are generally spontaneous but there is a strong association 
with neurofibromatosis type 2 (NF2).  The majority of NF2 patients will 
develop meningiomas and approximately 60% of spontaneous tumours will 
have mutations of the NF2 gene on chromosome 22q.67  The NF2 gene 
product, the protein merlin (schwannomin) belongs to the 4.1 family of 
proteins that links the cytoskeleton to proteins of the cytoplasmic membrane.  
Some meningiomas have been shown to be associated with loss of 
expression of other 4.1 family proteins e.g. 4.1B (DAL-1) and 4.1R.68 
1.2.1.e Histopathology 
The histological appearance of meningiomas is very variable.  Broadly they 
fall into the World Health Organisation (WHO) grades 1, 2 and 3 
representing benign, atypical and anaplastic lesions respectively.69 
85-90% of lesions are WHO grade 1 benign lesion and are split into 9 
variants: meningothelial (Figure 1.2), fibrous/fibroblastic, transitional 
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(mixed), psammomatous, angiomatous, microcystic, secretory 
lymphoplasmacyte-rich and metaplastic. 
There are three variants of grade 2 lesions.  The most common are atypical 
which are defined as tumours having 4 or more mitoses per high powered 
field or three or more of the following features: increased cellularity, 
presence of small cells with high nuclear/cytoplasmic ratios, prominent 
nucleoli, pattern-less growth or foci of necrosis.  Meningiomas that show 
brain invasion but otherwise appear benign are known to act in a more 
aggressive manner and are therefore classified as grade 2 lesions. 
The other grade 2 lesions are the less common clear cell and chordoid 
variants. 
WHO grade 3 or anaplastic lesions show a more aggressive and invasive 
phenotype.  There are again 3 variants: the most common are anaplastic 
meningiomas which show an obvious malignant morphology with 20 or more 
mitoses per high powered field and often significant brain invasion.  The 
other rarer grade 3 variants are rhabdoid and papillary. 
Immunohistochemically meningiomas typically are positive for vimentin and 
epithelial membrane antigen although the latter can sometimes be 
somewhat patchy.  The Ki-67 expression is generally low in grade 1 
meningiomas (<5%) and is higher in grade 2 and 3 lesions but these levels 
are variable and have not been made part of diagnostic criteria.  Secretory 
meningiomas do show expression of cytokeratins and carcinoembryonic 
antigen (CEA).  Immunoreactivity for S-100 or CD-34 has been shown in 
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some cases but is less prevalent than it is in schwannomas and other fibrous 
tumours. 
 
Figure 1.2 – Histology of a Meningioma.  Indistinct cytoplasmic boundaries, nuclear 
clearing (‘pseudoinclusions’), cellular whorls, and a psammoma body are all apparent in 
this view of a meningotheliomatous (syncytial) meningioma.  (Image courtesy of 
PathConsult - http://www.pathconsultddx.com)70 
 
1.2.1.f Macroscopic appearance and localisation 
The majority of meningiomas are intracranial with some spinal and 
intraorbital.  They are generally durally based and are typically found in a 
variety of locations such as convexity, parafalxine, sphenoid wing, olfactory 
groove, petrous ridge, tentorial, posterior fossa, parasellar and optic nerve 
sheath.  Intraventricular meningiomas do occur as there are meningothelial 
cells present in the choroid plexus and tela choroidea.35 
On magnetic resonance imaging they generally appear as a uniformly 
enhancing, durally based lesion (Figure 1.3).  There would generally be an 
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attachment to the dura with a tail sign at the edge of the lesion.  
Meningiomas can invade into overlying bone and it is common to see a 
reactive hyperostosis in those circumstances. 
A B
C D
 
Figure 1.3 – MR Scan of patient with a large olfactory groove meningioma.  A – axial T2, B 
– post contrast axial T1, C – sagittal T1 and D – sagittal T1 post contrast MR scans 
showing a large, brightly enhancing, extra-axial lesion arising from the floor of the 
anterior fossa. 
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1.2.1.g Treatment 
Given the relatively high prevalence of meningiomas in the aging population, 
treatment would generally be given only for symptomatic or growing lesions.  
1.2.1.g.i Surgery 
For the majority of patients surgical resection would be the treatment of 
choice.  The location of the lesion is critical to determine the surgical 
approach and pre-operative surgical goal. 
It has been recognised for many years that the more complete the resection, 
the less likely of recurrence of a meningioma.  This was first formally 
assessed by Simpson in 1957 who described a grading system with a score 
of 1 to 5 depending upon the extent of resection (Table 1.2).71 
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Simpson 
Grade 
Description Cases Recurrences 
 
I 
Complete removal of tumour and dural 
attachment 
90 8 (8.9%) 
 
II 
Complete removal of tumour with 
coagulation to dural attachment 
114 14 (15.8%) 
 
III 
Complete removal of tumour without 
removal or coagulation of dural attachment 
24 7 (29.2%) 
 
IV 
Partial removal leaving intradural tumour in 
situ 
51 20 (39.2%) 
 
V 
Simple decompression with or without 
biopsy 
9 8 (88.9%) 
 
Table 1.2 – The original Simpson grade descriptions and rates of recurrence.71 
 
1.2.1.g.ii Radiotherapy/radiosurgery 
It would be usual to consider conventional radiotherapy post surgery for any 
tumours that were anaplastic or if there had been a partial resection of an 
atypical tumour.  Furthermore radiotherapy is a treatment option as a 
primary treatment in patients where surgery would be high risk.  This would 
usually halt the progression of a growing tumour with reports of 95% 
tumour control at 5 years.72  Radiosurgery is a treatment option for smaller, 
surgically inaccessible or high risk tumours with control rates of 85%-97% at 
5 years.72 
1.2.1.g.iii Endovascular embolisation 
There is an option to attempt pre-operative embolisation to reduce 
haemorrhage during a resection. Meningiomas tend to have a very rich blood 
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supply and there is the potential for significant, uncontrollable haemorrhage.  
Therefore the practice of pre-operative embolisation has become more 
established in recent years.  Generally, however, the bulk of the blood supply 
to the lesion is taken away during the approach to the lesion and 
embolisation should be restricted to larger or less accessible lesions as it is 
not without complication as a procedure.73, 74 
1.2.1.g.iv Chemotherapy 
Generally there is no role for chemotherapy for meningiomas, even for 
anaplastic variants.75, 76 
There has been a hope for some time that because of the presence of 
progesterone and also dopamine receptors in meningiomas that there may 
be the possibility of hormonally manipulating the tumours but as yet there is 
no proven agent that has achieved this.77  Hydroxyurea has been shown to 
have a therapeutic effect in some patients but there is no good phase III 
trial confirming this observation.78, 79 
1.2.1.h Prognosis 
As mentioned above tumour grade, location and extent of surgical resection 
have all been shown to have an influence on recurrence.  It is not clear from 
the literature, which of these factors has the most influence on an 
individual’s chance of their tumour recurring.35 
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1.2.2 Choroid plexus carcinomas 
1.2.2.a Definition 
Choroid plexus carcinomas are rare tumours of neuroectodermal origin.  
They have a papillary pattern that resembles normal choroid plexus. 
1.2.2.b Epidemiology 
Together with choroid plexus papillomas they represent approximately 0.5% 
of all brain tumours with an annual incidence of 0.3 cases per million.80, 81  
However, choroid plexus carcinomas are mainly seen in childhood and 
account for approximately 3% of paediatric brain tumours overall81, 82 and up 
to 20% of brain tumours presenting in the first year of life.83  Choroid plexus 
carcinomas represent 37% of choroid plexus tumours.81  The overall median 
age at diagnosis is 3.5 years.81 
1.2.2.c Aetiology 
There is no known environmental cause for choroid plexus carcinomas.35  
The majority of tumours are spontaneous but there are recognised genetic 
associations with the development of choroid plexus tumours. 
1.2.2.d Molecular pathology 
There are both germline and somatic abnormalities at several genetic loci 
associated with the development of these tumours. 
1.2.2.d.i TP53 Gene 
The TP53 gene is located on chromosome 17p13.1 and expresses the 
protein product p53 which has an influence on tumour suppression via a 
variety of mechanisms including DNA repair, apoptosis, cellular 
differentiation and angiogenesis.84  Mutation of the gene causes loss of 
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function of p53 together with prolongation of the half life of the protein.  
This means that increased immunohistochemical staining for p53 protein can 
be used as a surrogate marker of gene mutation.85 
Choroid plexus carcinomas are one of the tumours found in Li Fraumeni 
families with TP53 germline mutations.86-89  In addition spontaneous 
germline and somatic p53 mutations are both described in patients with 
choroid plexus carcinoma.90  Positive nuclear staining for p53 protein is 
evident in the majority of choroid plexus carcinomas (10 of 11) whilst it is 
only rarely seen in choroid plexus papillomas (1 of 12).91  TP53 mutations 
have not been extensively studied in choroid plexus papillomas however 
germline mutations have been reported.92, 93  
1.2.2.d.ii hSNF5/INI1 Gene 
The hSNF5/INI1 gene is located on chromosome 22q11.2 and encodes a 
member of the SWI/SNF ATP-dependant chromatin-remodelling complex.94  
Germline mutations of the gene have been described as rhabdoid 
predisposition syndrome and families with the mutation develop both renal 
and extra-renal malignant rhabdoid tumours, choroid plexus carcinomas, 
atypical teratoid rhabdoid tumours (AT/RT) and medulloblastomas.94, 95  
Somatic mutations of the hSNF5/INI1 gene have also been reported in 
choroid plexus carcinoma.90  There are several studies describing the 
genotypic and phenotypic overlap between choroid plexus carcinomas and 
AT/RT.96, 97  However, it has been reported that the majority of choroid 
plexus carcinomas have preserved hSNF5/INI1 protein expression on 
immunohistochemistry.98, 99  It is therefore suggested that tumours described 
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as being choroid plexus carcinoma with hSNF5/INI1 mutations may actually 
be AT/RTs.98 
There is no evidence of hSNF5/INI1 point mutations in choroid plexus 
papilloma.92 
1.2.2.e Histopathology 
Generally choroid plexus tumours show a cellular architecture that resembles 
normal choroid plexus.35  There is a single layer of well-differentiated 
cuboidal epithelium around a fibro-vascular stalk.  There are finger like 
projections that gives the typical papillary appearance.  There is some 
controversy in the histological classification of choroid plexus tumours.  For 
benign WHO grade 1 tumours (Figure 1.4) there should be a lack of 
malignant features and less than 1 mitosis per ten high powered fields.  The 
average MIB-1 labelling index is 3.7%.100 
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Figure 1.4 – Histology of a Choroid Plexus Papilloma.  This example's delicate 
fibrovascular fronds are covered by an orderly, low columnar epithelium.  (Image courtesy 
of PathConsult - http://www.pathconsultddx.com)70 
 
The World Health Organisation recently recognised atypical choroid plexus 
tumours (WHO grade 2) as lesions showing increased cellularity, nuclear 
pleomorphism and particularly increased mitotic activity with two or more 
mitoses per ten high powered fields.101 
Choroid plexus carcinomas are classified as grade 3 tumours by the World 
Health Organisation.  Typically the features seen in a choroid plexus 
carcinoma would be cellular anaplasia, loss of papillary architecture, nuclear 
pleomorphism, necrosis and giant cell formation but often these features do 
not correlate with biological behaviour of an individual tumour (Figure 
1.5).102  One particular area of controversy is the classification of a lesion as 
a choroid plexus carcinoma based purely upon evidence of local brain 
invasion.103  It was felt for many years that this was a prime differentiating 
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feature of carcinomas but there have now been lesions identified with 
invasion and otherwise benign histological appearance that do act in a 
biologically benign way.104  The mean MIB-1 index for choroid plexus 
carcinomas is 14%.100 
 
Figure 1.5 – Histology of a choroid plexus carcinoma.  This example, compared to the 
choroid plexus papilloma, shows cellular anaplasia, loss of papillary architecture and 
nuclear pleomorphism.  MIB-1 immunostaining (insert) shows a high proliferative index.  
(Image courtesy of Dr William Halliday, Hospital for Sick Children, Toronto) 
 
It is a recognised phenomenon that choroid plexus papillomas can progress 
histologically to have a carcinoma phenotype.105 
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1.2.2.f Macroscopic appearance and localisation 
There does not appear to be any difference in localisation of choroid plexus 
papillomas and carcinomas.  In children approximately 75% of all choroid 
plexus tumours are located in the lateral ventricles (Figure 1.6).  As the 
location becomes more caudal, the median age at presentation increases 
being 1.5 years in the lateral ventricles, 1.5 years in the third ventricle, 22.5 
years in the fourth ventricle and 35.5 years in the cerebello-pontine angle.81  
The presence of metastases at presentation is recognized in 12% of patients 
being more common in choroid plexus carcinomas.81 
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Figure 1.6 – MR scan of a patient with a choroid plexus carcinoma.  A – axial T1, B – axial 
T1 post contrast, C – axial T2 and D – sagittal T1 post contrast images showing a brightly 
enhancing lesion in the left lateral ventricle with evidence of brain invasion. 
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1.2.2.g Treatment 
1.2.2.g.i Surgery 
In the available meta-analyses of choroid plexus carcinoma the primary 
prognostic factor is the extent of surgical resection with 2 year survival rates 
of 72% (+/- 10%) for gross total resection vs. 34% (+/- 10%) with 
incomplete resection.81  However, given the increased vascularity, large size 
of these tumours and median age of presentation gross total resection can 
be difficult and is achieved in only 33% - 64%81, 106-108 of cases in the 
literature.  For incomplete resections second surgery should be considered as 
it has been shown to improve survival (2-year overall survival 69% versus 
30% with no second surgery).106 
1.2.2.g.ii Radiotherapy 
Results of adjuvant therapy for residual disease are mixed.  Radiotherapy is 
a limited option in choroid plexus carcinomas because the neurocognitive 
and endocrine sequelae would be marked given the young age at 
presentation of the majority of patients.  A survival advantage has been 
shown following radiotherapy for patients with both gross total resection and 
residual disease.81, 109, 110  However, the groups in these studies were not 
matched for age which is a potential independent prognostic factor.81 
1.2.2.g.iii Chemotherapy 
With only small case series and a limited number of systematic studies in the 
literature, determining the benefit of chemotherapy as adjuvant therapy has 
been restricted.  Studies utilising a variety of protocols have demonstrated 
residual tumour control in a proportion of patients.81, 111-113  A recent meta-
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analysis has however shown a survival advantage in choroid plexus 
carcinoma patients.110  This advantage was maintained irrespective of 
whether radiotherapy was given or if a gross total resection was achieved.110  
Given the definite advantage of gross total resection, chemotherapy has 
been used by a variety of institutions to either reduce the size or more 
importantly the vascularity of choroid plexus carcinomas in order to facilitate 
second look surgery.103, 112, 114, 115  Although these reports qualitatively 
describe a benefit to this approach the extent of the effect and impact on 
patient outcome has not been determined. 
1.2.2.h Prognosis 
As mentioned above the ability to surgically achieve a gross total resection 
appears to be the most significant factor in outcome for choroid plexus 
carcinomas.81  Age at presentation is also felt to be an independent 
prognostic factor in addition to the more difficult prospect of achieving a 
complete surgical resection in these younger children.  Strong evidence for 
adjuvant therapies is difficult to attain given the small numbers of this rare 
tumour presenting to individual units each year.  As it stands the evidence 
would suggest survival advantage for both radiotherapy109 and 
chemotherapy110 following best surgical resection. Overall one, five, and ten 
year projected survival rates of choroid plexus carcinoma patients are 71, 41 
and 35% respectively.81 
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1.2.3 Low grade astrocytomas 
1.2.3.a Definition 
Astrocytomas account for approximately 60% of all glial neoplasms.35  The 
World Health Organisation categorises these tumours as low grade (WHO 
grades 1 and 2) and high grade (WHO grade 3 and 4).69  Within the low 
grade tumours there are two major categories, the more common diffuse 
infiltrating lesions and the less common circumscribed lesion.  The latter 
circumscribed lesions are generally seen in children and young adults and 
have a more favourable outcome. 
1.2.3.b Epidemiology 
Low grade astrocytomas account for 15% of adult and 25% of children’s 
brain tumours.  Age of presentation is biphasic with a childhood peak at 6-12 
years and adult peak between the third and fifth decades with a median age 
of 35 years.35  Overall incidence of diffuse low grade gliomas is 0.09 (95% CI 
0.08-0.10) per 100,000.36 
The most common form of circumscribed astrocytomas are pilocytic 
astrocytomas (WHO grade 1) which form 10-15% of all paediatric brain 
tumours and over 25% of posterior fossa tumours in children.35  The annual 
incidence of pilocytic astrocytomas is 0.34 (95% CI 0.32-0.36) per 
100,000.36 
1.2.3.c Aetiology 
Apart from ionizing radiation, which is the cause for a very limited number of 
brain tumours, there are no convincing environmental aetiological factors 
identified for patients with astrocytomas.116  Within low grade astrocytomas 
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there is a recognised strong association with neurofibromatosis type 1 and 
the development of pilocytic astrocytomas, particularly tumours of the optic 
pathway/hypothalamus.117 
1.2.3.d Molecular pathology 
The only genetic alteration consistently associated with low grade gliomas is 
mutation of the p53 gene.118  The location of the p53 gene is on 17p13.1 an 
area often deleted in astrocytomas of all grades and loss of heterozygocity of 
chromosome 17p is present in 50-60% of diffuse astrocytomas and up to 
80% of gemistocytic tumours.35  Increased expression of the platelet derived 
growth factor receptor alpha and its ligand PDGFα is also common 
particularly in tumours with loss of heterozygocity on chromosome 17p.119  
Mutations affecting codon 132 of the isocitrate dehydrogenase 1 gene 
(IDH1) are found in more that 60% of diffuse astrocytomas.120  In contrast 
to oligodendrogliomas, combined loss of heterozygocity on chromosomes 1p 
and 19q is rare in diffuse astrocytomas.121 
Pilocytic astrocytomas commonly carry either duplications of the BRAF 
oncogene on chromosome 7q34 or more rarely BRAF activating mutations.  
This leads to increased mitogen-activated kinase signaling.122  Pilocytic 
astrocytomas in neurofibromatosis type 1 patients commonly carry allelic 
losses at the NF1 gene locus on 17q11.2.  This is rarely seen in spontaneous 
tumours.123 
In comparison to diffuse astrocytomas, most pilocytic astrocytomas do not 
show allelic loss on chromosome 17p or mutations of the p53 or IDH1 genes. 
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1.2.3.e Histopathology 
Microscopy shows a well differentiated tumour of astrocytic lineage with low 
to moderate cellularity and without necrosis, microvascular proliferation or 
high mitotic activity.35  There are three histological subtypes of diffuse 
astrocytoma and four subtypes of circumscribed tumours. 
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1.2.3.e.i Fibrillary astrocytomas 
This is the most common type of diffuse astrocytoma (Figure 1.7) and is 
composed of multipolar neoplastic astrocytes with scant cytoplasm and fine 
cell processes that go to build up a fibre-rich glial matrix. 
 
Figure 1.7 – Histology of a diffuse fibrillary astrocytoma.  Conspicuous cytoplasmic 
processes, mild nuclear pleomorphism, and only modest hyperchromasia are evidenced by 
the cells of this well-differentiated astrocytoma. The absence of mitotic activity supports 
its classification as a low-grade lesion. Note the dyscohesive growth pattern.  (Image 
courtesy of PathConsult - http://www.pathconsultddx.com)70 
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1.2.3.e.ii Gemistocytic astrocytoma 
Gemistocytes are cells with an enlarged eosinophilic cytoplasm, eccentric 
nucleus and stout processes (Figure 1.8).  To make the diagnosis of a 
gemistocytic astrocytoma there needs to be greater than 20% of the cells 
evident demonstrating the gemistocytic phenotype.  It was previously 
thought that this subtype had a worse prognosis and be more considered a 
grade 3 rather than its actual grade 2 classification.  However in recent years 
the evidence for this has been questioned.124 
 
Figure 1.8 – Histology of a gemistocytic astrocytoma.  Gemistocytic cells are plump with 
glassy pink cytoplasm.  Radially arranged gemistocytes project short cytoplasmic 
processes towards centring blood vessels to form pseudorosettes.  (Image courtesy of 
PathConsult - http://www.pathconsultddx.com)70 
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1.2.3.e.iii Protoplasmic astrocytoma 
This is a rare variant of diffuse astrocytoma, composed of tumour cells with 
eosinophilic cytoplasm and a few flaccid processes embedded in a 
microcystic or mucoid matrix (Figure 1.9).  There is a suggestion in the 
sparse literature that they may favour younger male patients with a fronto-
temporal location and similar biological behaviour to fibrillary variants.125 
 
Figure 1.9 – Histology of a protoplasmic astrocytoma.  The features consist of a relatively 
homogenous, small astrocytic cell population with short, delicate processes.  (Image 
courtesy of PathConsult - http://www.pathconsultddx.com)70 
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1.2.3.e.iv Pilocytic astrocytoma 
This is the most common variant of circumscribed low grade astrocytomas.  
The histological appearance is one of low to moderate cellularity with a 
biphasic pattern consisting of areas with bipolar (piloid) cells and multipolar 
(microcystic) tumour cells (Figure 1.10).35  An important diagnostic feature 
of pilocytic astrocytomas is the presence of Rosenthal fibres.  These are 
intracytoplasmic eosinophilic hyaline masses that are characteristic but not 
pathognomonic of pilocytic astrocytomas as they are also seen in gliosis and 
Alexander’s disease. 
 
Figure 1.10 – Histology of a pilocytic astrocytoma.  The biphasic cellular populations and 
architecture of the classic pilocytic astrocytoma are in evidence. The lesion's process-
bearing spindle cell (piloid) constituents fashion a densely fibrillar matrix, whereas its 
process-poor (protoplasmic) elements aggregate in regions of myxoid change that often 
progress to microcyst formation.  (Image courtesy of PathConsult - 
http://www.pathconsultddx.com)70 
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1.2.3.e.v Pilomyxoid astrocytoma 
These are a variant of pilocytic astrocytomas that were first described in 
1999126 and have recently been added to the World Health Organisation 
classification of CNS tumours.69  They are characterised by a monomorphic 
population of bipolar neoplastic astrocytes on a background of a myxoid 
matrix (Figure 1.11).  In contrast to pilocytic astrocytomas, Rosenthal fibres 
are often missing.  They are typically found in optic chiasm/hypothalamic 
region and have a higher risk of local recurrence and dissemination 
compared to pilocytic astrocytomas.126  The World Health Organisation 
therefore classifies them as a grade 2 tumour. 
 
Figure 1.11 – Histology of a pilomyxoid astrocytoma.  Spindled cytologic features, diffuse 
myxoid change, and focal perivascular pseudorosetting (centre top) characterize this 
emerging entity.  (Image courtesy of PathConsult - http://www.pathconsultddx.com)70 
55 
 
1.2.3.e.vi Pleomorphic xanthoastrocytoma 
These are another rare variety of generally circumscribed astrocytic tumours.  
They are often cystic and tend to occur peripherally in the cortex, extending 
into the leptomeninges with the temporal lobe being the most common 
location.35  Histologically they show a fascicular growth pattern with the 
hallmark of bizarre, pleomorphic multinucleated giant cells (Figure 1.12).  
The tumours are classified as grade 2 by the World Health Organisation and 
have a reasonably favourable prognosis with a 10 year survival of greater 
than 70%.127 
 
Figure 1.12 – Histology of a pleomorphic xanthoastrocytoma.  Spindle and giant cells, 
including bizarre multinucleated forms, combine to give this relatively indolent neoplasm 
a most disturbing appearance. Note hyaline, granular, and vacuolar cytoplasmic 
alterations, the last attesting to lipid accumulation.  (Image courtesy of PathConsult - 
http://www.pathconsultddx.com)70 
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1.2.3.e.vii Subependymal giant cell astrocytoma. 
These are well circumscribed lesions typically arising from the ventricular 
wall at the foramen of Monroe.  They are very closely associated with 
tuberous sclerosis although spontaneous cases have been described.  It was 
initially thought that these cases were due to a forme fruste of tuberous 
sclerosis secondary to somatic mosaicism.  More recently, cases have been 
described where a two hit loss of heterozygocity and mutation have been 
shown in one of the tuberous sclerosis genes only within the tumour itself 
ruling out a somatic moscaicism.128 
Subependymal giant cell astrocytomas are moderately cellular tumours 
composed of pleomorphic large astrocytic cells with abundant glassy 
eosinophilic cytoplasm and round gangloid nuclei with distinct nucleoli 
(Figure 1.13).   
Subependymal giant cell astrocytomas are classified as grade 1 tumours by 
the World Health Organisation and have a favourable clinical outcome.  
Recent studies have shown that the pathway activated in tuberous sclerosis 
involves the mammalian target of Rapamycin receptor and that 
Subependymal giant cell astrocytomas do respond to blocking of this 
pathway with Rapamycin therapy.129 
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Figure 1.13 – Histology of a subependymal giant cell astrocytoma.  Tumour cells that can 
achieve giant proportions, often polygonal in contour and closely apposed in lobular array, 
are responsible for this neoplasm's name (but not evident in all cases).  (Image courtesy 
of PathConsult - http://www.pathconsultddx.com)70 
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1.2.3.f Macroscopic appearance and localisation 
Diffuse astrocytomas predominantly grow in the cerebral hemispheres 
(Figure 1.14) although the brainstem is a recognised location in children.  
The lesions tend to be ill-defined masses that enlarge existing structures 
with blurred anatomical margins.  There may be infiltration along white 
matter tracts and across the corpus callosum into the contralateral 
hemisphere. 
A B
C D
 
Figure 1.14 – MR scan of a patient with a grade II astrocytoma of the insular region.  A – 
axial T1, B – axial T1 post contrast, C – axial T2 and D – coronal flair images showing an 
extensive left fronto-temporal lesion, low signal on T1 and high signal on T2 with no 
enhancement. 
 
The posterior fossa is the most common location for pilocytic astrocytomas 
(Figure 1.15).  They tend to be based in the cerebellar hemispheres and are 
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often cystic with a brightly enhancing mural nodule.  The cyst wall may or 
may not itself enhance.35 
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Figure 1.15 – MR scan of a patient with a pilocytic astrocytoma of the posterior fossa.  A – 
axial T1, B – axial T1 post contrast, C – coronal T1 post contrast, D – sagittal T1, E – 
sagittal T2 and F – sagittal T1 post contrast images showing an enhancing, partly cystic 
lesion arising from the right cerebellar hemisphere. 
 
1.2.3.g Treatment 
1.2.3.g.i Observation 
For low grade astrocytomas diagnosed without raised intracranial pressure or 
neurological deficit there is a management option to observe the patient, 
clinically and radiologically.  There have been a variety of studies that have 
shown that a course of management such as this does not have any impact 
on overall survival.130, 131  There is no doubt , however that undertaking 
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biopsies in patients with radiological low grade gliomas will show more 
aggressive histology a proportion of times.  This, together with the 
psychological stress that the uncertainty of diagnosis may bring would 
advocate at least an initial biopsy at the time of presentation.35  If during a 
period of observation there is evidence of growth or new enhancement 
within a tumour then this would generally mandate histological confirmation 
of the lesion with a biopsy/resection. 
1.2.3.g.ii Surgery 
Options for surgical intervention for patients with low grade astrocytomas 
include biopsy (either stereotactic or open) and open resection.  Stereotactic 
biopsy of low grade astrocytomas is generally a safe, well tolerated 
procedure with morbidity and mortality rates less than 1%.132  The issue 
with undertaking any form of biopsy is that a low grade lesion undergoing 
the start of malignant transformation would often be heterogeneous in 
histological appearance and there is therefore the possibility of being falsely 
reassured with a low grade result on biopsy.  Therefore biopsies of multiple 
areas are advocated in these circumstances.133 
The role of the extent of resection in diffuse low grade gliomas is a 
controversial topic.  There are no randomised controlled trials examining this 
question and there are now unlikely ever to be such trials given the general 
lack of equipoise, limited numbers of patients and potential for long survival 
times.35  There are many cohort studies that have tried to answer this 
question including more recent larger studies and systematic reviews.134, 135  
There is a general weighting of the evidence in favour of greater resection of 
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lesions to have a progression free and overall survival advantage.  In a study 
of 216 patients from 2008, those with at least 90% extent of resection had 
5- and 8-year overall survival rates of 97% and 91%, respectively, whereas 
patients with less than 90% extent of resection had 5- and 8-year OS rates 
of 76% and 60%, respectively. After adjusting each measure of tumour 
burden for age, Karnofsky performance score (KPS), tumour location, and 
tumour subtype, overall survival was predicted by extent of resection 
(hazard ratio = 0.972; 95% CI, 0.960 to 0.983; P < .001).135  Various 
surgical adjuncts such as image guidance, intra-operative imaging and intra-
operative monitoring are all utilised to try and achieve maximum surgical 
resection.136-138 
For circumscribed low grade astrocytomas the surgical goal is to try and 
achieve a gross total resection.  If this is accomplished for pilocytic 
astrocytomas then the 25 year survival rate is approximately 95%. 
1.2.3.g.iii Radiotherapy 
There have been several well conducted randomized controlled trials in this 
area of treatment.  The dose response in two studies showed that lower 
dose treatment resulted in equivalent disease control with fewer 
complications to high dose treatments.139, 140  As a result a standard dose of 
45-50.4 Gy in 25-28 fractions of 1.8 Gy is accepted as standard practice in 
the UK and internationally. 
In terms of the timing of radiotherapy in the disease course, another well 
conducted randomized controlled trial showed no benefit to overall survival 
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in patients receiving radiotherapy at the time of histological diagnosis 
compared with those receiving radiotherapy at the time of a malignant 
progression of their tumour.141, 142  In this study there was an improvement 
in progression free survival from 3.4 to 4.8 years with initial radiotherapy at 
histological diagnosis, but this study generally supports an initial 
observational strategy in order to avoid earlier complications of radiation 
therapy in the disease course.  However this approach is being readdressed 
with the availability of more advanced techniques for focally delivering 
radiotherapy that are now more generally available.35 
Radiotherapy for circumscribed astrocytomas is generally used when there 
has been failure to control the disease surgically.  In these circumstances 
there is reasonable expectation of local control with approximately 60% 
response at 10 years following radiotherapy.143 
1.2.3.g.iv Chemotherapy 
The most commonly used chemotherapy agents for diffuse low grade 
gliomas are temozolomide, procarbazine, CCNU and vincristine.  The use of 
temozolomide is becoming the mainstay of current treatment with response 
rates from 31-61% and its use as an alternative to radiotherapy post surgical 
resection of low grade astrocytomas has been explored.144, 145 
Chemotherapy for circumscribed astrocytomas would usually be reserved for 
disease that cannot be treated surgically where radiotherapy is contra-
indicated, notably in the under 3 age group.  For pilocytic astrocytomas the 
standard first line treatment internationally is vincristine and carboplatin with 
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radiographic response rates of 52% in patients with recurrent disease and 
62% in newly diagnosed patients.146-148 
1.2.3.h Prognosis 
Malignant transformation is a well described phenomenon in low grade 
astrocytomas, with 13% to 86% of initially diagnosed low grade tumours 
reported to have recurred at a higher histological grade.35  This means that 
although there is significant variation in the literature, most studies give a 
median survival for low grade astrocytomas of between 7 to 9 years.149-153  
This figure appears to have improved over recent decades.  A study from 
Norway showed the median survival for low grade astrocytomas improved 
from the period 1970-1981 where it was 4.5 years (95% CI 3.4–5.7) to 9.1 
years (95% CI 7.4–10.9) in the period 1982-1993.  The most recent figures 
for survival for diffuse low grade astrocytomas are 1, 5 and 10 year survival 
rates of 73.5%, 46.9% and 37.7%.36 
There are several clinical factors that have been shown to be associated with 
improved survival in low grade astrocytomas.  These include age less than 
40 at diagnosis, presence of seizures at diagnosis, absence of neurological 
deficits at diagnosis, Karnofsky Performance Score greater than or equal to 
70 and mini mental state examination score greater than 26 out of 30.140, 149, 
154-159  In terms of tumour factors a pre-operative maximum diameter of 
greater than 5-6 cm and the presence of contrast enhancement are poor 
prognostic factors.140, 149  The effect of surgical resection on survival is 
discussed above in section 1.2.3.f.ii. 
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For pilocytic astrocytomas gross total resection is the most important 
prognostic factor as discussed above.  Subtotal resections do reduce 
progression free survival,160, 161 however, there is a recognised incidence of 
tumour involution of between 14-45% with subtotal resections leaving small 
volumes of tumour.162-164  Overall survival rates for pilocytic astrocytomas at 
1, 5 and 10 years are 96.1%, 92.0% and 90.3%.36 
 
1.2.4 Oligodendrogliomas 
1.2.4.a Definition 
Oligodendrogliomas are diffusely infiltrating, well differentiated gliomas that 
are preferentially located in the cerebral hemispheres of adult patients 
composed of neoplastic cells resembling oligodendrocytes. 
1.2.4.b Epidemiology 
Oligodendrogliomas represent 5% of all reported brain tumours.  The 
median age of diagnosis is 41-49 with an annual incidence of 0.67 (95% CI 
0.64-0.71) per 100,000 population.36 
1.2.4.c Aetiology 
As with astrocytomas there are no strongly associated aetiological factors in 
the development of oligodendrogliomas 
1.2.4.d Molecular pathology 
Oligodendrogliomas typically show allelic loss on chromosome arms 1p and 
19q in approximately 80% of cases.  In most instances this is due to an 
unbalanced t(1;19)(q10;p10) translocation.165.  IDH1 mutations are common 
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as with diffuse astrocytomas.120  There is evidence that hypermethylation of 
the O6-methylguanine methyltransferase (MGMT) gene is found in 
oligodendrogliomas, particularly those with 1p 19q loss.166 
1.2.4.e Histopathology 
There are two grades of oligodendroglial tumours, grade 2 and grade 3 
(anaplastic).69 
Grade 2 oligodendrogliomas are moderately cellular, diffusely infiltrating 
tumours consisting of isomorphic cells with round hyperchromatic nuclei 
(Figure 1.16).35  Nodular areas of increased cellularity may be present but if 
the mitotic activity is low this does not automatically categorise them into 
grade 3.  The cells suffer from artefactual swelling that results in clear cells 
with central spherical nuclei and well defined cell margins (fried egg 
appearance). 
Anaplastic oligodendrogliomas show increased mitotic activity, microvascular 
proliferation and necrosis, with or without pseudopalisading.  Otherwise the 
typical cellular architecture of oligodendrogliomas is still recognisable. 
Oligoastrocytoma tumours exist with a mixture of distinct neoplastic cell 
types that may be either intermingled (diffuse variant) or in separate areas 
within the tumour (compact variant).35  The tumours show distinct 
populations of both astrocytic and oligodendroglial lineage.  They can show 
typical anaplastic features within both cellular components to be classified as 
grade 3 anaplastic oligodendrogliomas. 
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Figure 1.16 – Histology of an oligodendroglioma.  Uniform, round nuclei and clear 
perinuclear halos (artefacts of delayed fixation) typify well-differentiated 
oligodendrogliomas.  (Image courtesy of PathConsult - 
http://www.pathconsultddx.com)70 
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1.2.4.f Macroscopic appearance and localisation 
The most common location for oligodendrogliomas is in the frontal lobes with 
the mass centred in the white matter and frequently invading into cortex 
(Figure 1.17).  Rarely, they can develop in the cerebellum, brainstem or 
spinal cord.  Calcification within the tumour is a common finding in 
oligodendrogliomas.35 
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Figure 1.17 – MR scan of a patient with an oligodendroglioma.  A – axial CT scan, B – axial 
flair, C – axial T1 post contrast and D – Sagittal T1 post contrast images showing a partly 
calcified non-enhancing lesion in the left frontal lobe. 
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1.2.4.g Treatment 
1.2.4.g.i Surgery 
The principles for surgical management of oligodendrogliomas are similar to 
those for astrocytomas (see 1.2.3.g.ii).  One added factor in recent years has 
been the recognition of improved response to chemotherapy in 
oligodendrogliomas, particularly when there is loss of 1p 19q.167  This may 
alter the surgical strategy, either by biopsying an apparent low grade glioma 
sooner or being less aggressive surgically with a know oligodendroglioma 
with 1p19q loss. 
1.2.4.g.ii Radiotherapy 
There is no randomised controlled trial comparing observation against 
radiotherapy for either low grade or anaplastic tumours.  There is , however 
good evidence that radiotherapy at doses of 54-60 Gy given in fractions of 
1.8-2 Gy provides durable control for patients with both low grade142 and 
grade 3 oligodendrogliomas.168 
It is recognised that up to 30% of patients with oligodendrogliomas will 
experience leptomeningeal seeding.35  Even with this high rate craniospinal 
radiotherapy is not routinely given to these patients because of the side 
effects and likelihood of response to chemotherapy of disseminated disease. 
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1.2.4.g.iii Chemotherapy 
The classic therapy for oligodendrogliomas is the PCV regimen of 
procarbazine, lomustine/CCNU and vincristine.  This regimen had shown 
response rates of more than 50% and median survival times of 15-24 
months in patients with recurrent oligodendroglial tumours.169 
Temozolomide has generally replaced PCV as first line therapy for 
oligodendrogliomas for both primary170 and relapsed tumours.171 
The finding of improved survival with oligodendrogliomas was first described 
in 1998.167  Subsequent studies have confirmed this finding but also found 
that there is no survival benefit without adjuvant treatment, particularly 
chemotherapy.  It is therefore felt that this is a factor predictive of response 
to treatment rather than an independent prognostic factor in itself.172 
1.2.4.h Prognosis 
Given the generally good response to chemotherapy in the majority of 
oligodendrogliomas, survival rates are generally better than those for 
astrocytomas.  Survival at 1, 5 and 10 years is 90.5%, 75.5% and 56.1% in 
grade 2 oligodendrogliomas and 77.4%, 50.4 and 33.8% in anaplastic 
oligodendrogliomas respectively. 
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1.2.5 High Grade Astrocytoma 
1.2.5.a Definition 
Tumours in this category would be WHO grade 3 anaplastic astrocytomas 
and WHO grade 4 Glioblastomas.69 
Glioblastoma is the most common glial neoplasm which is preferentially 
located in the cerebral hemispheres of adult patients.  Broadly they are 
categorised into primary glioblastomas that occur de novo with no pre-
existing lesion and secondary glioblastomas which represent malignant 
change within a lower grade diffuse glial tumour.35 
Anaplastic astrocytomas are astrocytic gliomas with increased cellularity, 
cytological atypia and increased mitotic activity.  As with glioblastomas they 
can occur de novo or secondary to a lower grade astrocytoma.35 
1.2.5.b Epidemiology 
Glioblastoma comprises 80% of malignant gliomas and 18.5% of all brain 
tumours.  Median age at diagnosis for glioblastomas is 64 years.  Anaplastic 
astrocytomas form 10-25% of astrocytic gliomas and overall 2.7% of brain 
tumours.  The median age of diagnosis for anaplastic astrocytomas is 51.36 
Overall malignant gliomas comprise approximately 2% of all cancers with an 
annual incidence of 5 per 100,000 population.  However, given the younger 
age of presentation and overall poor life expectancy, these tumours have a 
relatively greater impact on loss of years of working life than other more 
common tumours.36 
  
71 
 
1.2.5.c Aetiology 
As with low grade gliomas, the only environmental aetiological factor that 
has been identified is therapeutic ionising radiation.173  There are several 
genetic conditions that are predisposed to developing high grade 
astrocytomas.  The autosomal dominant p53 gene germline mutation Li-
Fraumeni syndrome are known to develop malignant astrocytomas as one of 
tumours related to the condition.88  Turcot’s syndrome is a genetic condition 
involving familial polyposis of the colon with an increased risk of colon 
cancer.  These patients have a higher rate of developing malignant 
astrocytomas.174.  Low grade astrocytomas occurring in patients with 
tuberous sclerosis and neurofibromatosis type 1 and 2 have the potential to 
progress to malignant tumours. 
1.2.5.d Molecular pathology 
Genetic analysis has shown marked differences between primary and 
secondary gliomas.175 
Primary glioblastomas more frequently demonstrate EGFR amplification, 
homozygous deletion of CDKN2A and p14ARF, CDK4 amplification, MDM2 or 
MDM4 amplification, RB1 mutation/homozygous deletion, monosomy 10 and 
PTEN mutation.176. 
p53 mutations are more commonly associated with secondary glioblastomas, 
being present in over 60% compared to 30% of primary glioblastomas. 
In secondary glioblastomas, EGFR, MDM2 or MDM4 amplification and PTEN 
mutation is rare.  Allelic loss on chromosome 10 is generally confined to 
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markers on 10q.  Allelic loss of 19q and 13q, promoter hypermethylation of 
the RB1 gene and overexpression of PDGFRA are more common in 
secondary glioblastoma.  IDH1 point mutations are also far more common in 
secondary glioblastoma.120 
Although the genetic alterations in primary and secondary glioblastomas are 
very different, there are common pathways that both target, namely the p53 
pRb1, Pten/Pi3k/Akt and mitogen-activated protein kinase pathways.176, 177 
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1.2.5.e Histopathology 
Glioblastomas are highly cellular tumours composed of cells with a variety of 
morphologies (Figure 1.18).  Nuclear atypia is common and mitotic activity is 
usually high.  It is essential to see microvascular proliferation and or necrosis 
to make the diagnosis.69 
There are two variants of glioblastoma in the WHO classification, giant cell 
glioblastoma and gliosarcoma. 
 
Figure 1.18 – Histology of a glioblastoma.  Dense cellularity, striking pleomorphism, and 
zones of coagulative necrosis lined by ‘palisading’ tumour cells characterize the 
prototypical glioblastoma.  Note the complex ‘glomeruloid’ quality of the microvascular 
proliferation at right.  Astrocytic elements are seen on the left side.  (Image courtesy of 
PathConsult - http://www.pathconsultddx.com)70 
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1.2.5.e.i Giant cell glioblastoma 
This variant is characterised by numerous, pleomorphic, multinucleated giant 
cells.  Some giant cell glioblastomas demonstrate a collagen and reticulin 
fibre-rich matrix.  On imaging and clinically they tend to be well 
circumscribed lesions and this may be why there is some evidence that they 
can do better than classical glioblastomas.35 
1.2.5.e.ii Gliosarcomas 
These tumours show a biphasic pattern of gliomatous and sarcomatous 
elements.  The gliomatous elements have the typical appearance of a 
glioblastoma and stain positive for glial fibrillary acidic protein (GFAP).  The 
sarcomatous elements are rich in reticulin fibres and composed of GFAP-
negative spindle cells.  The outcome for gliosarcoma is felt to be slightly 
worse than a classical glioblastoma.178 
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1.2.5.f Macroscopic appearance and location 
The vast majority of glioblastomas arise in the cerebral hemispheres (Figure 
1.19).  They appear as peripherally enhancing, centrally necrotic lesions with 
surrounding oedema on imaging.  There is frequently invasion to adjacent 
structures and through the corpus callosum to the contralateral hemisphere. 
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Figure 1.19 – MR scan of a patient with a glioblastoma.  A – axial T1, B – axial T1 post 
contrast, C – axial T2 and D – coronal T1 post contrast images showing a left temporal 
peripherally enhancing lesion, which, as in this example, can have a well demarcated 
boundary (arrows with tails).  There is a large amount of surrounding oedema (arrows 
without tails). 
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1.2.5.g Treatment 
1.2.5.g.i Surgery 
There is ongoing debate on the role and influence of surgical intervention in 
high grade astrocytomas/glioblastomas.  There is consensus that histological 
confirmation of a lesion in those fit to undergo a biopsy is an appropriate 
management strategy.  In terms of the effect of extent of resection in 
outcome of these tumours, there has never been a randomised controlled 
trial comparing biopsy with maximal surgical resection.  There is however a 
growing body of evidence that suggests the greater the extent of resection 
then the better the outcome.179, 180 
In addition to the potential benefits of surgical resection, there are new 
surgical technologies available that can deliver local therapies directly to the 
tumour.  The currently most used example is Gliadel wafers, which are a 
polymer that provides a sustained release of carmustine (BCNU) directly to 
the resected tumour bed.181  In a phase III trial the median survival has 
been shown to increase from 11.6 to 13.9 months with the use of Gliadel.181 
1.2.5.g.ii Radiotherapy 
There have been multiple trials showing a benefit to survival following 
fractionated radiotherapy for glioblastomas.182  The standard dose is 
generally 54Gy to 60Gy in 30 fractions of 1.8Gy to 2Gy. 
With its wider availability stereotactic radiosurgery is becoming increasingly 
utilised in the treatment of glioblastoma.  This is particularly in the setting of 
nodular recurrence following previous fractionated radiotherapy.  As yet 
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there is no strong evidence of a significant improvement in tumour control or 
survival.183 
1.2.5.g.iii Chemotherapy 
For many years patients with high grade gliomas were treated with systemic 
chemotherapy following radiotherapy or at the time of relapse.  For 
glioblastoma there was no good clinical evidence to support this and for 
anaplastic astrocytoma there were only a few non-controlled trials showing a 
benefit.  In 2001 a randomised controlled trial of chemotherapy  following 
radiotherapy versus radiotherapy alone showed no benefit with 
chemotherapy for either glioblastoma or anaplastic astrocytoma.184 
In recent years, however, temozolomide, an oral alkylating agent, given 
concomitantly with radiotherapy has been show to increase median survival 
by 2.5 months and give a 2 year survival of 26% compared to 8% in patients 
treated with radiotherapy alone.185  The DNA repair gene O6-methylguanine 
DNA methyltransferase (MGMT) plays an important role on the effect of 
temozolomide in glioblastomas.  When it is epigenetically silenced by 
hypermethylation the benefits of temozolomide versus radiotherapy alone 
are significantly higher with an increase of 6.4 months in median survival to 
a median of 21.7 months.  MGMT promoter methylation was evident in 45% 
of glioblastoma patients and the effect is so strong that all future trials 
involving temozolomide will need to stratify patients based upon their MGMT 
methylation status.186 
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1.2.5.h Prognosis 
Despite recent advances, the overall prognosis for high grade astrocytomas 
remains poor.  No therapy will reliably offer long term control of the 
tumours. 
Proven factors related to prognosis are age and Karnofsky performance 
score at presentation.35  Patients over 65-70 or who have a Karnofsky 
performance score of less than 70 will have a worse outcome. 
Survival rates at 1, 5 and 10 years for anaplastic astrocytoma are 60.3%, 
29.4% and 22.4% and for glioblastoma are 29.6%, 3.4% and 2.4% 
respectively.36 
 
1.2.6 Medulloblastoma 
1.2.6.a Definition 
Medulloblastomas are a malignant embryonal tumour of the cerebellum, 
mainly occurring in children, with predominantly neuronal differentiation and 
a tendency to disseminate through CSF pathways. 
1.2.6.b Epidemiology 
Medulloblastomas are the most common malignant brain tumour in children.  
The annual incidence is approximately 0.5 per 100,000 with a peak age of 
presentation of 7 years.  Infants and young adults can also be affected.  
There is generally a slight male predominance with approximately 65% of 
patients being male.187 
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1.2.6.c Aetiology 
Most cases of medulloblastoma are sporadic but there have been several 
familial tumour syndromes with an association with medulloblastomas 
including Gorlin syndrome, Rubenstein-Tyabi syndrome, Li-Fraumeni 
syndrome, ataxia-telangiectasia, Turcot syndrome, neurofibromatosis and 
tuberous sclerosis.35 
1.2.6.d Molecular pathology 
In recent years there has been much discovered about the molecular 
pathways that are involved in the formation of medulloblastomas.  The cell 
of origin of medulloblastomas is felt to be the granule cell progenitor.188  
Overactive sonic hedgehog signalling promotes granule cell progenitor 
proliferation and stimulates the development of medulloblastomas. 
Although there is still some debate about the details, several groups have 
shown a reproducible molecular classification of medulloblastoma subtypes 
that have overlap with histological subgroups and strong associations with 
prognosis and survival.189-192 
The most frequent genetic alteration in medulloblastomas is loss of 
chromosome 17p which is found in over 50% of cases and associated with 
gain of 17q, hence forming the isochromosome 17q.  This genetic 
abnormality is associated with classic and large cell/anaplastic histological 
variants.  Target genes that have been implicated on 17p are the REN 
(KCTD11) and HIC1 genes.193, 194 
80 
 
WNT pathway activation is seen in 15% of medulloblastomas and is most 
frequently caused by somatic CTNNB1 mutations indicated by nuclear 
accumulation of its gene product β–catenin.  This molecular subtype is 
associated with a subgroup of the classic histological variant which lacks 
chromosome 17 alterations (otherwise typical in classical variant) but having 
chromosome 6q losses.  This subtype is seen in older children and has a 
more favourable prognosis. 
Desmoblastic histological variant medulloblastomas also often lack 17p losses 
but are associated with sonic hedgehog pathway (SHH) abnormailities.195  
These include mutations in the tumour suppressor gene PTCH on 
chromosome 9q.  PTCH encodes a receptor component of the SHH pathway 
that control granule cell progenitor proliferation in cerebellar development.  
Inactivating mutations of PTCH or the Human Supressor of Fused (hSUFU) 
gene on chromosome 10 leads to uncontrolled activation of the SHH 
pathway and over-proliferation of granule cell progenitor cells.  This is the 
mechanism by which germline mutations of the PTCH gene (Gorlin 
syndrome) or hSUFU gene predispose to medulloblastomas.196, 197 
Amplification of the MYC gene (most commonly MYCC and MYCN) on 
chromosome 8q24 occurs in 5-10% of cases.  This is associated with the 
large cell/anaplastic histological variants and an overall poor prognosis.198-200 
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1.2.6.e Histopathology 
As already described the histological variants of medulloblastoma are closely 
associated with molecular profiles of the tumours.  There are five subtypes 
of medulloblastoma in the WHO classification.69, 201 
1.2.6.e.i Classic medulloblastoma 
Medulloblastomas are composed of densely packed, small, round tumour 
cells with scant cytoplasm, round or carrot shaped nucleus and condensed 
chromatin (Figure 1.20).  The classic variant occurs in approximately 70% of 
cases.  There may be formation of Homer-Wright rosettes. 
 
Figure 1.20 – Histology of a medulloblastoma.  The classic medulloblastoma is a highly 
cellular neoplasm composed of diminutive, undifferentiated-looking elements possessed 
of little definable cytoplasm and prone to nuclear moulding.  (Image courtesy of 
PathConsult - http://www.pathconsultddx.com)70 
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1.2.6.e.ii Desmoplastic/Nodular medulloblastoma 
Desmoplastic medulloblastoma comprises of 10-20% of cases and is made 
up of islands of well differentiated cells surrounded by large amounts of 
reticulin and collagen.  It generally carries a more favourable prognosis.202 
1.2.6.e.iii Medulloblastoma with extensive nodularity 
These tumours show large nodules and advanced neurocytic differentiation 
with smaller areas resembling desmoplastic medulloblastoma.  It occurs in 
infants and with treatment the prognosis appears to be favourable. 
1.2.6.e.iv Anaplastic medulloblastoma 
Cases of medulloblastoma showing severe and diffuse anaplasia qualify for 
the diagnosis of anaplastic.  This variant is associated with a poor outcome. 
1.2.6.e.v Large cell medulloblastoma 
This rare subtype is characterised by large tumour cells with eosinophilic 
cytoplasm, enlarged nuclei and single prominent nucleoli.  Mitoses and 
apoptotic figures are abundant with large areas of necrosis commonly seen.  
Clinically this variant has very aggressive behaviour and is associated with a 
poor prognosis. 
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1.2.6.f Macroscopic appearance and localisation 
Medulloblastomas typically arise in the midline of the posterior fossa dorsal 
to the fourth ventricle (Figure 1.21) although the desmoplastic variants are 
often more centred in a cerebellar hemisphere.  On pre contrast CT scan 
they appear hyperdense as a consequence of their cellularity. 
At the time of diagnosis 30% will have evidence of metastatic spread 
through the CSF pathways. 
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Figure 1.21 – MR scan of a patient with a medulloblastoma.  A – sagittal T1, B – sagittal T1 
post contrast, C – axial T1 post contrast and D – coronal T1 post contrast images showing 
a uniformly enhancing, somewhat nodular lesion arising from the cerebellar vermis, 
causing a secondary obstructive hydrocephalus.  It is isointense on pre-contrast T1 
images suggesting a cellular tumour. 
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1.2.6.g Treatment 
It has been recognised for some years that the goal of surgical resection of 
medulloblastoma should be to achieve a gross total resection or be leaving 
less than 1.5cm3 of tumour as anything more that this significantly worsened 
survival.203 
Given the location of the tumour, obstructive hydrocephalus is a common 
presenting finding and overall about 20-30% of patients will require a 
permanent CSF diversion at some point of their treatment.35 
1.2.6.h Radiotherapy 
Radiotherapy has been shown to be beneficial for medulloblastomas but it is 
limited by its long term complications in younger children.  Most children 
under 3 would not be treated with post operative radiotherapy but attempts 
would be made to hold the disease with chemotherapy until they had 
reached at least 3 years of age. 
Standard doses would be 36 Gy in 20 fractions to the craniospinal axis and 
54 Gy boost in 30 fractions to the posterior fossa.  Attempts have been made 
to spare the dose as much as possible given the cognitive sequelae even in 
children over 3 years old.  One study described a reduced dose of 
radiotherapy to the standard risk (age >3, <1.5cm3 residual tumour post 
operation and no metastases at presentation) group of 23.4 Gy to the 
craniospinal axis, 36 Gy to the posterior fossa and 55.8 Gy to the tumour 
bed.  High risk patients received 36-39.6 Gy to the craniospinal axis, with a 
3D conformal boost totalling 55.8 Gy to the tumour bed.  Survival at 5 years 
was 85% in the standard risk and 70% in the high risk group.204. 
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As well as the cognitive side effects there is risk following radiotherapy of 
developing a second malignancy which has been reported as 10%.205 
1.2.6.i Chemotherapy 
The medical treatment of medulloblastoma is constantly evolving.206, 207  
However, there are a variety of different agents and regimens that have 
been trialled in multicentre settings that have not clearly shown great 
advantage over the others.  With increasing knowledge of the molecular 
basis of medulloblastomas it is hoped that more individually targeted and 
effective therapies will be available in the future. 
1.2.6.j Prognosis 
Many of the important prognostic factors have already been discussed above 
and it is clear that the molecular characteristics of the tumours will have 
more influence in terms of prognosis and treatment in the future. 
With improvements in survival rates the quality of survival of children must 
be carefully considered and assessment and support of development is 
essential in this vulnerable group.208 
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1.2.7 Ependymoma 
1.2.7.a Definition 
Ependymomas are glial tumours with cellular features of ependymal 
differentiation.  They arise from radial glial-like stem cells209 in the cerebral 
subventricular zone lining the fourth ventricle and within the spinal cord. 
1.2.7.b Epidemiology 
Ependymomas are the third most common CNS tumour in children following 
astrocytoma and medulloblastoma.  They represent 5% of CNS tumours in 
adults, 10% in children under 15 years and 30% in children under 3 years of 
age.  The overall annual incidence is approximately 0.34 (95% CI 0.32-0.34) 
per 100,000.36 
1.2.7.c Aetiology 
No environmental factors have been identified in the development of 
ependymomas.  Approximately 2-5% of patients with neurofibromatosis type 
2 develop ependymomas which usually occur in the spine.35 
1.2.7.d Molecular pathology 
The most common chromosomal change is the loss of chromosome 22 in 30-
60% of cases.210  The actual gene on chromosome 22 remains to be 
identified since the NF2 gene is mutated in only a small subgroup of patients 
and hSNF5/INI1 mutations are absent.  p53 mutations and amplifications of 
CDK4 and EGFR are usually absent in ependymomas.  However expression 
of ERBB2, ERBB4 and EGFR is often up-regulated and EGFR over-expression 
is linked to poor prognosis.211, 212 
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There are marked genetic differences in ependymomas depending upon their 
location with supratentorial ependymomas expressing elevated levels of 
EPHB-EPHRIN and NOTCH pathway members, whereas spinal ependymomas 
showed up regulated expression of HOX genes.209 
Increased expression of the catalytic subunit of human telomere reverse 
transcriptase (hTERT) has a negative effect on survival.  Five-year overall 
survival was 84% (SEM, 7%) and 41% (SEM, 7%) for hTERT-negative and 
hTERT-positive tumours, respectively (P = .001).213, 214 
1.2.7.e Histopathology 
The diagnostic hallmarks of ependymoma are perivascular pseudorosettes 
which are tumour cells extending radial fibrillary processes towards vessels 
and true ependymal rosettes which are canals and tubuli composed of a 
single layer of cuboidal tumour cells (Figure 1.22). 
The World Health Organisation classifies ependymomas into four broad 
categories; grade 2 ependymomas, grade 3 anaplastic ependymomas, 
myxopapillary ependymomas and subependymomas. 
The classic or benign grade 2 ependymomas are further split into four 
histological variants.  Cellular ependymoma is characterised by a 
hypercellular appearance with narrow perivascular pseudorosettes, a fairly 
uniform cellular appearance but with a low proliferative index.  Papillary 
ependymomas are rare tumours that contain tubulovillous architecture as 
their characteristic feature.  Clear cell ependymomas have clear cytoplasm 
with a perinuclear halo which resembles oligodendrogliomas, neurocytomas, 
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clear cell carcinomas and haemangioblastomas.  Its immunoreactivity to glial 
fibrillary acidic protein (GFAP) and features on electron microscopy would 
usually differentiate it from these other tumour types.  Tanycytic 
ependymomas consist of elongated cells arranged in fascicles.  Ependymal 
rosettes and perivascular pseudorosettes are poorly delineated with these 
tumours. 
 
Figure 1.22 – Histology of an ependymoma.  The cytoplasmic processes of ependymal 
tumour cells condense about blood vessels to form pseudorosettes.  In addition, true 
ependymal rosettes are seen with ependymal cells forming tubular structures.  (Image 
courtesy of PathConsult - http://www.pathconsultddx.com)70 
 
Anaplastic (grade 3) ependymomas are malignant tumours with high 
cellularity, nuclear atypia, hyperchromatism, necrosis, vascular proliferation 
and high mitotic index.  They are estimated to occur in 30% of 
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ependymomas.  Historically the differentiation between these and grade 2 
lesions has been controversial, leading to the finding of similar outcomes in 
both tumour grades.215  This has particularly been when ependymomas in 
different locations have been analysed together, where there is now good 
evidence that they are biologically distinct lesions.209 
Myxopapillary ependymomas almost exclusively occur at the conus, but have 
been reported throughout the cranial spinal axis.  They are characterized by 
GFAP-expressing, cuboidal to elongated tumour cells radially arranged in a 
papillary manner around vascularised stromal cores. Mitotic activity is very 
low. A mucoid matrix material accumulates between tumour cells and blood 
vessels, and fills the tumour microcysts. They are classified as WHO grade 1 
tumours and have a favourable prognosis, particularly with complete 
excision. 
Subependymomas are typically well demarcated, non-enhancing lesions 
located in the walls of the ventricular system.  They are characterized by 
clusters of isomorphic nuclei embedded in a dense fibrillary matrix of glial 
cell processes with frequent occurrence of small cysts. Mitoses are very rare 
or absent. They are classified as WHO grade 1 tumours and surgical excision 
is curative. 
1.2.7.f Macroscopic appearance and localisation 
Ependymomas can occur anywhere within the cranial spinal axis, usually 
related to the CSF pathways.  The majority (>90%) are cranial with 65-70% 
of these being infratentorial.35  Supratentorial ependymomas are equally 
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divided between the parenchyma and ventricular system (75% lateral and 
25% third ventricle). 
A typical lesion in the posterior fossa would show some calcification on CT 
scan and on MR scan would show cellular signal characteristics (isointense to 
grey matter on T1 and T2) with a fourth ventricular location and extension of 
the tumour out of the foramina of Luschka and Magendie.  There is often 
some heterogeneous enhancement seen post contrast (Figure 1.23). 
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Figure 1.23 – CT and MR scans of a patient with a posterior fossa ependymomas.  A – axial 
CT, B – MR axial T1, C – axial T2, D – coronal T1 post contrast images showing a partly 
calcified lesion located in the fourth ventricle, extending out into the left foramen of 
Luschka with cellular signal characteristics and patch enhancement. 
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1.2.7.g Treatment 
1.2.7.g.i Surgery 
There is consensus that gross surgical excision of ependymomas should be 
the surgical goal where possible with five year survival rates of 88% where 
this is achieved compared with 53% where only a subtotal resection was 
performed.35  Complete tumour removal reduced the rate of spinal seeding 
from 9.5% to 3.3% with subtotal. 
However, gross total removal of infratentorial lesions is only achieved in 50-
70% of cases.35 
Hydrocephalus is common at presentation of posterior fossa ependymomas 
and even with aggressive tumour removal 30-50% of patients will still 
require some form of CSF diversion. 
1.2.7.g.ii Radiotherapy and radiosurgery 
Intracranial ependymomas appear to be relatively radiation resistant 
tumours.  The use of adjuvant radiotherapy following surgery is somewhat 
controversial for some indications but there is reasonable agreement that it 
is beneficial for patients with posterior fossa tumours, subtotally resected 
tumours, WHO grade 3 tumours and all patients presenting with 
disseminated disease.  Standard doses of 54-59.4 Gy fractionated over a 5-6 
week period to the tumour bed with a 1-2cm margin are usually given. 
For children under 3 years of age there has been a general avoidance of 
radiotherapy because of the concerns over significant compromise to 
cognitive development.  However a recent study has shown good tumour 
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control with conformal radiotherapy in the under 3 population, but long term 
cognitive consequences remain to be seen.216 
1.2.7.g.iii Chemotherapy 
The desire to avoid radiotherapy in young patients has led to the 
investigation of chemotherapy as an adjuvant therapy.  This has been shown 
to be effective in delaying radiotherapy but the long term consequences of 
this management strategy have also not been fully investigated.217  Overall 
response rated for most chemotherapy regimens in ependymomas have 
been in the order of 20%. 
1.2.7.h Prognosis 
One of the greatest problems with defining prognosis for ependymomas has 
been the difficulty with classification and the mixing of biologically different 
tumours within the analysis of various studies. 
Overall survival at 1, 5 and 10 years is 88.5%, 72.5% and 65.0% 
respectively.36  However age has a significant impact on survival with 1, 5 
and 10 year survival rates of 86.1%, 53.4% and 47.1% for patients aged 0-
14 years and 92.3%, 86.2% and 80.4% for patients aged 20-44 years.36 
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1.3 Vascular Endothelial Growth Factor (VEGF) 
 
1.3.1 Introduction 
The vascular system of the skin comprises the blood and lymphatic 
circulations, both of which are located in the dermis.  Early in embryogenesis 
the blood vascular system evolves from the primary capillary plexus.218  The 
development of the lymphatic vasculature during embryogenesis lags behind 
that of the blood vessels, suggesting that both processes are regulated by 
different signals.219  Over one hundred years ago, Florence Sabin proposed a 
theory on the venous origin of the lymphatic vasculature;220 it is only in 
recent years that studies have provided experimental evidence in support of 
Sabin’s model.221, 222  VEGF signalling often represents a critical rate-limiting 
step in angiogenesis - the formation of new blood vessels from a pre-existing 
vascular bed.223, 224  Substantial evidence implicates VEGF as a primary 
angiogenic factor and mediator of pathological angiogenesis.225 
 
1.3.2 VEGF: a historical perspective 
The observation that tumour growth was accompanied by increased 
vascularity was made more than a century ago by several investigators, 
including the celebrated pathologist Rudolf Virchow, in German-language 
publications.224  In 1939, Ide et al. postulated the existence of a tumour-
derived blood vessel growth-stimulating factor.226  In 1945, Algire et al. 
advanced this concept, proposing that “the rapid growth of tumour 
transplants is dependent upon the development of a rich vascular supply”.227  
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Algire also suggested that vascular proliferation was a critical step in 
tumourigenesis, because it was likely to confer a growth advantage on the 
tumour cells relative to normal cells.227  In 1968, the first experiments to test 
the hypothesis that tumours produce angiogenic factors were performed by 
Greenblatt and Shubi228 and Ehrmann and Knoth.229  They demonstrated that 
tumour angiogenesis was mediated by diffusible factor(s) produced by the 
tumour cells.  In 1971, Folkman proposed that anti-angiogenesis might be an 
effective approach to treat human cancer230 and attempted to isolate a 
“tumour angiogenesis factor” from human and animal tumours.  
Subsequently, the angiogenic effects of various factors, including epidermal 
growth factor (EGF), transforming growth factor (TGF)-α, TGF-β, tumour 
necrosis factor (TNF)-α and angiogenin were reported.231 
Independent and unrelated lines of research converged toward the 
identification of VEGF.  In 1983, Senger et al. described the partial 
purification of a protein able to induce vascular leakage in the skin, which 
was named “tumour vascular permeability factor” (VPF).232  In 1989, Ferrara 
and Henzel reported that they had isolated a diffusible endothelial cell-
specific mitogen from medium conditioned by bovine pituitary follicular 
cells.233  They named the isolated protein “vascular endothelial growth 
factor” (VEGF) to reflect the restricted target cell specificity of this molecule.  
Subsequently, cDNA cloning of the genes for both VPF234 and VEGF,235 also 
in 1989, demonstrated that they were the same molecule. 
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It is now understood that VEGF belongs to a family of closely related 
vascular growth factors that have a unique role in controlling growth and 
differentiation of multiple anatomic components of the vascular system 
(Figure 1.24).  In addition to VEGF (also known as VEGF-A) the VEGF-family 
also includes placental growth factor (PlGF);236, 237 VEGF-B,238, 239 VEGF-C,240, 
241 VEGF-D242, 243 and a viral form, VEGF-E.244  VEGF-C and VEGF-D primarily 
regulate lymphangiogenesis.221, 245  In the remainder of this thesis VEGF-A 
will be referred to as VEGF. 
 
Figure 1.24 - VEGF-A is the founding member of a family of closely related growth factors 
and is well established as a pro-angiogenic cytokine.  The VEGF receptors (VEGFRs) are 
expressed on the endothelial cells of both blood and lymphatic vessels.  VEGFR-1 is 
exclusively expressed on blood-vessel endothelial cells (BECs), VEGFR-3 is exclusively 
expressed on lymphatic endothelial cells (LECs); and VEGFR-2 is expressed on both BECs 
and LECs.  (Courtesy of Professor MJ Detmar, Boston, MA, USA.) 
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1.3.3 Angiogenesis 
1.3.3.a The angiogenic pathway: molecular regulation of 
angiogenesis 
The adult blood vasculature is usually quiescent but retains the ability to 
initiate a rapid physiological or pathological angiogenic response if the 
balance between endogenous inhibitors and stimuli is altered - the 
“angiogenic switch”.246  New vessel growth and maturation are highly 
complex and coordinated processes, requiring the sequential activation of a 
series of receptors by numerous ligands in endothelial cells.247-249  The 
sequence of events involved in angiogenesis includes: increased vascular 
permeability and leakage; degradation of basement membrane; endothelial 
cell proliferation and migration through the surrounding extra cellular matrix 
(ECM) and maturation and stabilisation of the newly formed vessel bed. 
The first stage of angiogenesis includes capillary vasodilation and 
hyperpermeability with subsequent extravasation of plasma proteins, 
including prothrombin and fibrinogen, into the surrounding ECM.  Fibrin 
derived from this cascade provides a provisional scaffold to support 
endothelial cell adhesion and migration.250  Local enzymatic degradation of 
the confining basement membrane is required for endothelial cells to egress 
from the parent vessel and sprout into the surrounding tissue.251  This 
process involves secretion and activation of matrix metalloproteinases 
(MMPs),252, 253 zinc-dependent extracellular endopeptidases, growth factors 
(e.g. VEGF) or cell-matrix interactions.254 MMPs known to be secreted by 
endothelial cells include MMP-1, MMP-2, MMP-9 and membrane-type-
97 
 
MMP.254, 255  MMPs possess the capacity to degrade all components of the 
ECM and appear to be important for neovascularisation.  The evidence for 
this includes: MMP-2-deficient mice which have reduced angiogenic 
responses; and specific MMP inhibitors which prevent new blood vessel 
formation both in vitro and in vivo.256, 257  MMPs are likely to contribute to 
neovascularisation pathways in several ways including the facilitation of 
movement of proliferating vascular sprouts through the surrounding stroma 
and liberation of stimulatory angiogenic factors normally sequestered in 
inactive form within the ECM. 
Movement of endothelial cells is further mediated through interactions with 
the matrix via integrins.  These integrins include v3 which is constitutively 
expressed at low levels on quiescent blood vessels but up regulated on the 
surface of endothelial cells of newly formed capillaries following exposure to 
stimuli such as VEGF.258, 259  The interaction between VEGF and v3 
activates a calcium-dependent signalling pathway which promotes 
endothelial cell migration.260  Disruption between matrix and integrin using 
v3 antagonists results in endothelial cell apoptosis and termination of the 
angiogenic response.259  v3 also binds directly to MMP-2 on the surface of 
proliferating, invading endothelial cells thereby facilitating cell surface 
localisation of this enzyme and potentiating its ECM matrix degradative 
effects.261  A non-catalytic carboxy-terminal haemopexin-like domain of 
MMP-2 (known as PEX) is also generated during angiogenesis.  PEX is 
responsible for blocking binding of v3 and MMP-2 and hence produces a 
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negative feedback system to down-regulate new blood vessel formation after 
the initial stimulus262. 
Pericytes, pluripotential perivascular cells of mesenchymal origin, are 
involved in the final step in angiogenesis - the assembly of endothelial cells 
into tubes and remodelling of the immature vascular bed.  Interactions 
between pericytes and endothelial cells, via long cytoplasmic processes, are 
of key importance in the stabilisation of newly formed, leaky blood 
vessels.263  The function of pericytes in these pathways of maturation and 
maintenance are in turn under the influence of the BB isoform of platelet-
derived growth factor (PDGF)264 and angiopoietin (Ang)-1 and -2.265 
The angiopoietins are produced by mesenchymal cells and are expressed at 
sites of blood vessel proliferation and remodelling.  The Ang family of 
proteins appears to play complementary and co-ordinated roles in vascular 
development with VEGF.  They bind to the Tie (tyrosine kinase with 
immunoglobulins and EGF homologous domains) receptors, of which two 
have been described: Tie-1 and Tie-2.266  Although a ligand for Tie-1 has not 
yet been confirmed, Ang-1 binds to Tie-2 leading to increased permeability 
and sprouting of endothelial cells and pericyte recruitment to the vascular 
bed.267  Ang-2, which exhibits 60% homology with Ang-1, also binds to Tie-2 
but acts as a natural antagonist to Ang-1.268  Ang-2 de-stabilises mature 
blood vessels by displacing Ang-1 from its receptor Tie-2.  Inter-relationships 
between the VEGF and angiopoietin families are further demonstrated by 
studies where disruption of a stable vascular bed by Ang-2, in the absence of 
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VEGF, leads to vessel regression; if VEGF is highly expressed, however, 
further neovascularisation occurs.269  This model may be of 
clinicopathological relevance in situations where VEGF levels are elevated, 
Ang-2 is highly expressed and active neovascularisation is occurring.  In 
addition, strategies to block VEGF might not work solely by inhibition of its 
direct angiogenic effects but perhaps by allowing Ang-2-induced regression 
to proceed uninterrupted.  Fiedler et al have found that Ang-2 is a key 
cytokine which can up regulate both inflammation and angiogenesis – two 
processes thought to involve relatively few common molecular 
mechanisms.270, 271  The study findings suggest that on blood-vascular 
endothelial cells (BECs), Ang-2 operates as a counterbalance to the anti-
inflammatory Ang-1.270  Not only does Ang-2 destabilise mature vessels, it 
also promotes inflammation and VEGF-induced angiogenesis.  The study 
demonstrates that the effects of both Ang-1 and Ang-2 are mediated 
through the same receptor, Tie-2.  Activation of Tie-2 by Ang-1 seems to 
down-regulate inflammation (paracrine regulation) by blocking nuclear 
transcription factor kappa B (NF-κB;272  and prevents the uncontrolled onset 
of inflammatory reactions induced by minor amounts of TNF-α.270  However, 
the study illustrates that TNF-α induces production and secretion of Ang-2 by 
the endothelium itself (autocrine regulation).270  Thus, competitive binding of 
Ang-2 to Tie-2 blocks the anti-inflammatory function of Ang-1 and sensitises 
the endothelium to the TNF-α signals.  Furthermore, Ang-2 also sensitises 
endothelial cells to VEGF, thus promoting angiogenesis, vascular 
rearrangement, endothelial cell migration and proliferation.270, 271 
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1.3.3.b Anti-angiogenic regulators 
1.3.3.b.i Thrombospondins 
Angiogenesis is under the control of both stimulatory and inhibitory 
regulators.  The best characterised of the inhibitory molecules are the 
thrombospondins (TSPs) 1-5 of which TSP-1 and -2 have been the most 
extensively studied.  TSP-1 is a multifunctional matrix protein produced by 
various cell types including dermal microvascular endothelial cells.273  It 
accumulates in the basement membrane of quiescent vessels but is absent in 
actively forming endothelial sprouts.274  It has been shown to inhibit 
angiogenesis both in vitro and in vivo and appears to inhibit endothelial cell 
migration by binding to matrix proteins in addition to endothelial cell surface 
receptors and integrins such as v3.
275, 276  TSP-2, similar to TSP-1 in 
structure, also exerts powerful anti-angiogenic effects.277 
1.3.3.b.ii Tissue inhibitors of metalloproteinases 
MMP activity is inhibited by specific tissue inhibitors of metalloproteinases 
(TIMPs) 1- 4 which bind and inactivate MMP in a 1:1 stoichiometric fashion 
and possess anti-angiogenic properties.278, 279  TIMP-1 and TIMP-2 have 
been the most completely characterised molecules of the group and appear 
to inhibit the activity of most MMPs, although TIMP-1 preferentially inhibits 
MMP-1 and TIMP-2 blocks MMP-2.280  A newly described family with anti-
angiogenic properties, METH-1 and METH-2, which contain 
metalloproteinase and thrombospondin domains, specifically inhibits human 
endothelial cell proliferation in vitro although their mode of action is at 
present unknown.281 
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1.3.3.b.iii Protein fragments 
Negative regulators of new blood vessel formation can be stored in the ECM, 
often as cryptic segments within larger proteins which are not themselves 
inhibitors.  Examples of such molecules include: angiostatin,282 a 38 kilo 
Daltons (kDa) fragment of plasminogen; and endostatin,283 a 20kDa carboxy-
terminal fragment of collagen XVIII.  These factors exert their 
angioinhibitory effects by reducing endothelial cell migration and proliferation 
and by promoting apoptosis.282, 284 
1.3.3.c Vascular structure and function in brain tumours 
Normal brain structure is highly specialised and brain tumours disrupt this 
structure.  As well as endothelial cells and pericytes, astrocytes form part of 
the structure that selectively restricts the exchange of molecules between 
the intracerebral and extracerebral circulations.  This is termed the blood 
brain barrier (BBB). 
Tight junctions between endothelial cells prevent any hydrophilic molecule 
over 500kDa from passively entering the brain.  In addition to this there are 
several active transport proteins that exclude exogenous compounds from 
the brain such as the P-glycoprotein/multi-drug resistance proteins (P-
gp/MDR) that contribute to drug resistance in brain tumours.285  It is felt that 
this is why there is an increased incidence of brain metastases in extracranial 
tumours treated with new biological agents, where this barrier creates a 
sanctuary for the tumour cells.286 
Brain tumour vessels show typical neoplastic features of marked 
angiogenesis with endothelial proliferation.287  The blood brain barrier is 
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disrupted in large areas of the tumour vasculature but there is preservation 
of its function within some of the tumour vessels with less transvascular 
transport than in the same tumour types grown subcutaneously.288  The 
abnormal leakiness of tumour vessels adds to tumour tissue extracellular 
fluid accumulation causing oedema and an increase in tumour tissue fluid 
pressure which has been shown to be a cause of reduced drug delivery to 
tumours.289 
 
1.3.4 Activities of VEGF 
1.3.4.a Role of VEGF in physiological angiogenesis 
Angiogenesis, the formation of new blood vessels from a pre-existing 
vascular bed, is important for a number of physiological processes such as 
tissue repair, reproduction290 and endocrine gland function. 
1.3.4.a.i Embryonic and postnatal development 
In 1996, two studies demonstrated an essential role of VEGF in embryonic 
vasculogenesis, angiogenesis and early haematopoiesis in mice and that 
inactivation of a single VEGF allele resulted in embryonic lethality between 
11 and 12 days.291, 292  Further investigations identified a critical VEGF gene-
dosage dependence during development.  For instance, conditional VEGF 
gene inactivation in VEGF loxP mice, using a Nestin promoter-driven Cre-
recombinase (causes recombination), showed that severe reductions in the 
dosage of VEGF from neural progenitor cells led to decreases in vascularity 
and subsequent hypoxia, resulting in the specific degeneration of the 
cerebral cortex and neonatal lethality.293, 294  In contrast, even modest 
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increases in VEGF gene expression, achieved by the insertion of a LacZ 
cassette in the 3’-untranslated region of the VEGF gene, result in severe 
abnormalities in heart development and embryonic lethality at embryonic day 
12.5 – 14.295  VEGF-C also plays an essential role in development, as its 
inactivation results in embryonic lethality due to defective lymphatic 
development and fluid accumulation in tissues221.  However, by comparison, 
inactivation of placental growth factor (PlGF)296 or VEGF-B297 does not result 
in major development abnormalities. 
In early postnatal life VEGF is required not only for proliferation but also for 
survival of endothelial cells.298  VEGF has a key role in neonatal renal 
development299 although in adult mice,298 rats300 and in juvenile primates301 
VEGF neutralisation has no significant effect on glomerular function. 
1.3.4.a.ii Skeletal growth and endochondral bone formation 
Endochondral bone formation is a fundamental mechanism for longitudinal 
bone growth during which cartilage, an avascular tissue, is replaced by bone 
in the process of endochondral ossification.302  It is reported that a VEGF 
gradient is needed for directional growth and cartilage invasion by 
metaphyseal blood vessels298, 303 and VEGF blockade in developing mice and 
primates is accompanied by almost complete arrest of this process together 
with impaired trabecular bone formation and marked expansion of the 
hypertrophic chondrocyte zone.298, 301  An important corollary is that 
cessation of anti-VEGF treatment is followed by capillary invasion, restoration 
of bone growth, and normalisation of the growth plate architecture. 
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1.3.4.a.iii Angiogenesis in endocrine glands 
Angiogenesis is key for normal cyclical ovarian function.  Selection of a 
dominant follicle in monovular species,304 follicular growth, and the 
development of the corpus luteum are dependent on the proliferation of new 
capillary vessels.305  Angiogenesis associated with corpus luteum 
development also plays a key role in the delivery of cholesterol to luteal cells 
for progesterone biosynthesis.306  Subsequently, the blood vessels regress, 
suggesting the coordinated action of inducers as well as inhibitors of 
angiogenesis in the course of the ovarian cycle.268, 307  Previous studies have 
observed that the VEGF mRNA expression is temporally and spatially related 
to the proliferation of blood vessels in the ovary308, 309 and that 
administration of VEGF inhibitors delays follicular development310 and 
suppresses luteal angiogenesis in rodents311, 312 and primates.301, 313-315 
Studies have identified a novel angiogenic factor, endocrine gland derived 
VEGF (EG-VEGF), which is selectively expressed in steroidogenic tissues and 
which plays a cooperative role with VEGF in the regulation of angiogenesis in 
the human ovary.316  EG-VEGF is not structurally related to VEGF but belongs 
to a unique gene family having distant homology to Dickopf, an inhibitor of 
Wnt signalling.317, 318 
Investigators have also demonstrated that VEGF is required for the formation 
of a dense network of fenestrated capillaries in some, but not all, pancreatic 
islets.  In addition, glucose tolerance tests reveal that the VEGF-induced 
capillary network is not strictly required for blood glucose control but is 
essential for fine tuning blood glucose regulation.319 
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1.3.4.b Role of VEGF in physiological lymphangiogenesis 
VEGF is well established as a pro-angiogenic cytokine.  However, depending 
on the target tissue, it may also induce lymphangiogenesis320, 321 and support 
the growth of isolated LECs.322  At least some of the effects of VEGF on 
lymphatic vessels might be indirect, secondary to oedema or to recruitment 
of inflammatory cells that produce VEGF-C and VEGF-D.323, 324  In addition, 
several other molecules are known to be important for later stages of 
lymphatic development.  These include Ang-2;325 podoplanin, a cell surface 
glycoprotein;326, 327 Net, a member of the Ets transcription factor family;328 
and the integrin α9β1 complex which might be involved in lymphatic vessel 
stabilisation.329  Interestingly, the vascular expression pattern of neuropilin 
(NP)2 resembles that of VEGFR-3.  VEGF-C binds to NP2, suggesting that 
NP2 could act as a co-receptor for VEGFR-3.330 
1.3.4.c Mitogenesis and endothelial survival 
VEGF is a survival factor for endothelial cells, both in vitro and in vivo.331-337  
In vitro, VEGF prevents endothelial apoptosis by mechanisms mediated by 
the phosphatidylinositol 3-kinase (PI3 kinase) /Akt pathway336, 338 and also 
induces expression of the anti-apoptotic proteins Bcl-2, A1,335 X-linked 
inhibitor of apoptosis (XIAP),339 and survivin340 in endothelial cells.  In vivo, 
the ability of VEGF to prolong the survival of endothelial cells is dependent 
on developmental stage.  For instance, VEGF inhibition results in extensive 
apoptotic changes in the vasculature of neonatal, but not adult, mice.298  It 
has also been shown that VEGF stimulates surfactant production by alveolar 
Type II cells, resulting in a protective effect from respiratory distress 
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syndrome in mice.341  Studies in amyotrophic lateral sclerosis have illustrated 
the potential role of VEGF as a neuronal protective factor.342 
1.3.4.d Effects of VEGF on bone marrow cells and haematopoiesis 
VEGF has been shown to promote monocyte chemotaxis343 and to have 
haematopoietic effects.344  Delivery of VEGF to adult mice has been reported 
to inhibit the development of dendritic cells345, 346 and it has been suggested 
that in this way VEGF facilitates tumour growth through escape from the 
host immune system.  VEGF also increases production of B-cells and the 
generation of immature myeloid cells.347   
1.3.4.e Enhancement of vascular permeability and haemodynamic 
effects 
VEGF, through mechanisms which involve nitric oxide (NO),348-350 plays a key 
role in the regulation of vascular permeability and has been shown to induce 
endothelial fenestration in some vascular beds.351  There has been much 
debate whether there is a correlation between vascular permeability and 
angiogenesis.  Some investigators have suggested that an increase in 
microvascular permeability is necessary for angiogenesis as it permits 
extravasation of fibrin, which can act as a scaffold for endothelial cell 
proliferation and migration.352, 353  However, others354 have reported that 
members of the Src family are differentially involved in mediating VEGF-
dependent permeability and that enhanced vascular permeability is not a 
requirement for VEGF-dependent angiogenesis. 
VEGF induces vasodilatation in vitro in a dose-dependent fashion355, 356 and 
has a tonic homeostatic role in the regulation of blood pressure.  The 
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mechanism is likely to involve endothelial NO synthase, but remains to be 
fully elucidated.  Hypotension has been observed to be a dose-limiting side 
effect in human trials in which VEGF was systemically administered357 and 
conversely, administration of anti-VEGF monoclonal antibodies to cancer 
patients results in blood pressure elevation.358 
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1.3.5 VEGF Isoforms 
The human VEGF gene is localised on chromosome 6p21.3359 and has nine 
possible exons.360, 361  As a result of alternative exon splicing a number of 
different VEGF isoforms, of varying amino acid length, can be generated 
(Figure 1.25).225  Commonly occurring VEGF isoforms include - VEGF121, 
VEGF165, VEGF189, VEGF206.
360, 361  However, less frequent isoforms have also 
been described including - VEGF145,
362 VEGF183,
363 and VEGF162.
364  
Substitution of exon 8 for exon 9 by alternate splicing is reported to convert 
pro-angiogenic forms into inhibitory forms such as VEGF165b.
365  Mouse and 
rat isoforms are shorter by one amino acid. 
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Figure 1.25 - The VEGF gene is located on chromosome 6 - at 6p21 - and is highly 
polymorphic.  The two polymorphisms occurring at highest frequency in the promoter and 
5 prime untranslated regions of the gene are situated at positions -460 and +405 
(numbering from transcription start).  As a result of alternative exon splicing a number of 
different VEGF isoforms, of varying amino acid length, can be generated.  Commonly 
occurring VEGF isoforms include - VEGF121, VEGF165, VEGF189, VEGF206.   
 
VEGF165 is the major VEGF isoform
366 and is a heparin-binding homodimeric 
glycoprotein of 45kDa233 which structurally forms an antiparallel homodimer 
(two VEGF monomers oriented side-by-side and head-to-tail) covalently 
linked by two disulphide bridges between cystine-51 and cystine-60.367  The 
dominant feature within the VEGF monomer is the cystine knot motif that is 
found in other growth factors of the “cysteine-knot superfamily”, whose 
members are characterised by a common motif of eight spatially conserved 
cysteines, which are involved in intra- and intermolecular disulfide bonds.367, 
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368  VEGF165 has optimal characteristics of bioavailability and biological 
potency because although it is secreted, a significant fraction remains bound 
to the cell surface and ECM.369  In contrast, VEGF121 is an acidic polypeptide 
which fails to bind heparin and thus remains freely diffusible.225, 366  VEGF189 
and VEGF206 are highly basic and therefore bind heparin with high affinity 
and are almost completely sequestered in the ECM.366  The ECM-bound 
isoforms may be released in a diffusible form by heparin or heparanase, 
which displaces or liberates them from their binding to heparin sulphate 
moieties.  Loss of the heparin-binding domain results in a reduction in the 
mitogenic activity of VEGF370 and other studies have demonstrated that the 
heparin-binding VEGF isoforms provide essential stimulatory cues for the 
initiation of vascular branch formation.371 
1.3.6 VEGF Receptors 
VEGF binds to two, specific, structurally related, high- affinity type III 
receptor tyrosine kinases (RTKs), VEGFR-1 (also known as flt-1; fms-like 
tyrosine kinase) and VEGFR-2 (also known as KDR; kinase-insert-domain-
containing receptor), triggering signal transduction pathways that mediate 
the angiogenic and permeability modulating responses.372  VEGF-C binds not 
only to VEGFR-2 to induce angiogenesis,240, 373 but also to a third, 
structurally related, receptor, VEGFR-3 (also known as flt-4), on lymphatic 
endothelium to induce lymphangiogenesis.240, 374  VEGFR-3 also binds VEGF-
D.374  Both VEGFR-1 and VEGFR-2 have seven Ig-like domains in the 
extracellular region, a single-transmembrane component, and a consensus 
tyrosine kinase sequence that is interrupted by a kinase insert domain.375-377  
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Neuropilins (NPs), cell surface glycoproteins important in neuronal 
development, have been identified as a family of co-receptors for VEGF.225 
VEGF, VEGFR-1 and VEGFR-2 represent a regulatory system essential for 
both normal and pathological angiogenesis378-382 and both receptors are 
almost exclusively expressed within endothelial cells and preferentially within 
proliferating endothelium. 
1.3.6.a VEGFR-1 
VEGFR-1 is expressed in two forms:381, 383  a full-length, membrane bound 
receptor capable of transducing signal, and a truncated, soluble receptor 
capable of sequestering ligand or dimerising with full-length receptor and 
preventing signal transduction – soluble (s)VEGFR-1.381  Gene-targeting 
studies have demonstrated the essential role of this molecule during 
embryogenesis. VEGFR-1 knockout mice die in utero at approximately the 
ninth day.379, 384  In these mice endothelial cells develop but fail to organise 
in vascular channels.  VEGFR-1 binds VEGF, PlGF385 and VEGF-B.238  The 
binding site for VEGF (and PlGF) has been mapped primarily to the second 
Ig-like domain.333, 386, 387  VEGFR-1 has a greater affinity for VEGF than 
VEGFR-2,388-390 yet VEGFR-2 is phosphorylated approximately 10-fold more 
efficiently upon ligand binding.382, 391 
VEGFR-1 expression is up-regulated by hypoxia via a hypoxia-inducible factor 
(HIF)-1 dependent mechanism.392  High levels of sVEGFR-1 reportedly occur 
in plasma during pregnancy and in patients with essential hypertension.393-395  
Significantly lower levels have been observed in the plasma of patients with 
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cardiovascular disease and in smokers.396, 397  In contrast to sVEGFR-1, 
which is an alternatively spliced cellular product, circulating sVEGFR-2 is 
thought to derive from shedding of the receptor from endothelial cell 
membrane into the circulation.  Thus, circulating levels of both VEGF 
receptors could be regarded as surrogate markers of endothelial cell activity 
– with increased endothelial cell turnover likely to result in shedding of 
membrane bound receptor into the plasma. 
Although VEGFR-1 was the first RTK to be identified as a VEGFR,391 the 
precise function of this molecule is still the object of debate.  Park et al. 
proposed that VEGFR-1 may be a “decoy” receptor that functions to limit 
VEGF/VEGFR-2 mediated angiogenesis by sequestering VEGF ligand and 
rendering it less available to VEGFR-2.385  Gille et al. identified a repressor 
motif in the juxtamembrane region of VEGFR-1 that impairs PI3 kinase 
activation and endothelial cell migration in response to VEGF.398  However, 
there is evidence that the tyrosine kinase domain of VEGFR-1 does play an 
angiogenic role and other studies have indicated that VEGFR-1 is able to 
interact with various signal-transducing proteins and generate, in some 
circumstances, a mitogenic signal.399, 400 
Induced VEGFR-1/VEGFR-2 heterodimers can transduce signal.380  VEGF-
induced NO release appears to be mediated by VEGFR-1, and this NO 
release in turn acts as a molecular switch, inhibiting VEGFR-2 mediated 
proliferation and affecting de-differentiation of endothelial cells into capillary-
like structures.378  Autiero et al. have proposed that PlGF regulates inter- and 
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intramolecular cross-talk between the VEGF RTKs.401  Activation of VEGFR-1 
by PlGF resulted in transphosphorylation of VEGFR-2, thus amplifying VEGF-
driven angiogenesis through VEGFR-2.401  Experimental findings have also 
suggested that a key function of VEGFR-1 signalling in the vascular 
endothelium is not the regulation of angiogenesis but, rather, the paracrine 
release of tissue-specific growth/survival factors, possibly in a vascular bed-
specific fashion.402  Other studies suggest that at least in some 
circumstances, VEGFR-1 may transmit a pro-survival signal in endothelial 
cells, possibly mediated by induction of the anti-apoptotic gene survivin.403 
1.3.6.b VEGFR-2 
VEGFR-2 has a key role in developmental angiogenesis and haematopoiesis.  
In VEGFR-2 null mice, defective vasculogenesis leads to a failure to develop 
blood islands and organised blood vessels which results in intrauterine death 
between day 8.5 and day 9.5.404  The VEGF binding site has been mapped to 
the second and third Ig-like domain405 and VEGFR-2 undergoes dimerisation.  
It has been suggested that VEGFR-2 is the major mediator of the mitogenic, 
angiogenic, and permeability-enhancing effects of VEGF.  VEGFR-2 activation 
by VEGF results in PI3 kinase/Akt-dependent activation of several integrins406 
and also induces endothelial cell growth by activation of the Raf-Mek-Erk 
pathway.  VEGFR-2 activation has been shown to be required for the anti-
apoptotic effects of VEGF for human umbilical vein endothelial cells with the 
pro-survival effect mediated by the PI3 kinase/Akt pathway.336 
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1.3.6.c VEGFR-3 (Flt-4) 
In adults, the expression of VEGFR-3 is confined to the lymphatic 
endothelium.407  VEGF-C and VEGF-D, which bind to, and activate, VEGFR-3, 
induce lymphangiogenesis (e.g. in the differentiated chick chorioallantoic 
membrane and when delivered to mouse skin using adenoviruses or by 
transgene expression.408-410  Conversely, inhibition of these ligands by the 
expression of a soluble VEGFR-3–Ig fusion protein in mice starting at 
embryological day 15 caused regression of the developing lymphatic vessels 
by endothelial cell apoptosis.411 
1.3.6.d Neuropilin (NP)1 and 2 
Some tumour and endothelial cells were reported to express cell surface 
VEGF-binding sites distinct in affinity and molecular mass from the VEGF 
RTKs.412  It was also observed that VEGF121 failed to bind these sites, 
indicating that exon 7-encoded basic sequences were required for binding to 
this putative receptor.412  Subsequently, Soker et al. identified NP1, a 
molecule previously implicated in neuronal guidance, which enhanced the 
binding of VEGF165 to VEGFR-2.
413  NP1 has also been shown to bind directly 
with VEGFR-1, suggesting that one of the mechanisms by which VEGFR-1 
functions as a negative regulator of VEGF activity is competing for NP1 
binding.414  Other studies have linked another of the NP family, NP2, to 
lymphatic vessel development.415 
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1.3.7 Role of VEGF in Pathological Conditions 
VEGF has been implicated in the pathogenesis of a large number of 
pathological conditions including solid tumours, haematological malignancies, 
intraocular neovascular syndromes, cerebral oedema and diseases of the 
female reproductive tract.290  VEGF up-regulation has also been implicated in 
various inflammatory disorders including wound healing, rheumatoid arthritis 
and psoriasis.416, 417  Reinders et al. provided evidence for a role of VEGF as 
a proinflammatory mediator in allograft rejection.  VEGF was found to be 
functional in the trafficking of human T-cells into skin allografts in vivo in the 
humanised severe combined immunodeficiency (SCID) mouse.418 
Whereas tissue repair and tumour growth are predominantly associated with 
sprouting angiogenesis (i.e., the outgrowth of new capillaries from pre-
existing vessels419, 420), the predominant type of angiogenesis observed 
during inflammation consists of vascular enlargement of pre-existing vessels 
rather than the formation of new blood vessels.421  However, endothelial cell 
proliferation and vascular hyperpermeability are shared by both types of 
angiogenesis, and enlarged and hyperpermeable dermal microvessels are 
also a consistent feature of the skin inflammation associated with delayed-
type hypersensitivity (DTH) reactions.422 
Lymphatic vessels provide one of the main routes for tumour metastasis, 
especially for tumours of the breast, lung and gastrointestinal tract, which 
frequently colonise draining regional lymph nodes.  Compared to the blood 
vasculature, relatively little is known about the biology of lymphatic vessels 
in tumours, the regulation of tumour lymphangiogenesis or the mechanisms 
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that determine the interactions of tumour cells with the lymphatic vessels.  
Although peritumoural lymphatic vessels contribute to tumour metastasis, 
opposite views exist as to whether intratumoural lymphatics have any role in 
tumour metastasis.423  Many human tumours express VEGF-C, and increased 
VEGF-C expression correlates with lymph node metastasis in, for example, 
thyroid, prostate, gastric, colorectal and lung cancers.424, 425  In breast 
cancer, VEGF-C expression correlates with lymph node positive tumours, 
whereas VEGF-D showed expression predominantly in inflammatory breast 
carcinoma.426  Interestingly, although there are no lymphatic vessels in brain 
tumours, VEGF-C and VEGFR-3 have both been shown to be expressed in 
haemangioblastomas and glioblastomas.427  Another study showed 
correlation of VEGFR-3 and tumour grade in grade 2 to 4 gliomas.428  The 
mechanisms regulating VEGF-C or VEGF-D expression in tumours are not 
fully understood.  Although VEGF-C is commonly expressed in cancer, it is 
not known to what extent tumour cells are directly responsible for the 
secretion of lymphangiogenic growth factors, such as VEGF-C and VEGF-
D.429 
Studies using various rodent models have provided evidence that tumour 
lymphangiogenesis facilitates lymphatic metastasis.  Similarly, 
overexpression of VEGF-C or VEGF-D in murine tumours increased the 
number of peri- and/or intra-tumoural lymphatic vessels and enhanced 
metastasis to regional lymph nodes.245, 430-432  The secreted, soluble VEGFR-
3–Ig fusion protein produced by transfected human breast or lung carcinoma 
cells that have a high VEGF-C expression, or delivered by a systemic route 
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using adenoviruses, inhibits tumour lymphangiogenesis and lymph node 
metastasis in immunodeficient mice, further supporting the role of 
lymphatics in tumour development.430, 433 
 
1.3.8 VEGF in brain tumours 
VEGF and its receptors have been shown to be expressed in brain tumours 
and it is felt to play a major role in tumour angiogenesis and formation of 
peri-tumoural oedema (Figure 1.26).434-436  VEGF has been shown to be 
expressed in gliomas,436 haemagioblastomas,437 meningiomas,438 
medulloblastomas439 and ependymomas.440 
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Figure 1.26 – The biology of VEGF in brain tumours. A - VEGF is a multifunctional cytokine 
that is stimulated to be produced by tumour and peripheral blood mononuclear cells by 
various triggers including hypoxia and hypoglycaemia.  B - VEGF binds to two receptors 
flt-1 and KDR which are present in both membrane bound and soluble forms.  C - 
Following receptor binding, signalling pathways cause both new vessel formation and 
increased vascular permeability. D - New vascular supply allows delivery of the necessary 
substrates for tumour growth and progression. 
 
1.3.8.a Astrocytomas 
Low grade astrocytomas have a vascular pattern that is similar to normal 
brain, whereas glioblastomas are amongst the most vascular solid tumours 
seen.441  Thus it is felt that in order for a low grade tumour to progress, 
there is a need for an “angiogenic switch”.12, 434 
In glioblastomas, VEGF expression is 50 times that of normal brain.436  This 
expression is spatially restricted to perinecrotic (palisading) cells442, 443 
suggesting that hypoxia is able to induce VEGF in vivo.  There is a positive 
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correlation of VEGF levels and general vascularity of tumours.444  Abnormal 
vessel morphometry (e.g. vessel shape, length, compactness and 
branching), which is also associated with VEGF levels445 has been shown to 
correlate with grade of astrocytoma and survival.446   In addition 
cerebrospinal fluid levels of VEGF have been shown to correlate with tumour 
grade in astrocytomas.447 
VEGFR-2 is confined to vascular cells of high grade gliomas, whereas VEGFR-
1 is expressed in low and high grade gliomas, whilst neither are expressed to 
any significant level in normal brain.  The levels of the receptors correlate 
with VEGF levels in tumours suggesting a co-ordinated up regulation as a 
component of tumour progression, possibly mediated via autocrine action of 
VEGF itself.442, 448  In addition to this as well as tumour grade VEGF also 
correlates with survival in astrocytomas.449-452 
Although vascular proliferation is a hallmark for malignant progression in 
low-grade astrocytomas, pilocytic astrocytomas seem to be an exception. 
Leung et al. found high level of VEGF transcripts with up-regulation of its 
receptors VEGFR-1 and VEGFR-2 in 14 pilocytic astrocytomas.453  These 
findings suggest that VEGF expression in pilocytic astrocytoma may be 
responsible for the pronounced vascular proliferation and cyst formation 
commonly observed in these tumours.  As hypoxia in low-grade 
astrocytomas has been not shown, it is still speculative, how VEGF is 
regulated in these tumours.  A proposed mechanism to explain the 
expression of VEGF mRNA in low-grade astrocytomas is loss of function of 
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tumour suppressor gene p53.454  However, immunohistochemical studies 
have failed to show a correlation between p53 accumulation (the mutant 
protein has an increased half-life) and VEGF expression.442, 455 
 
1.3.9 VEGF and Therapeutic Angiogenesis 
“Therapeutic angiogenesis” may be beneficial for conditions characterised by 
inadequate tissue perfusion as, at present, there are no effective alternatives 
to surgical reconstruction procedures.  Early studies indicated that intra-
arterial or intramuscular administration of VEGF165 could significantly 
augment perfusion and development of collateral vessels in a rabbit model of 
chronic hind limb ischaemia.456, 457  Arterial gene transfer with cDNA 
encoding VEGF also led to revascularisation in the same rabbit model to an 
extent comparable to that achieved with the recombinant protein.458, 459 
In clinical trials, arterial gene transfer of naked plasmid DNA encoding 
VEGF165 resulted in angiographic and histological evidence of angiogenesis 
after 4 weeks in a single patient with severe limb ischaemia.460  However, a  
placebo-controlled phase II study (174 patients) in which recombinant 
human VEGF165 was administered as a single intracoronary infusion, followed 
by three iv injections, did not demonstrate clinical benefit after 60 days, 
although some improvement in angina class was measured at a later time 
point.357  Another controlled trial has reported an increase in vascularity 
following adenovirus-mediated delivery of VEGF165 in limb ischaemia 
patients.461  Several groups are exploring the possibility that more persistent 
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exposure to VEGF may achieve better results than in earlier trials.  In this 
context, studies using a conditional VEGF switch showed that early cessation 
of the VEGF stimulus is followed by regression of newly formed vessels in the 
heart and liver but, after a critical duration of exposure, vessels persisted for 
several months and improved organ perfusion was observed.462 
Other studies have shown that both recombinant463 and adenovirus-
delivered464 VEGF leads to enhanced blood vessel formation and ossification 
in models of bone damage - findings which may have future clinical 
implications. 
 
1.3.10 Anti-VEGF therapy in Brain Tumours 
VEGF inhibition has been shown to suppress pathological angiogenesis in a 
wide variety of models, including genetic models of cancer, leading to the 
clinical development of a variety of VEGF inhibitors.  This was particularly 
attractive in brain tumours given the high degree of endothelial proliferation 
and pro-angiogenic growth factor expression seen.416 
Initial encouraging phase II results were followed by setbacks, such as the 
lack of efficacy of SU5416 (a VEGFR-2 tyrosine kinase inhibitor, 
Semaxanib®; developed by SUGEN Inc. a subsidiary of Pfizer Inc., New 
York, NY, USA) in a phase III study in metastatic colorectal carcinoma in 
combination with chemotherapy, or the lack of survival benefit in patients 
with refractory metastatic breast cancer treated with a humanised anti-VEGF 
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monoclonal antibody (bevacizumab; Genentech, South San Francisco, CA, 
USA) plus chemotherapy as a third-line therapy.465 
However, a large phase III study in colorectal carcinoma was the first to 
provide unequivocal evidence that VEGF inhibition, using bevacizumab in 
combination with chemotherapy, may provide a substantial clinical benefit, 
including increased survival.466  In terms of side-effect profile hypertension 
was more common in the bevacizumab-treated group but was readily 
managed in all cases with oral anti-hypertensitive agents.466  An increased 
incidence of thrombosis and proteinuria was observed in a phase II but not 
in a subsequent phase III study.  Bevacizumab (Avastin) was approved by 
the US FDA on 26th February 2004 as a first-line treatment for metastatic 
colorectal carcinoma. 
Subsequent to this there have been various studies on bevacizumab in 
glioblastoma, and as a consequence of two particular studies, the FDA 
approved its use for glioblastomas on May 6th 2009.467, 468  The first trial 
randomly assigned 167 patients with recurrent glioblastoma to bevacizumab 
therapy with or without irinotecan.467  Response rates were reported to be 
between 28% and 38%, and 6 month progression free survival rates ranged 
from 43% to 50%. As had been reported in previous studies, most patients 
reduced their corticosteroid doses by 50% or more due to the marked 
antipermeability effect of bevacizumab. Adverse events were infrequent, with 
8 (4.9%) intracerebral haemorrhages reported, the majority of which were 
not life-threatening, and 23 (14.1%) thromboembolic complications noted. 
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The other phase 2 trial evaluated by the FDA involved bevacizumab 
monotherapy in 48 heavily pre-treated patients with recurrent GBM.468 The 
radiographic response rate was 35%, and the 6 month progression free 
survival rate was 29%. In addition to hemorrhagic and thromboembolic 
complications, common toxicities observed in these studies included 
hypertension, proteinuria, fatigue, and wound-healing complications. 
As well as targeting VEGF, small molecular inhibitors of VEGFR-2 are 
currently being investigated.  A phase II trial of cediranib which inhibits all 
known subtypes of VEGFR was undertaken in patients with recurrent 
glioblastomas.469  Results were comparable to those reported for 
bevacizumab, with a response rate of 56% and a 6 month progression free 
survival rate of 26%. 
Other vascular inhibitors include PDGFR, because of its role in pericyte 
recruitment.470  The integrins v3 and v5 are highly expressed by tumour 
endothelial cells and facilitate angiogenesis as described earlier.  Cilengitide 
(EMD121974) inhibits these integrins and appears promising in GBM patients 
with methylation of the MGMT gene promoter.471 
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1.3.11 Genetics  
1.3.11.a Genetic mapping of complex disease 
Over the last 20 years it has become possible to identify the genes 
underlying many monogenic or Mendelian diseases through development of 
techniques such as genetic linkage and positional cloning methodology.  
However, detection of the genetic aetiology of complex or multifactorial 
diseases is more complicated as by definition these conditions also have 
contributory environmental components.  However, recent advances in the 
definition of haplotype structure and linkage disequilibrium (LD) within the 
human genome have provided new tools for the study and mapping of 
complex diseases.  In common complex diseases there may be numerous 
susceptibility genes reported and replication of findings may be difficult.  In 
different populations, a variety of genetic loci might confer genetic 
susceptibility to a particular disease.  This phenomenon is called locus 
heterogeneity and may arise from difficulty in defining disease phenotype - 
complex diseases typically vary in severity of symptoms and age of onset.  
This problem may be diminished by stringent application of clinical diagnostic 
criteria and through the sub grouping of patients.472-474 
1.3.11.b Allelic structure of complex diseases 
Two models have been proposed to explain the genetic basis for complex 
diseases – the common disease/common variant (CD/CV) hypothesis and the 
genetic heterogeneity hypothesis.  The CD/CV hypothesis suggests that for 
complex diseases, the genetic risk is conferred by relatively high frequency 
disease-predisposing alleles present at a small number of loci.  The 
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alternative, genetic heterogeneity hypothesis, proposes that numerous loci 
have rare alleles, each of which can cause the disease.472, 475, 476  Neither 
model has been confirmed but the CD/CV model has more support based on 
statistical models of human population expansion and differences in the 
kinetics of rare and common alleles.477-479 
The mutation rate is approximately the same for both rare and common 
alleles.  Rare alleles causing Mendelian disease mutations are highly 
penetrant and are usually under very strong selection pressure due to their 
adverse effect.477-479  Susceptibility variants in complex disease appear to 
have moderate or low penetrance and therefore are much less prone to 
selection and thus able to reach higher frequencies.  Common alleles are 
likely to be ancestral in origin, whereas rare alleles have relatively rapid 
turnover due to selection thus allele frequency remains low.  In designing a 
genomics study, knowledge regarding the allelic structure of the disease to 
be investigated is key.  Association studies are more likely to be successful if 
there are a few predominating alleles.  Allelic heterogeneity can be 
accommodated by linkage analysis although locus heterogeneity may explain 
unsuccessful replication of linkage loci in genome scans.478, 480 
There are, however, only a few examples of successful susceptibility gene 
mapping for complex diseases such as the APOE4 allele in Alzheimer’s 
disease.  Although these disease variants may have higher penetrance and 
simpler allelic architecture than other complex diseases,478 the susceptibility 
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alleles are fairly prevalent in the population thus supporting the CD/CV 
hypothesis. 
1.3.11.c Single nucleotide polymorphisms 
Single nucleotide polymorphisms (SNPs) are single base pair variations in 
genomic DNA for which different alleles exist in normal individuals and where 
the least frequent allele has a frequency of 0.01 or greater in the general 
population (Figure 1.27).  In addition to bi-allelic polymorphism the term is 
sometimes also incorrectly used to describe tri- and tetra-allelic 
polymorphisms together with insertion and deletion variants.  Bi-allelic 
variants comprise 4 different types, with the cytosine / thymine (C/T) - 
guanine / adenine (G/A) transition accounting for approximately two-thirds 
of SNPs.481  It has been estimated that the total number of SNPs in the 
human genome may be about ten million,482 with about 3 million of these 
accounting for common SNPs (minor allele frequency > 20%) or one in 
every 1 kilo bases (kb).482-484  Region-specific differences in SNP density 
occur with SNPs being most frequent in non-coding regions rather than in 
coding regions.  Those SNPs which do occur within coding regions tend to be 
synonymous SNPs, which do not result in alteration of the amino acid 
sequence and are probably a result of selection against deleterious alleles.472, 
475 
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The random nature and low mutation rate of base-changing events confer 
reasonable stability to SNP alleles.485  Consequently over 80% are common 
to all human populations (but with different allele frequencies).483  Due to 
the frequency within the genome of SNPs and because it is possible to use 
high-throughput methods to rapidly genotype them, common SNPs are 
thought to be good markers for genome-wide mapping of complex diseases. 
  
C
C
G
T
C
C
A
A
C
C
C
C
T
C
G
G
C
A
G
G
T
T
G
G
G
G
A
G
C
C
C
G
T
C
C
A
A
C
C
C
C
T
C
T                         A                       T                         A                       
G
G
G
C
A
G
G
T
T
G
G
G
G
A
G
5’ 5’
3’ 3’
G                C                       
T          T
C
C
G
T
C
C
A
A
C
C
C
C
T
C
G
G
C
A
G
G
T
T
G
G
G
G
A
G
C
C
C
G
T
C
C
A
A
C
C
C
C
T
C
T                         A                       T                         A                       
G
G
G
C
A
G
G
T
T
G
G
G
G
A
G
5’ 5’
3’ 3’
G                C                       
C               GT C
C
C
G
T
C
C
A
A
C
C
C
C
T
C
G
G
C
A
G
G
T
T
G
G
G
G
A
G
C
C
C
G
T
C
C
A
A
C
C
C
C
T
C
T                 A
G
G
G
C
A
G
G
T
T
G
G
G
G
A
G
5’ 5’
3’ 3’
G                C                       
C               GC C
C
C
G
T
C
C
A
A
C
C
C
C
T
C
G
G
C
A
G
G
T
T
G
G
G
G
A
G
C
C
C
G
T
C
C
A
A
C
C
C
C
T
C
C                 G
G
G
G
C
A
G
G
T
T
G
G
G
G
A
G
5’ 5’
3’ 3’
G                C                       
Figure 1.27 - Single nucleotide polymorphisms (SNPs).  These are single base pair variations in genomic 
DNA for which different alleles exist in normal individuals.  Bi-allelic variants comprise 4 different types, 
with the cytosine / thymine (C/T) - guanine / adenine (G/A) transition accounting for approximately 
two-thirds of SNPs.  For bi-allelic polymorphisms individuals can have one of three possible genotypes.  
The SNP illustrated above is a C/T transition and possible genotypes include TT, TC or CC.   
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1.3.11.d Association studies 
Association studies are effective tools in the study of complex diseases due 
to their greater statistical power than linkage analysis when there is locus 
heterogeneity.473, 474  Most association studies in complex disease have been 
performed as candidate-gene studies.  Candidate genes are usually selected 
on the basis of their possible biological function in disease pathogenesis and 
allelic variants of the candidate gene tested for association.486, 487  To date, 
most association studies have used non-synonymous coding SNPs of 
candidate genes although SNPs within promoter regions or other important 
regulatory elements may also be disease-causing variants. 
The case-control study design is the most commonly employed strategy in 
association studies.  However, study design is key and patient and control 
groups need to be selected carefully and adequately matched otherwise 
statistically significant associations may reflect differences between the cases 
and controls rather than the actual influence of the studied allele.  As any 
systematic allele frequency differences between cases and controls can 
appear to be an association,486, 488 isolated populations have been suggested 
as a good case-control sample set because of the homogenous 
background.489  However, population substructure must then be 
considered.490  Control ascertainment may also be improved by using a 
prospective study cohort, as this will also allow monitoring of environmental 
factors.  Furthermore, sample size should be sufficiently large to detect 
significant results and findings should always be replicated in other 
populations.488 
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To reduce the effect of population stratification family-based, as opposed to 
population-based, controls can be used in association analysis.  The 
transmission disequilibrium test (TDT) is the most commonly used family-
based association test.491, 492  However, family-based testing is less powerful 
statistically than case-control studies and generally requires much larger 
sample sizes.  Indeed, as disease onset is often late in complex disease, 
parents of the index case may be deceased.488 
1.3.11.e Genome-wide linkage analysis 
Genetic linkage means that alleles from two loci segregate together rather 
than independently in meiosis because of their close proximity on a 
chromosome.  The extent of linkage between two loci is measured by the 
recombination fraction (), which is the fraction of meiotic events that show 
recombination between the loci of all possible meioses.  For unlinked loci  = 
0.5 and for completely linked loci  = 0.493, 494  If the loci are syntenic, i.e. 
they lie on the same chromosome, then they might be expected always to 
segregate together, with no recombinants.  However, during prophase of 
meiosis I, pairs of homologous chromosomes synapse and exchange 
segments.  Only two of the four chromatids are involved in any particular 
crossover.  A crossover will create two recombinant chromatids and leave 
two non-involved chromatids non-recombinant.  Thus one crossover 
generates 50% recombinants between loci flanking it.495 
Linkage analysis is used to locate a disease gene based on its close proximity 
to a segregating marker allele on the same chromosome. The standard tools 
for polymerase chain reaction (PCR) linkage analysis are microsatellites; 
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these are mostly (CA)n repeats.  Tri- and tetranucleotide repeats are 
gradually replacing dinucleotide repeats as the markers of choice because 
they give cleaner results - dinucleotide repeat sequences are peculiarly prone 
to replication slippage during PCR amplification.495  Morton (1955) 
demonstrated that logarithm (log10) of the odds of linkage (LOD) scores 
represent the most efficient statistic for evaluating pedigrees for linkage, and 
derived formulae to give the LOD score (as a function of ) for various 
standard pedigree structures.496  The LOD score is calculated as the ratio 
between the alternative assumptions that the loci are linked or are not linked 
as a function of the recombination fraction.  LOD scores may then be 
calculated for a range of  values and the most likely recombination fraction 
is the one that produces the highest positive LOD score.  In a set of families, 
the overall probability of linkage is the product of the probabilities in each 
individual family.493, 494, 496 
Standard LOD score analysis is a parametric linkage approach where the 
inheritance pattern, penetrance of the trait and gene frequency must be 
known or correctly estimated.  If these parameters are incorrectly defined, 
the results can be skewed.  In complex diseases, parametric analysis often 
uses both recessive and dominant inheritance models with different gene 
frequencies and penetrance values to see which model gives the highest 
LOD score.  However, when performing multiple tests, the threshold for a 
significant linkage score has to be increased accordingly. 
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Non-parametric linkage analysis is the method of choice for mapping 
complex disease genes since prior knowledge of the parameters that define 
the mode of inheritance is not required.493  Non-parametric linkage analysis 
is based on the higher than expected sharing of alleles by affected 
individuals.  Affected-sibling pair (ASP) analysis is the predominant method 
used and involves monitoring of alleles which are identical by descent 
(IBD).493, 497  However, the major disadvantage of this methodology is loss of 
statistical power because it is often difficult to determine whether two alleles 
are identical by state (IBS) or IBD.  Consequently more families are needed 
than for parametric analysis493 and the analysis is limited to pedigrees of 
moderate size since computational time increases exponentially with the 
number of individuals included.498 
For simple Menedelian traits, a parametric LOD score >3 in two-point 
analysis has traditionally been used as significant evidence of linkage and 
this corresponds to a 5% significance level for a specific locus and a 9% 
genome-wide significance level.  To minimise false-positive linkage results in 
complex diseases, more stringent criteria have been suggested.  According 
to the widely accepted criteria of Lander and Kruglyak, the linkage results 
are classified into the following three categories: suggestive of linkage, 
significant evidence of linkage and highly significant evidence of linkage.499  
These would be expected to occur 1, 0.05 and 0.001 times in a genome scan 
respectively.  These criteria have been questioned and only replication of a 
significant linkage result in a further sample can be interpreted as confirmed 
linkage.500 
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1.3.11.f Linkage disequilibrium (LD) mapping 
LD is where alleles at two or more linked loci on the same chromosome 
occur together more often than by chance.  LD is disrupted by 
recombination, mutation and gene conversion events.  Mean LD declines 
with chromosomal distance, but there is large variation between different 
chromosomal regions.  Recombination will rarely separate loci that lie very 
close together on a chromosome, because only a crossover located precisely 
in the small space between the two loci will create recombinants.495  
Therefore sets of alleles on the same small chromosomal segment tend to be 
transmitted as a block through a pedigree.  Considerable variation exists in 
the size of the blocks in different genomic regions (from 1kb to 200kb).  
Such a block of alleles is a haplotype and these mark recognisable 
chromosomal segments which can be tracked through pedigrees and 
populations.495  The European and Asian haplotypes are almost identical479, 
501 - characteristics in agreement with the “out of Africa” theory.502   
The allelic structure of haplotype blocks is promising for genome-wide LD 
mapping as they can be treated for mapping purposes as alleles at a single 
highly polymorphic locus.495  Over 80% of the haplotypes of a block are 
defined by less than 10% of the total SNPs of the block.  Therefore only 2 or 
3 SNPs per block, known as tag SNPs, may be needed to identify a block.  
However, the haplotype map for the whole genome must first be constructed 
– involving the typing of millions of SNPs in order to identify the tag SNPs.  
Subsequently, a much smaller subset of SNPs will need characterisation for 
whole genome LD mapping.501, 503, 504 
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1.3.11.g Use of population isolates 
Population isolates have proven useful for mapping and cloning Mendelian 
disease genes.  They offer the advantages of common environment and 
culture thus helping to reduce some of the background environmental noise 
surrounding complex diseases.  Some population isolates such as Finland, 
have the advantage of good genealogical records.489  Nevertheless, the 
population history and structure of genetic isolates together with the 
expected disease allele frequency are key considerations when choosing a 
population isolate for complex disease genetic study.505  In young population 
isolates (<100 generations), such as Finland and Iceland, allelic 
heterogeneity is reduced, but due to a relatively large number of founders it 
may still be too high for successful mapping of a common complex disease.  
Very young isolates (<20 generations), such as sub-isolates in the 
Netherlands and French Canada have study advantages as they have 
experienced a very narrow bottleneck following rapid genealogical 
expansion.  In these populations the allelic heterogeneity is reduced and LD 
is thought to extend over longer sections of DNA compared with young 
isolates.489, 506 
 
1.3.12 The VEGF gene 
1.3.12.a General considerations 
The gene for VEGF is located on chromosome 6p.21 (Figure 1.25).359, 507  
The VEGF gene is highly polymorphic (Figure 1.28) with at least 15 SNPs 
described in the promoter region and 5’-untranslated region.13, 508, 509  It is 
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therefore likely that this area of the VEGF gene represents a genetic “hot 
spot” and may be a region of key biological importance.510  In a Manchester, 
UK based population of 115 mixed race healthy individuals, Watson et al 
identified the presence of 15 polymorphic sequences within the VEGF gene 
after screening 1262 base pairs (bp) of the VEGF promoter and all of exon 1 
using PCR-single-stranded conformation polymorphism (SSCP) analysis.13  
Eight of the polymorphisms identified either created a new restriction 
endonuclease recognition site or destroyed an existing site.13  PCR-restriction 
fragment length polymorphism (RFLP) typing strategies were developed for 
ten of the polymorphisms described including the two most common 
polymorphisms at -460 and +405.13 
The two most common promoter/5’-UTR SNPs are a CT transition at 
position –460 (Genebank accession number rs833061) in the promoter 
region and a GC transversion at position +405 (Genebank accession 
number rs2010963) in the 5’-UTR.  These SNPs are useful for association 
studies as they occur at highest frequency in this area of the gene and have 
been implicated as candidate SNPs in diseases with a putative angiogenic 
basis.511, 512  Watson et al have previously documented significant linkage 
disequilibrium between the -460 and the +405 SNPs in the VEGF gene.13  To 
ascertain haplotypes for the two polymorphisms at -460 and +405 they 
developed a combined sequence specific priming (SSP) PCR typing system 
which identified the cis/trans orientation of each allele.  The -460 C/+405 G 
haplotype was found to be the most commonly observed haplotype in the 
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normal population.  The -460 C/+405 C haplotype was very rare and only 
observed in one out of the 230 chromosomes analysed (frequency=0.004).13 
 
Figure 1.28 - The gene for vascular endothelial growth factor (VEGF) is highly 
polymorphic.  A small section of the VEGF gene sequence showing a large number of 
polymorphisms (highlighted in yellow). 
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1.3.12.b Regulation of VEGF gene expression 
VEGF gene expression is tightly regulated, mostly at the transcriptional level, 
but also at the translational and post-translational levels. 
Hypoxia is the major regulator, via binding of hypoxia inducible factor (HIF)-
1 and HIF-2, each consisting of two subunits (α and β) to the hypoxia-
responsive element (HRE) located in the VEGF promoter.513, 514  Other 
mechanisms regulating VEGF transcription include several growth factors 
[e.g., epidermal growth factor (EGF), platelet-derived growth factor (PDGF), 
insulin-like growth factor (IGF)-1, tumour necrosis factor (TNF)-α, 
transforming growth factor (TGF)-α, TGF-β] and inflammatory cytokines 
(e.g., IL-1a, IL-1b, IL-6, IL-10 and IL-13).372 
Hormones are also important regulators of VEGF gene expression.  Thyroid 
stimulating hormone (TSH) has been shown to induce VEGF expression in 
several thyroid carcinoma cell lines.515  Adrenocorticotrophic hormone 
(ACTH) is able to induce VEGF expression in cultured human fetal adrenal 
cortical cells516 and several studies have implicated sex steroids as an 
important stimulus for VEGF regulation in hormone-sensitive tissues.  The 
gonadotropins have been shown to be potent inducers of VEGF transcription 
in the ovary, both in vivo311, 443 and in vitro.517  Oestradiol has been shown to 
directly activate VEGF transcription through a variant oestrogen response 
element located 1.5kb from the transcription start518 and progestins have 
also been reported to induce VEGF gene transcription in endometrial 
carcinoma cells.519 
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1.3.12.b.i Transcriptional factors 
There have been a number of potential binding sites identified in the 5’-
flanking region of the VEGF gene with the most important being specific 
protein-1 (Sp1), hypoxia-inducible factor 1 (HIF-1), signal transducer and 
activator of transcription-3 (Stat-3) and activator protein-1 (AP-1).520 
Via phosphorylation modification, the transcriptional activity of Sp-1 can be 
regulated by affecting its DNA binding ability.521  There have been four 
possible Sp-1 binding sites identified in the -38 to -109bp relative to the 
transcriptional start site.520  These binding sites are essential for basal 
transcription of the VEGF gene and TNF-α dependent promoter activation in 
a human gliomas cell line.522  Other factors may have an influence on Sp-1 
activity including tumour suppressor genes von Hippel Lindau (VHL), p53, 
p73 and oncogenes such as Ras, Src and HER2/neu.  These genes can also 
have an effect on the transcriptional activity of HIF-1.520  Stat3 binding sites 
have been localised to -842 to -849bp and it is activated by a variety of 
factors including EGF, PDGF, VEGF and IL-6.523  There are a putative four 
AP-1 binding sites in the promoter region of the VEGF gene and the 
signalling occurs through the protein kinase C (PKC) and MAP kinase 
pathway.520 
1.3.12.c Biological effect of VEGF single nucleotide polymorphisms 
As mentioned above the VEGF gene is highly polymorphic and there have 
been many studies looking at the various polymorphisms in relation to 
disease associations, functional significance and prognosis in relation to both 
individual SNPs and more functionally the associated haplotypes (Table 1.3).  
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As can be seen from the table there is a huge amount of variation in results 
with contradictory findings in many studies. 
Table 1.3 – The major papers describing VEGF SNP biology.  The table summarises the 
available evidence on the topic of VEGF SNP biology.  Nomenclature of SNPs varies in the 
literature with some groups defining the distance of the SNP from transcription start and 
others from translation start.  The equivalent SNPs are: -1540 CA (Genebank accession 
number rs699947) = -2578; -460 CT (rs833061) = -1498; -116 GA (1570360) = -
1154; +405GC (rs2011063) = -634).  The +936 CT is in the 3’ untranslated region and 
is consistently named. 
Study -460 
Associations 
+405 
Associations 
Genotype 
Functional 
Haplotype 
Haplotype 
Functional 
Other SNPs & 
Prognostic 
Watson 200013 
  Stimulated VEGF 
Production 
+405 GG>GC>CC 
   
Renner 
2000524 
  +936 T allele 
decreased plasma 
VEGF in healthy 
subjects 
   
Awata 
2002511 
 +405 CC 
diabetic 
retinopathy 
+405 CC 
increased basal 
serum VEGF in health 
subjects 
   
Shahbazi 
2002525 
  -1540 CC & -116 GG 
increased stimulated 
VEGF 
  -1540 C Allele & 
-116 G Allele 
increases renal 
allograft failure 
McCarron 
2002526 
     -116 AA 
Prostate Cancer 
Howell 
2002527 
   -1540/-116/+405 
CAC 
melanoma less 
advanced disease 
 -116 AA genotype 
melanoma less 
advanced and thinner 
disease 
Lambrechts 
2003342 
 +405 GG 
amyotrophic 
lateral sclerosis 
+405 G Allele 
impairs IRES B 
translation 
-116 A Allele 
reduces VEGF 
Transcription 
-1540/-116/+405 
AAG & AGG 
amyotrophic lateral 
sclerosis 
-1540/-116/+405 
AAG & AGG 
low VEGF Production 
-116 AA 
amyotrophic lateral 
sclerosis 
Stevens 
2003528 
    -1540/-460/-160/-
152/-116/+405 
ACTAGG>ACCAAG=w
ild type CTCGGC 
Basal & stimulated 
VEGF Production 
 
Chen 
2003529 
-460 T allele 
calcium 
oxylate kidney 
stones 
     
Yang 
2003530 
  -2549 18bp DD 
genotype increased 
VEGF transcription 
  -2549 18bp DD 
genotype 
diabetic nephropathy 
Lin 2003531 
-460 T allele 
Prostate 
Cancer 
     
Ray 
2004532 
-460 C allele 
proliferative 
diabetic 
retinopathy 
     
Hsieh 
2004533 
-460 T allele 
increased risk 
endometriosis 
     
Boiardi 
2004534 
 +405 C allele 
giant Cell 
arteritis 
-2549 18 bp 
Insertion/Deletion 
polymorphism II 
genotype 
increased stimulated 
VEGF production 
  -2549 18bp Insertion 
giant cell arteritis 
Cooke 
2004535 
 +405 G allele 
retinopathy of 
prematurity 
    
Young 
2004417 
 +405 CC 
Psoriasis 
    
Papazoglou 
2004536 
     +936 T allele 
severe pre-eclampsia 
Papazoglou 
2004537 
     +936 T allele 
pre-term delivery 
Salvarani 
2004538 
 +405 C allele 
Bechet’s 
disease 
-2549 18bp II 
increased stimulated 
VEGF in healthy adults 
  -2549 18bp I 
Bechet’s disease 
+936 T allele uveitis 
139 
 
Study -460 
Associations 
+405 
Associations 
Genotype 
Functional 
Haplotype 
Haplotype 
Functional 
Other SNPs & 
Prognostic 
Szeto 
2004539 
     -1540 A allele 
worse survival for 
peritoneal dialysis 
patients 
-1540 CC genotype 
high serum & low 
peritoneal dialysate 
VEGF levels 
Kariyazono 
2004540 
 +405 G allele 
coronary 
artery lesions 
in Kawasaki’s 
    
Koukourakis 
2004541 
  +405 GG 
decreased VEGF 
expression and 
vascular density in 
non-small cell lung 
cancer (NSCLC) 
  -1540 CC 
decreased VEGF 
expression & vascular 
density in NSCLC 
-116 GG 
increased VEGF 
expression in NSCLC 
Wolf 
2004542 
     +936 C allele 
increased FDG PET 
uptake in breast 
cancer 
Lu 
2005543 
     +405 GG genotype 
worse overall survival 
-460/+405/+936 TCC 
haplotype 
better overall survival 
in breast cancer 
Jin 
2005544 
     +405 CC genotype & 
-1540/+405 CC 
haplotype 
large tumours and 
high grade in breast 
cancer 
Kim 
2005545 
     -1540 CC genotype 
poor grade in bladder 
cancer 
Medford 
2005546 
     +936 T allele 
ARDS & increased 
APACHE scores 
Bhanoori 
2005547 
 +405 GG 
endometriosis 
 -460/+405 T/C 
lower in 
endometriosis 
  
Tzanakis 
2006548 
     +405 CC genotype 
larger, higher grade 
tumours & worse 
survival in gastric 
cancer 
Rueda 
2006549 
     -116 G & +405 C 
alleles 
-116/+405 GC 
haplotype 
increased risk of 
Henoch-Schönlein 
purpura with 
nephritis 
Sfar 
2006550 
 +405 C allele 
prostate 
cancer 
   -116 A &  
+405 C alleles 
development and 
higher grade in 
prostate cancer 
Hefler 
2007551 
     -1540/-116/+405 
CGC homozygous 
haplotype 
worse overall survival 
in ovarian cancer 
Kim 
2007552 
     +936 T allele 
worse survival in all 
gastric cancer 
-460 C allele 
worse survival in 
stage 0 & 1 gastric 
cancer 
 
Kong 
2007553 
     +405 CC genotype 
better survival in 
hepatocellular cancer 
Langsenlehner 
2007554 
     +405 C allele 
small tumour size in 
breast cancer 
Kim 
2008555 
     +936 T allele 
better survival in 
acute myeloid 
leukaemia (AML) 
-1540/-460/+405 
CTG haplotype 
worse survival in AML 
Kim 
2008556 
     +405 GG genotype & 
+936 T allele & 
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Study -460 
Associations 
+405 
Associations 
Genotype 
Functional 
Haplotype 
Haplotype 
Functional 
Other SNPs & 
Prognostic 
-1540/+405/+936 
CGC haplotype 
worse survival in 
colorectal cancer 
Lurje 
2009557 
     +405 C allele 
worse progression 
free survival in stage 
II colon cancer 
Maltese 
2009558 
   -1540/-460/+405 
ACG & CCC 
haplotypes 
increased risk of 
colorectal cancer 
 -1540 AA genotype 
increased risk of 
colorectal cancer 
Masago 
2009559 
     -1540 AA genotype 
-460 CC genotype 
-116 A allele 
worse survival in 
advanced non-small 
cell lung cancer 
Pastuszczak 
2009560 
     +405 GG genotype 
Worse 30 day 
mortality following 
coronary artery 
bypass grafting 
Smerdel 
2009561 
     -460 CT & +405 CG 
genotypes 
better survival in 
ovarian cancer 
Lambrechts 
2009562 
   -1540/-116/+405 
AAG & AGG 
no longer associated 
in amyotrophic lateral 
sclerosis meta 
analysis 
 -1540 AA genotype 
Amyotrophic lateral 
sclerosis in males 
only 
Bradbury 
2009563 
     +936 C allele & 
-460/+405/+936 CGC 
worse survival in 
oesophageal cancer 
Dassoulas 
2009564 
     -1540 A & +936 T 
alleles 
trend to association 
with colorectal cancer 
-1540 A, +405 C & 
+936 T alleles 
worse survival in 
colorectal cancer 
Steffensen 
2010565 
   -1540 C allele 
-460 T allele 
+405 C allele 
increased serum 
VEGF in ovarian 
cancer 
 -1540/-460/-116/ 
+405/+936 ACGGC 
Improved survival in 
ovarian cancer 
 
Hansen 
2010566 
     -1540 CA, -460 CT & 
+405 CG genotypes 
Response to 
chemotherapy in 
colorectal cancer 
Kim 
2010567 
     -1540 C & -460 C 
allele and 
-1540/-460/+405 
ACG homozygous 
haplotype 
disease progression 
in chronic myeloid 
leukaemia 
Hansen 
2010568 
  -460 T allele & 
+405 C allele 
increased VEGF 
expression in normal 
but not cancerous 
colorectal tissue 
   
Riuz 
2010569 
     -116 GG genotype 
local invasion in head 
and neck cancer 
Lorenzen 
2010570 
     +936 T allele 
worse event free 
survival oesophageal 
cancer 
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There are a variety of oncological and non-oncological diseases where 
positive findings have been made, with the common theme of the diseases 
being a putative link with angiogenesis. 
From a functional perspective, a significant correlation has been observed 
between VEGF protein production and the VEGF +405 polymorphism in both 
healthy13 and disease states.342, 511, 532  Watson et al observed a significant 
correlation between +405 genotype and LPS-stimulated peripheral blood 
mononuclear cell (PBMC) VEGF protein production in healthy subjects, with 
lowest VEGF protein production observed for CC homozygotes and highest 
production for GG homozygotes.13  Further work from the Manchester group 
using a promoter readout assay to analyse the effect of the VEGF -460/+405 
polymorphisms on VEGF gene expression, showed that a complex haplotype 
containing the VEGF -460C and +405G alleles, is associated with 71% higher 
basal VEGF promoter activity when compared with wild type.528  The study 
describes two promoter haplotypes containing the VEGF -460C and +405G 
alleles, which differ in activity - those containing the -160 CT (minor allele 
frequency 0.017) or the -116 GA (minor allele frequency 0.3) 
polymorphisms.528  This suggests that one or both of these SNPs may be 
functionally influential in VEGF production in a haplotype which contains the 
VEGF -406C and +405 G alleles.512, 528 
Elevated serum VEGF levels have also been associated with the +405 C allele 
in patients with retinopathy and Type 2 diabetes.511  However, it is arguable 
that it is inappropriate to measure VEGF in serum, as platelets represent a 
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large source of stored VEGF which can be released on serum collection.571  
Elevated plasma levels of VEGF have been documented in association with 
the +405 C allele in patients with amyotrophic lateral sclerosis342 and the 
+405 G allele was observed to reduce both internal ribosome entry site 
mediated VEGF expression and translation of the large (L)-VEGF isoform.342 
The 5'-UTR of VEGF  contains two internal ribosome entry sites, (IRES)-A at 
nucleotide +744 to +1037 and IRES-B at nucleotide +90 to +482, both of 
which are involved in enhancing  the translation of adenine-uracil-guanine 
(AUG)-initiated VEGF.572  However, the predicted secondary structure of the 
IRES-B sequence is significantly remodelled for the +405 G allele and it has 
been suggested that this could make the IRES-B site less optimal for IRES-
dependent VEGF translation.342  L-VEGF is 205 amino acid residues longer 
than the AUG-initiated VEGF forms due to initiation of VEGF translation at 
the first (out of four) cytosine-uracil-guanine (CUG) codons which is situated 
at position +498 in the 5'-UTR.573  Analysis of the secondary structure of the 
5'-UTR shows that this initiation codon is located in the immediate vicinity of 
+405 GC.  Thus sequence variation at this site could significantly alter the 
structure of the translation initiation codon and could result in reduced 
production of VEGF.342  L-VEGF is proteolytically cleaved at the peptide signal 
sequence, converted to the shorter isoforms (VEGF121, VEGF165 and VEGF189) 
isoforms and secreted into the extracellular milieu.573  The role of L-VEGF is 
not clear although it may serve as a reservoir for generation of the shorter 
isoforms.572  Therefore, a reduction in both internal ribosome entry site 
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mediated VEGF expression and translation of the large L-VEGF isoform could 
result in lower plasma levels of VEGF in patients with the +405 G allele.342 
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Chapter 2  – Prognostic factors relating to sex steroid 
receptors in meningiomas 
 
2.1 Clinical Material and Methods 
All patients with a histologically confirmed diagnosis of Meningioma operated 
on between 1988 and 1998 in the Department of Neurosurgery, Royal 
Preston Hospital were recruited for this study.  Clinical information was 
obtained from the hospital case notes together with special files 
prospectively kept for the Meningioma follow up clinic run in the department.  
Where patients were lost to follow up, an attempt was made to contact their 
General Practitioner to confirm their current status.  Recurrence was defined 
as either reappearance at the site of a previously fully resected tumour or 
enlargement in size of the residual tumour on follow up imaging. 
2.1.1 Steroid Receptor Immunohistochemistry 
The tumours were evaluated for presence of progesterone receptors (PR) 
and oestrogen receptors (ER) using immunohistochemistry. 
The antibodies used were a polyclonal rabbit anti-human antibody (Dako UK 
Ltd., Ely, Cambridgeshire) and a monoclonal mouse anti-human oestrogen 
receptor α, clone 1D5 (Dako UK Ltd., Ely, Cambridgeshire). 
The archival formalin fixed paraffin embedded tissue blocks of the 
meningiomas were sectioned at 5μm, mounted on glass slides and dewaxed 
in xylene and graded alcohols.  Epitope retrieval was achieved by 
microwaving in a pH 9 citrate buffer for 20 minutes.  The primary antibodies 
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were applied to consecutive levels of the Meningioma for 30 minutes at room 
temperature.  The Dako duet kit solution (Dako UK Ltd., Ely, 
Cambridgeshire) containing biotinylated goat anti-mouse/rabbit 
immunoglobulin was applied followed by the streptavidin label and the 
chromogen diaminobenzidine which ultimately stains the receptors brown.  
The sections were counterstained with haematoxylin, dehydrated, mounted 
and examined by light microscope.  A positive result was registered when 
more that 10% of the cells were stained brown.  Known positive controls of 
ductal breast carcinoma were run in each batch.  Negative controls were 
prepared by omitting the primary antibody and replacing it with normal 
serum. 
The sections were examined by two histopathologists and a neurosurgeon 
assessing for nuclear and cytoplasm positivity for both progesterone and 
oestrogen receptors.  In addition the meningioma histological subtype was 
determined by both the histopathologists. 
Steroid hormone receptors are found in the cytoplasm of cells but are only 
functionally active in the nucleus.  The immunohistochemical analysis of the 
receptors has the advantage over cytosol assays in that the receptors can be 
localised to the biologically active nucleus. 
2.1.2 Statistical Analysis 
The Chi squared or Fisher’s exact test with the Mantel-Haenszel estimate of 
common odds ratio were undertaken to compare differences in proportions.  
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Kaplan-Meier survival analysis with log rank testing and the Cox proportional 
hazards model were used to estimate differences in survival. 
 
2.2 Results 
 There were 102 patients in total during this time period with 74 females and 
28 males.  Mean age at presentation was 60 years 9 months (range 27 to 
87).  Mean follow up was 7 years 7 months (maximum 17 years 2 months). 
2.2.1 Histological Subtypes 
The distribution of histological grade was typical with 88 (87%) being grade 
1.  Overall 11 (10%) were grade 2 or atypical and 3 (3%) were grade 3 or 
anaplastic (Figure 2.1).
 
Figure 2.1 - Distribution of Meningioma histological subtypes.  The majority of tumours 
were grade 1.  Grade 2 (atypical) and grade 3 (anaplastic) tumours are exploded on the 
pie chart 
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2.2.2 Steroid Receptor Status 
There was 100% Agreement in designation of tumour receptor status 
between the 3 independent assessors (Figure 2.2). 
Nuclear progesterone staining was positive in 56 (55%) of all tumours.  
Cytoplasmic progesterone receptor staining was positive in 90 (88%) of 
tumours including 35 out of the 46 nuclear progesterone receptor negative 
patients.  Nuclear oestrogen receptor staining was very rare with only 1 case 
(1%) positive in the whole cohort.  Oestrogen receptor cytoplasmic staining 
was more frequently seen in 54 (53%) of all tumours. 
A B
C
 
Figure 2.2 – Immunohistochemistry results of steroid receptors.  Sections showing 
immune-staining for tumours that are: A – nuclear and cytoplasm receptor positive; B – 
cytoplasm receptor positive and C – nuclear and cytoplasm negative. 
There was a significantly higher proportion of males that were progesterone 
receptor negative compared to females (Figure 2.3). 
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Figure 2.3 - Progesterone receptor status by gender.  Meningiomas in males are 
significantly more likely to be progesterone receptor negative; males 60.7% females 
37.8% PR negative (χ2 = 4.312, df = 1, p = 0.038) 
  
0
10
20
30
40
50
60
70
80
Female Male
N
u
m
b
e
r 
o
f 
P
a
ti
e
n
ts
PR Negative
PR Positive
Progesterone Receptor Status by Gender
*
149 
 
There was a strong association with progesterone receptor status and 
tumour grade.  All of the 14 grade 2 or 3 Tumours were progesterone 
receptor negative (Figure 2.4). 
 
Figure 2.4 - Progesterone receptor status by meningioma tumour grade.  There is a strong 
association with higher grade of tumour and negative PR status (χ2 = 20.555, df = 1, p = 
0.000003) 
 
2.2.3 Recurrence 
There were 9 patients that recurred at a mean time of 3 years 4 months and 
median time of 2 years 3 months from initial diagnosis (Range 1 year to 8 
years 9 months) (Table 2.1). 
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Non-
Recurrent 
(%) 
Recurrent 
(%) 
Total 
Odds 
Ratio 
Fisher’s/ 
χ2 
P value 
 
All Patients  93 (91) 9 (9) 102   
 
Gender 
Male 27 (96) 1 (4) 28 
NS 0.438 
Female 66 (89) 8 (11) 74 
 
Progesterone 
Receptors 
Nuclear +ve 55 (96.5) 2 (3.5) 57 
5.066 0.041* 
Nuclear -ve 38 (84) 7 (16) 45 
Cytoplasm +ve 83 (92) 7 (8) 90 
NS 0.286 
Cytoplasm -ve 10 (83) 2 (17) 12 
 
Oestrogen 
Receptors 
Nuclear +ve 1 (100) 0 (0) 1 
NS 1.000 
Nuclear -ve 92 (91) 9 (9) 101 
Cytoplasm +ve 48 (89) 6 (11) 54 
NS 0.495 
Cytoplasm -ve 45 (94) 3 (6) 49 
 
WHO Tumour 
Grade 
Grade 1 84 (94.5) 4 (4.5) 88 
11.667 0.002** 
Grade 2 & 3 9 (64) 5 (36) 14 
 
Simpson Grade 
Grade 1 27 (96) 1 (4) 28 
NS 0.100 
Grade 2 26 (96) 1 (4) 27 
Grade 3 6 (86) 1 (14) 7 
Grade 4 20 (77) 6 (23) 26 
Grade 5 2 (100) 0 (0) 2 
 
Dichotomised 
Simpson Grade 
Grade 1 & 2 53 (96) 2 (4) 55 
6.623 0.025* 
Grade 3,4 & 5 28 (80) 7 (20) 35 
 
Table 2.1 – Factors relating to recurrence of meningiomas.  There are significant 
associations with recurrence and progesterone receptor negativity, higher WHO grades 
and decreased resection as categorized by a dichotomised Simpson grade. 
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There was a strong association with atypical/anaplastic grade tumours 
(grade 2 and 3) and recurrence (Figure 2.5). 
 
Figure 2.5 - Recurrence by tumour grade.  There was a significantly higher risk of 
recurrence with grade 2 or 3 histology (χ2 = 14.586, df = 1, Fisher's Exact 2-sided p = 
0.002; Odds ratio = 11.667, 95% CI 2.646 to 51.438) 
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Kaplan-Meier plots show a significantly worse progression free survival for 
patients with atypical or anaplastic tumours (Figure 2.6). 
 
Figure 2.6 - Kaplan-Meier plot of progression free survival by tumour grade (grade 1 vs. 
grade 2 & 3).  There was a significantly higher recurrence rate in the grade 2 & 3 patients 
(Log rank = 17.127, p = 0.000035) 
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There was no difference in recurrence between males and females (Figures 
2.7 & 2.8) 
 
Figure 2.7 - Meningioma recurrence rate by gender.  There was no difference in recurrence 
rate between males and females (χ2 = 1.323, df = 1, Fisher's Exact 2-sided p = 0.438) 
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Figure 2.8 - Kaplan-Meier plot of progression free survival by gender.  There was no 
difference in recurrence of tumour between males and females (Log rank = 0.938, df = 1, 
p = 0.333) 
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Overall there was a non-significant trend of association with reduction of 
surgical resection on the Simpson grade and recurrence (Figure 2.9). 
 
Figure 2.9 - Recurrence by individual Simpson meningioma resection grade.  There was a 
non-significant trend of increase in recurrence with higher Simpson grades ie more 
residual tumour (χ2 = 7.780, df 4, p = 0.100) 
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When the Simpson grade is dichotomised between grades 1 and 2 (no 
residual tumour with either excision or diathermy of dura) and 3,4 and 5 
(dural origin unable to be diathermised, subtotal removal or biopsy) then 
there is a significant association with the grade 3,4 and 5 group and 
recurrence (Figures 2.10 & 2.11). 
 
Figure 2.10 - Recurrence rate with dichotomised Simpson grade.  There is a significant 
increase in recurrence with the grade 3,4 &5 group (χ2 = 6.364, df = 1, Fisher's Exact 2-
sided p = 0.025; Odds ratio = 6.623, 95% CI 1.289 to 34.483) 
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Figure 2.11 - Kaplan Meier plot of recurrence by dichotomised Simpson grade group.  
There is a significantly increased risk of recurrence with the grade 3,4 & 5 group (Log rank 
= 6.748, df = 1, p = 0.009) 
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There is an association with progesterone receptor negativity and 
meningioma recurrence (Figures 2.12 & 2.13). 
 
 
Figure 2.12 - Recurrence by progesterone receptor status.  There is an increase in 
recurrence rate for meningiomas that are progesterone receptor negative (χ2 = 4.536, df 
= 1, Fisher's Exact 2-sided p = 0.041; Odds ratio = 5.066, 95% CI 0.998 to 25.725) 
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Figure 2.13 - Kaplan-Meier plot of recurrence by receptor status.  There is a significantly 
increased risk of recurrence for meningiomas that are progesterone receptor negative 
(Log rank = 4.760, df = 1, p = 0.029) 
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2.2.4 Cox Proportional Hazards Model 
The significantly associated variables of tumour grade, extent of surgical 
resection classified by Simpson grade and progesterone receptor status were 
entered into a proportional hazards model.  The overall model was 
significant with only the dichotomised Simpson grade maintaining 
significance with atypical/anaplastic histology on the borderline of 
significance (Table 2.2).  In this multivariable model progesterone receptor 
negativity was not an independent predictor of recurrence. 
 
 
P 
value 
Risk 
Ratio 
95% CI for RR 
Lower Upper 
Atypical/Anaplastic 
(Tumour grade 2&3) 
.070 4.657 .882 24.596 
Progesterone Receptor 
Negative 
.431 2.204 .308 15.788 
Simpson Grade 3,4 & 5 .042 5.222 1.059 25.745 
Table 2.2 - Cox regression analysis results for factors relating to meningioma progression 
free survival.  Extent of resection as categorized by the dichotomized Simpson grade 
maintains significance with WHO tumour grade 2 & 3 borderline significant and 
progesterone receptor status not significant in this model. 
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Chapter 3 – The effect of neoadjuvant chemotherapy on 
operative blood loss and surgical resection for Choroid 
Plexus Carcinomas 
 
3.1 Clinical Material and Methods 
At the Hospital for Sick Children, Toronto, Canada 16 children with a 
diagnosis of Choroid Plexus Carcinoma were treated between 1982 and 
2004.  The charts, radiology and histology were reviewed for these patients. 
 
The patients were split into two groups: group 1 consisted of patients who 
did not receive any chemotherapy prior to the attempt at surgical resection 
of their tumour (n=8) and group 2 who following an initial biopsy to confirm 
the diagnosis of their lesion were given neoadjuvant chemotherapy prior to 
an attempted surgical resection (n=8).  The chemotherapy utilised was the 
ICE regimen (ifosfamide 3 g/m2 on days 1 and 2, etoposide 150 mg/m2 on 
days 1 and 2 and carboplatin 600 mg/m2 on day 3).  The patients received a 
median of 4 cycles of the ICE chemotherapy prior to the operation (range 2 
to 7). 
 
Blood loss for each operation was calculated in terms of red blood cell 
volume using the previously described technique(16) and the following 
formula: 
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CBL = RBC Volume Transfused + EBV x (Hct Pre Op – Hct Post Op) 
 
CBL, Calculated Blood Loss; RBC, Red Blood Cell; EBV, Estimated Blood 
Volume (80mls/Kg Weight); Hct, Hematocrit. 
 
Tumour volume was calculated from either CT or MR scans using a 3 
dimensional diameter method with the following formula:(17) 
 
Volume = 1/6 x π x D1 x D2 x D3 
 
D1 Anterior-Posterior Diameter; D2 Medial-Lateral Diameter; D3 Superior-
Inferior Diameter (Figure 3.1) 
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Figure 3.1 - Method for estimating tumour volume.  These T1 weighted MR scans with 
contrast in 3 orthognal planes demonstrate a choroid plexus carcinoma in the left lateral 
ventricle.  The estimation of tumour volume uses the formula for calculating the volume of 
a prolate ellipsoid by entering the three orthogonal diameters (D1-3) as measured on the 
scan. 
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3.1.1 Statistical Analysis 
Comparison of means was undertaken using t tests with Levene’s test for 
equality of variance.  Multivariable linear regression analysis was used to 
identify the relationship between blood loss and potential predictive 
variables.  Kaplan-Meier plots with the log rank test was used to analyse 
survival.  Statistical analysis was performed using SPSS for Windows release 
16.0.2  2008.  Chicago: SPSS inc. 
 
3.2 Results 
3.2.1 General 
The 16 patients consisted of 10 males and 6 females.  The median age at 
presentation of all the patients was 21 months with a median duration of 
symptoms of 4 weeks.  CSF diversion was required in 12 of 16 patients at 
some point during their treatment.  There was no difference in the pre-
operative characteristics of the two treatment groups in terms of tumour 
size, age or weight of patient (Table 3.1).  There was one peri-operative 
death secondary to haemorrhage in a child who had not received pre-
operative chemotherapy.  This child was excluded from survival analysis. 
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By Operations 
Group 1 
No-Chemotherapy 
(n=13) 
Group 2 
Pre-Operation Chemotherapy 
(n=11) 
 
 Mean SE Mean SE P Value 
Age 
 
3 yr 5 mo 1 yr 3 mo 1 yr 9 mo 7 mo 0.25 NS 
Patient Weight 
(kg) 
15.5 4.3 12.9 1.8 0.60 NS 
Size of Tumour 
(cm3) 
82.1 16.7 55.3 22.5 0.34 NS 
 
By Patient 
Group 1 
No-Chemotherapy 
(n=8) 
Group 2 
Pre-Operation Chemotherapy 
(n=8) 
 
 Mean SE Mean SE P Value 
Age 
 
3 yr 7 mo 1 yr 6 mo 2 yr 0 mo 9 mo 0.38 NS 
Patient Weight 
(kg) 
15.0 5.0 13.0 2.4 0.72 NS 
Size of Tumour 
(cm3) 
80.2 20.9 72.0 29.0 0.82 NS 
Table 3.1 – Characteristics of the two treatment groups by operations undertaken and 
patient.  There was no difference in the pre-operative age, weight or size of the tumour 
between groups. 
 
One patient experienced marked cerebral oedema following her first cycle of 
chemotherapy which led to a hemiparesis that ultimately resolved and 
cortical blindness that was permanent.  No other patients developed a 
permanent neurological deficit whilst on the chemotherapy regimen.  The 
number of cycles of chemotherapy administered was dependent upon both 
response of the tumour and also the patients clinical condition.  Symptoms 
from mass effect of the tumour with raised intracranial pressure were 
treated with steroids during the chemotherapy treatment, however 
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uncontrollable pressure symptoms were often the indication to discontinue 
chemotherapy and undertake surgical resection of the tumour. 
 
The 16 patients underwent a total of 24 operations where the pre-operative 
surgical goal was gross total resection.  For both groups, operations where 
only a biopsy was performed (less that 5% of total tumour volume removed) 
were not included in the analysis of blood loss and tumour volume reduction. 
 
Figure 3.2 shows the year of presentation of each of the patients.  The 
patients in the two treatment groups presented throughout the time period 
of the study with equal numbers from each group in the first and last 8 
patients to present. 
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Figure 3.2 - Graph demonstrating the year of presentation of each of the patients in the 
two treatment groups. 
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3.2.2 Blood Loss 
Operative blood loss was significantly reduced with pre-operative 
chemotherapy from a mean of 1.11 blood volumes in group 1 (n = 13, SE 
0.33) to 0.22 blood volumes in group 2 (n = 11, SE 0.07) (t = -2.66, p = 
0.02, two tailed)(Figure 3.3). 
 
Figure 3.3 - Mean operative blood loss as a percentage of total patient blood volume in the 
two treatment groups.  There was a significant reduction in blood loss in the neoadjuvant 
chemotherapy group (t = -2.66, p = 0.02, two tailed). 
 
A linear regression model was set up using blood loss/volume as the 
dependent variable and post-chemotherapy, age at operation and volume of 
tumour removed as independent variables.  Using the enter method, a 
significant model emerged (F = 4.125, p = 0.02. Adjusted R2 = 0.29).  P 
values for predictor variables are shown in table 2 with pre operative 
chemotherapy being the most significant variable and age at operation also 
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found to be significant.  The Beta value in table 2 indicates the relative 
contribution of the predictor variables to blood loss i.e. being in the post-
chemotherapy group contributes 52.9% of the total reduction (given the 
negative value) of blood loss seen.  Volume of tumour removed was not a 
significant variable in this model. 
 
Predictor variable Beta p 
Post-chemotherapy -0.529 p = 0.008** 
Age at operation -0.436 p = 0.042* 
Volume of tumour removed 0.343 p = 0.098 NS 
Table 3.2 – The predictors of blood loss in a linear regression model with blood 
loss/volume the dependent factor.  Neoadjuvant was the most significant factor with age 
at operation also significant but extent of surgical resection becoming non-significant in 
this model. 
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3.2.3 Extent of Surgical Resection 
Mean percentage of tumour removed was higher in group 2 (97.3%, n = 11) 
compared with group 1 (64.3%, n = 13) (t = 2.969, p = 0.01)(Figure 3.4).   
 
Figure 3.4 - Mean percent debulking between the two treatment groups.  There was a 
significantly higher mean percent debulking in the neoadjuvant chemotherapy group (t = 
2.969, p = 0.01). 
Gross total resection was ultimately achieved in seven out of eight patients 
in group 2 compared with only 4 out of eight in group 1. 
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3.2.4 Survival 
Kaplan-Meier survival analysis showed that gross total resection (Figure 3.5; 
Log rank = 6.107, df = 1, p=0.013) and age at presentation of 3 years or 
greater (Figure 3.6; Log rank = 4.860, df = 1, p=0.027) were associated 
with improved survival.   
 
Figure 3.5 - Kaplan-Meier plot for survival between total and partial resection groups.  
There is a significant survival advantage for those patients that underwent a gross total 
resection (Log rank = 6.107, df = 1, p=0.013). 
 
Overall Survival for Total and Partial Resection Groups (n=15)
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Figure 3.6 - Kaplan-Meier plot for survival between age groups.  There is a significant 
survival advantage for patients age 3 and over (Log rank = 4.860, df = 1, p=0.027). 
 
  
Overall Survival for Age Groups (n=15)
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Mean survival was 15 years 9 months (SE 2 years 11 months) in the gross 
total resection group compared with 1 year 11 months (SE 1 year 0 months) 
in patients with a partial resection (Figure 3.7). 
 
Figure 3.7 - Mean survival between total and partial resection groups.  There was a 
significant mean survial advantage for those patients in which a gross total resection was 
achieved (Log rank = 6.107, df = 1, p=0.013). 
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Looking at all the patients there was no survival advantage in the group 
receiving pre-operative chemotherapy.  However, in the under 3 age group 
(n = 9) there was a significant advantage in following this treatment 
paradigm (Figure 3.8). 
 
Figure 3.8 - Kaplan-Meier plot of overall survival between treatment groups in patients 
under 3 years old.  There was a significant survival advantage in the group receiving 
neoadjuvant chemotherapy (Log rank = 9.228, df = 1, p=0.002). 
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For the under 3 year olds, mean survival was 7 months (SE 3 months) in the 
group not receiving chemotherapy (n = 3) compared to 8 years 0 months 
(SE 11 months) in those who did (n = 6) (Figure 3.9; Log rank = 9.228, df = 
1, p=0.002). 
 
Figure 3.9 - Mean survival between treatment groups in patients under 3 years old.  There 
is a significant increase in mean survival in those patients receiving neoadjuvant 
chemotherapy (Log rank = 9.228, df = 1, p=0.002). 
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Chapter 4 – Single nucleotide polymorphisms of the 
vascular endothelial growth factor gene and their 
association with the development and survival of adult 
cerebral gliomas 
 
4.1 Clinical Material and Methods 
Samples from 129 patients with a confirmed diagnosis of glioma from 1980 
to 1997 in the Brigham and Women’s/Boston Children’s Hospital tumour 
bank were analysed.  Patient samples were either tumour or whole blood 
and were collected with prospective clinical information under Institutional 
Review Board approved protocols.  In addition 101 healthy adult controls 
were recruited for the study to donate whole blood.  The study adhered to 
the Declaration of Helsinki Guidelines and required all subjects to give 
written, informed consent. 
Clinical information was retrieved from the prospectively collected database 
of patients within the tumour bank. 
 
4.1.1 DNA Extraction 
DNA was extracted from tumour or whole blood using Qiagen DNA extraction 
kits.  Genomic DNA was isolated from whole blood and red cell pellets using 
Qiagen QIAamp DNA blood midi kit (Qiagen Ltd UK, Crawley, West Sussex, 
UK).  Samples of whole blood or red cell pellets were mixed with protease 
and incubated at 70oC for 10 minutes.  After further mixing with absolute 
ethanol the samples were loaded into QIAamp Midi columns and centrifuge 
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filtered, allowing DNA to remain within the filter but permitting residual 
waste to pass through.  After two washing steps the entrapped DNA was 
eluted from the filter with distilled water.  Quantification of DNA 
concentration and purity was performed using a spectrophotometer. 
 
4.1.2 VEGF SNP Genotyping 
Genotyping of the -460 and +405 VEGF SNPs (Genebank numbers rs833061 
and rs2010963) was performed using the SNP genotyping assay (Applied 
Biosystems, Foster City, CA).  A 10l rather than a 25l reaction volume was 
used but otherwise the assay was performed according to manufacturer’s 
instructions.  The primers and probes were designed using the assays-by-
design™ service for the -460 SNP (Applied Biosystems) and were available 
from the assays-on-demand™ service for the +405 SNP (Applied 
Biosystems).  Each PCR reaction contained 15ng genomic DNA, 5μl TaqMan 
Universal PCR Master Mix, No AmpErase UNG, 0.5μl 20X SNP Genotyping 
Mix, and 4.5μl DNase-free water.  PCR and genotyping analysis was 
performed using 96-well plates on an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems).  Thermal cycling conditions consisted of an 
initial denaturation step at 95oC for 10 minutes followed by 40 cycles at 92oC 
for 15 seconds (denature) and 60oC for one minute (anneal/extension). 
Allelic discrimination using the TaqMan assay is possible because the 
fluorescence signal generated by PCR amplification is indicative of which 
alleles are present within the sample. The technique is advantageous over 
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conventional techniques such as PCR-RFLP in that it requires no post-PCR 
manipulation or agarose gel electrophoresis.  
Two allele-specific probes are used which contain reporter and quencher 
dyes bound to a minor groove binder.  After strong probe binding, which is 
allele-specific, PCR causes probe disintegration (Figure 4.1).   
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Figure 4.1 - TaqMan allelic discrimination assay.  This utilizes two allele specific probes that 
when bound strongly with an allelic match, will result in disintegration at the next PCR cycle 
thus releasing the fluorescent dye from its quencher.  If there is no match then the probe will 
dislodge intact and not cause fluorescence. 
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Dissociation between reporter dye and quencher results in a fluorescent 
emissions which permits allelic discrimination.  The TaqMan genotyping 
method results in allele-specific fluorescent emissions which permits allelic 
discrimination using a computer software package (Figure 4.2). 
 
 
Figure 4.2 - Allelic discrimination software.  This program detects the fluorescence giving 
a read out of the genotype of the DNA in each well. 
 
Linkage disequilibrium for the -460 and +405 SNPs was investigated using 
the HelixTree programme (Golden Helix Inc, Montana, USA – 
www.goldenhelix.com) and the D’ and r2 normalised co-efficients of 
disequilibrium were estimated.  Haplotypes were determined from the 
unphased genotype data using the Expectation/Maximization (EM) algorithm 
and assigned to individuals using SNPHAP software (http://www-
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gene.cimr.cam.ac.uk/clayton/software/snphap.txt ).  This required 
confirmation that the populations were in Hardy-Weinberg equilibrium.30 
 
4.1.3 Statistical Analysis 
Hardy-Weinberg equilibrium for cases and controls at both the -460 and 
+405 SNPs was tested using Chi squared.  The Chi squared test with the 
Mantel-Haenszel estimate of common odds ratio was undertaken to compare 
differences in the observed genotype and haplotype frequencies.  Kaplan-
Meier survival analysis with log rank testing and the Cox proportional 
hazards model were used to estimate differences in survival. 
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4.2 Results 
 
4.2.1 General 
Ethnicity was similar in the patient and control groups (χ2 = 5.146, df = 3, p 
= 0.161).  There was a male predominance in the glioma group compared to 
the controls; however, there was no gender difference in -460 or +405 
genotype frequency for either group (-460 χ2 = 0.545, df = 2, p = 0.761;  
+405 χ2 = 3.236, df = 2, p = 0.198) (Table 4.1). 
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VEGF 
-460 Genotype 
χ2 
p value 
VEGF 
+405 Genotype 
χ2  
p value 
  Total CC (%) CT (%) TT (%)  CC (%) CG (%) GG (%)  
 
Controls 
All Controls 101 21 (21) 60 (59) 20 (20)  7 (7) 48 (47.5) 46 (45.5)  
 
Male Controls 26 8 (31) 16 (61) 2 (8) 
0.117 
0 (0) 12 (46) 14 (54) 
0.226 
Female Controls 75 13 (17) 44 (59) 18 (24) 7 (9) 36 (48) 32 (43) 
 
Patients All Patients 129 29 (22) 54 (42) 46 (36) 
0.014* 
vs. control 
19 (15) 53 (41) 57 (44) 
0.165 
vs. control 
 
Gender 
Male 77 19 (25) 31 (40) 27 (35) 
0.761 
10 (13) 28 (36) 39 (51) 
0.198 
Female 52 10 (19) 23 (44) 19 (37) 9 (17) 25 (48) 18 (35) 
 
Histology 
Astrocytoma 51 13 (26) 22 (43) 16 (31) 
0.055 
6 (12) 21 (41) 24 (47) 
0.219 
Oligodendroglioma 21 1 (5) 9 (43) 11 (52) 6 (29) 10 (48) 5 (24) 
Oligoastrocytoma 19 6 (31.5) 7 (37) 6 (31.5) 4 (21) 6 (32) 9 (47) 
Neuroepithelial 4 1 (25) 3 (75) 0 (0) 0 (0) 2 (50) 2 (50) 
Glioblastoma 34 8 (24) 13 (38) 13 (38) 3 (9) 14 (41) 17 (50) 
 
WHO 
Tumour 
Grade 
Grade 1  1 (12.5) 4 (50) 3 (37.5) 
0.723 
2 (25) 0 (0) 6 (75) 
0.200 
Grade 2  9 (35) 9 (35) 8 (30) 3 (12) 11 (42) 12 (46) 
Grade 3  11 (18) 28 (46) 22 (36) 11 (18) 28 (46) 22 (36) 
Grade 4  8 (24) 13 (38) 13 (38) 3 (9) 14 (41) 17 (50) 
 
Table 4.1 – Distribution of genotypes for adult gliomas.  For overall genotype there was a 
significant difference between patients and controls in distribution of frequencies at the 
VEGF -460 locus.  There was no difference in frequencies within the groups of gender, 
histology or tumour grade at either locus. 
 
Histological subtypes of the gliomas were 51 (40%) Astrocytomas, 21 (16%) 
Oligodendrogliomas, 19 (15%) Oligoastrocytomas, 34 (26%) Glioblastomas 
and 4 (3%) Neuroepithelial tumours.  The tumour grades for the study 
population were 8 (6%) grade one, 26 (20%) grade two, 61 (47%) grade 
three and 34 (27%) grade four. 
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4.2.2 VEGF -460 Locus 
At the VEGF -460 locus the overall distribution of genotype frequencies was 
significantly different to controls (Figure 4.3; χ2 = 8.556, df = 2, p = 0.014).  
The main factor for this was a significantly increased frequency of the TT 
genotype compared to controls (Figure 4.4; TT vs. non-TT χ2 = 6.961, df = 
1, p = 0.008; Odds ratio = 2.245, 95% CI 1.222 - 4.121). 
 
 
Figure 4.3 - Distribution of genotypes at the VEGF -460 locus.  There was a significant 
difference in frequency of genotypes between glioma patients and controls (χ2 = 8.556, df 
= 2, p = 0.014) but no difference in allele frequency (χ2 = 2.285, df = 1, p = 0.131). 
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Figure 4.4 - Distribution of homozygous genotypes at the VEGF -460 locus in adult 
gliomas.  There was a significant increase in the TT homozygous genotype in glioma 
patients compared to controls (TT vs. non-TT χ2 = 6.961, df = 1, p = 0.008; Odds ratio = 
2.245, 95% CI 1.222 - 4.121). 
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4.2.3 VEGF +405 Locus 
At the +405 locus there was no overall difference in genotype frequencies 
(Figure 4.5; χ2 = 3.605, df = 1, p = 0.165) but there was a trend of 
increased CC genotype that did not quite reach statistical significance (Figure 
4.6; CC vs. non-CC χ2 = 3.436, p = 0.06; Odds ratio = 2.319, 95% CI 0.934 
– 5.758). 
 
Figure 4.5 - Distribution of genotype and allele frequencies at the VEGF +405 locus.  There 
was no difference between in either genotype or allele frequency between glioma patients 
and controls (Genotype χ2 = 3.605, df = 2, p = 0.165; Allele χ2 = 1.070, df = 1, p = 0.300). 
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Figure 4.6 - Distribution of homozygous genotypes at the VEGF +405 locus in adult 
gliomas.  There was a trend towards increase in the CC homozygous genotype in glioma 
patients compared to controls (CC vs. non-CC χ2 = 3.436, df = 1, p = 0.064; Odds ratio = 
2.319, 95% CI 0.934 – 5.758).  
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4.2.4 Haplotype Analysis 
There was no significant difference in overall distribution of haplotype pairs 
comparing adult gliomas to controls (Figure 4.7).  There was however, in the 
glioma group a significant reduction in the frequency of subjects that carried 
a copy of the CG haplotype (Figure 4.8). 
 
  
Figure 4.7 - Distribution of haplotype pairs for the VEGF -460/+405 haplotype in adult 
gliomas.  There was no significant difference in haplotype pair frequencies (χ2 = 9.622, df 
= 5, p = 0.087). 
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Figure 4.8 - Individual haplotype frequencies for the VEGF -460/+405 haplotype.  There 
was a significantly reduced frequency of the CG haplotype in adult glioma patients 
compared to controls (χ2 = 6.961, df = 1, p = 0.008; Odds ratio = 0.446, 95% CI 0.243 to 
0.818). 
 
4.2.5 Tumour Grade 
There was no difference in tumour grade for any genotype of either the -460 
(χ2 = 3.656, df = 6, p = 0.723) or +405 SNPs (χ2 = 8.563, df = 6, p = 
0.200) (Table 4.1). 
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4.2.6 Survival Analysis 
Kaplan-Meier analysis of the grade 2 tumours (n=26) shows a significant 
survival advantage for the CC genotype (i.e. absence of the T allele) of the -
460 SNP, with mean survival of 10.9 years compared to 5.3 years for non-CC 
genotypes (Figure 4.9; Log rank = 5.679, df = 1, p = 0.017).  Five year 
survival was 89% for the -460 CC genotype group compared to 45% for the 
non-CC group (χ2 = 4.683, df = 1, p = 0.027). 
 
Figure 4.9 - Kaplan-Meier plot of overall survival in the grade 2 glioma patients between 
CC and non-CC genotypes at the VEGF -460 locus.  There was a significant survival 
advantage for the CC genotype patients (Log rank = 5.679, df = 1, p = 0.017) 
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For the grade 2 tumours at the +405 locus there appeared to be spreading 
of the Kaplan-Meier survival lines but this was not statistically significant 
(Figure 4.10;  Log rank = 1.915, df = 1, p = 0.166). 
 
Figure 4.10 - Kaplan-Meier plot of survival in adult grade 2 gliomas between VEGF +405 
genotypes.  There was spreading of the lines but no significant difference in survival 
comparing GG to non-GG genotypes (Log rank = 1.915, df = 1, p = 0.166). 
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Kaplan-Meier analysis of the grade 2 tumour patient’s -460/+405 haplotype 
assignments showed a significantly worse survival for patients who have the 
TG haplotype on either chromosome with mean survival of 3.2 years 
compared to 8.7 years for patients without the TG haplotype (Figure 4.11; 
Log rank = 7.01, df = 1, p = 0.008).  Five year survival figures were 20% 
for those patients with TG haplotype on either chromosome compared to 
76% for the Non-TG haplotypes (χ2 = 4.877, df = 1, p = 0.027). 
 
Figure 4.11 - Kaplan-Meier plot of survival in adult grade 2 gliomas between presence and 
absence of the VEGF -460/+405 TG haplotype.  There was a significant worsening in 
survival if the TG haplotype was present on either chromosome (Log rank = 7.01, df = 1, p 
= 0.008) 
 
For our group of grade 2 glioma patients Kaplan-Meier survival analysis for 
both age and Oligodendroglial histological subtype did not show any survival 
difference (Log rank = 0.46 - 1.34, p = 0.795 - 0.247) and these factors 
Adult Grade 2 Gliomas (n=26)
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were therefore not entered into further proportional hazards assessment for 
this population. 
 
4.2.7 Cox proportional hazard model 
Cox proportional hazards analysis was performed with -460 CC vs. Non-CC 
genotype and -460/+405 TG vs. Non-TG Haplotype as factors (Table 1).  
Significance was maintained in the model for both factors with risk ratios of 
5.3 for CC genotype (improved survival) and 5.0 for TG haplotype (worsened 
survival). 
 
P 
value 
Risk 
Ratio 
95% CI for RR 
Lower Upper 
CC Genotype (Improved 
Survival) 
0.032 5.304 1.155 24.355 
TG Haplotype (Worsened 
Survival) 
0.016 5.010 1.351 18.575 
Table 4.2 – Cox regression analysis results for VEGF -460 CC genotype and -460 /+405 TG 
Haplotype.  Significance is maintained for both factors in the model. 
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Chapter 5 – Single nucleotide polymorphisms of the 
vascular endothelial growth factor gene and their 
association with the development and survival of 
paediatric brain tumours 
 
5.1 Clinical Material and Methods 
This study utilised the Ontario molecular-epidemiological, case-control 
database of childhood brain tumours.  This was a Government backed, 
Province wide initiative in Ontario, Canada, that recruited all children with 
brain tumours along with age and gender matched healthy controls identified 
through Ontario Government records between 1997 and 2005.  Controls 
were recruited on a two per case basis.  Cases and controls donated whole 
blood for the purpose of DNA extraction.  The study was subject to ethical 
committee approval and written, informed consent from all parents was 
obtained. 
Clinical information was retrieved from the prospectively collected database 
of patients within the tumour bank which is held at the Hospital for Sick 
Children in Toronto.  Extent of resection was assessed using both operative 
reports and post operative radiological reports. 
 
5.1.1 DNA Extraction 
See Chapter 3.1.1 
 
5.1.2 VEGF SNP Genotyping 
See Chapter 3.1.2 
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5.1.3 Statistical Analysis 
Hardy-Weinberg equilibrium for cases and controls at both the -460 and 
+405 SNPs was tested using Chi squared.  The Chi squared test with the 
Mantel-Haenszel estimate of common odds ratio was undertaken to compare 
differences in the observed genotype and haplotype frequencies.  Kaplan-
Meier survival analysis with log rank testing and the Cox proportional 
hazards model were used to estimate differences in survival. 
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5.2 Results 
There were 193 cases representing the spectrum of paediatric brain tumours 
(Figure 5.1).   
 
Figure 5.1 – Frequency of histological paediatric tumour types in the study (n = 193). 
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5.2.1 VEGF -460 Locus 
Looking at the overall group of paediatric brain tumours there was no 
difference in the distribution of genotypes at the -460 locus (Table 5.1).  For 
all patients with Astrocytomas (n=89), there was no difference in either the 
genotype distribution or allele frequency at -460 (Figure 5.2). 
   
VEGF 
-460 Genotype 
χ2 
p value 
VEGF 
+405 Genotype 
χ2  
p value 
  Total CC (%) CT (%) TT (%)  CC (%) CG (%) GG (%)  
 
Controls All Controls 474 100 (21) 224 (47) 150 (32)  42 (9) 208 (44) 224 (47)  
 
Patients All Patients 193 42 (22) 94 (49) 57 (29) 0.867a 24 (12) 87 (45) 82 (43) 0.287a 
 
Histology 
Astrocytoma 89 12 (13) 53 (60) 24 (27) 0.081a 12 (14) 44 (49) 33 (37) 0.143a 
Low Gr Astrocytoma 79 8 (10) 49 (62) 22 (28) 0.024a* 12 (15) 39 (50) 28 (35) 0.070a 
Medulloblastoma 31 8 (26) 12 (39) 11 (35) 0.640a 5 (16) 13 (42) 13 (42) 0.396a 
Ependymoma 13 3 (23) 7 (54) 3 (23) 0.805a 1 (8) 5 (38) 7 (54) 0.896a 
 
Gender 
Male 112 25 (22) 53 (47) 34 (31) 
0.959b 
18 (16) 45 (40) 49 (44) 
0.265b 
Female 78 16 (21) 40 (51) 22 (28) 6 (8) 41 (52) 31 (40) 
 
WHO 
Tumour 
Grade 
Grade 1 108 18 (17) 59 (54) 31 (29) 
0.374b 
13 (12) 50 (46) 45 (42) 
0.999b 
Grade 2 11 3 (27) 5 (46) 3 (27) 1 (9) 5 (45.5) 5 (45.5) 
Grade 3 22 7 (32) 11 (50) 4 (18) 3 (14) 10 (45) 9 (41) 
Grade 4 38 11 (29) 14 (37) 13 (34) 4 (10) 17 (45) 17 (45) 
 
Table 5.1 – Distribution of genotypes for paediatric tumours at the VEGF -460 and +405 
Loci.  Looking at overall genotype distribution there was a significant difference between 
low grade astrocytomas and controls at the VEGF -460 locus.  a χ2 p value comparing 
genotype distribution of factor with control.  b χ2 p value comparing genotype distribution 
within the group. 
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Figure 5.2 - Genotype and allele frequencies for all paediatric astrocytomas at the VEGF -
460 locus.  There were no differences in either genotype or allele frequencies between 
cases and controls (Genotype χ2 = 3.887, df = 2, p = 0.143; Allele χ2 = 0.013, df = 1, p = 
0.908). 
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However looking at the low grade (grades 1 & 2) glioma group (n=79), there 
was an overall difference in genotype distribution with an increased 
frequency of the heterozygous CT genotype and a decrease in the 
homozygous CC genotype (Figures 5.3 & 5.4). 
 
Figure 5.3 - Distribution of genotype and allele frequency for paediatric low grade 
astrocytomas at the VEGF -460 locus.  There was a significant difference in genotype 
frequency but not allele frequency between cases and controls (Genotype χ2 = 7.478, df = 
2, p = 0.024; Allele χ2 = 0.706, df = 1, p = 0.401). 
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Figure 5.4 - Distribution of homozygous genotypes at the VEGF -460 locus for low grade 
paediatric astrocytomas.  There was a significant decrease in the CC homozygous 
genotype in low grade astrocytoma patients compared to controls (CC vs. non-CC χ2 = 
5.186, df = 1, p = 0.023; Odds ratio = 0.421, 95% CI 0.196 to 0.904). 
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5.2.2 VEGF +405 Locus 
Again, looking at all tumour types combined, there was no difference in 
genotype or allele frequency at the +405 locus.  For the group of 
Astrocytomas, there was a borderline significant increase in C allele 
frequency at +405 (Figure 5.5). 
 
Figure 5.5 - Distribution of genotype and allele frequency for all paediatric astrocytomas 
at the VEGF +405 locus.  There was a significant difference in allele frequency but not 
genotype frequency between cases and controls (Genotype χ2 = 3.887, df = 2, p = 0.143; 
Allele χ2 = 3.774, df = 1, p = 0.052). 
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For the low grade gliomas there was a significant increase in C allele 
frequency with a decrease in homozygous GG frequency at +405 (Figures 
5.6 & 5.7). 
 
 
Figure 5.6 - Distribution of genotype and allele frequency for paediatric low grade 
astrocytomas at the VEGF +405 locus.  There was a significant increase in C allele 
frequency but not genotype frequency between cases and controls (Genotype χ2 = 5.308, 
df = 2, p = 0.070; Allele χ2 = 5.114, df = 1, p = 0.024). 
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Figure 5.7 - Distribution of homozygous genotypes at the VEGF +405 locus for low grade 
paediatric astrocytomas.  There was a significant decrease in the GG homozygous 
genotype in low grade astrocytoma patients compared to controls (GG vs. non-GG χ2 = 
3.873, df = 1, p = 0.049; Odds ratio = 0.610, 95% CI 0.372 to 1.001). 
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5.2.3 Haplotype Analysis 
For the collective group of all paediatric tumours, there was no difference in 
haplotype frequency when compared to controls.  For all grades of 
Astrocytomas there was an overall difference in distribution of haplotype 
pairs compared to controls with a decreased frequency of TG haplotype on 
either chromosome (Figures 5.8 & 5.9). 
 
Figure 5.8 - Distribution of haplotype pairs for the VEGF -460/+405 haplotype in all 
paediatric astrocytomas.  There was significant difference in haplotype pair frequencies 
comparing cases with controls (χ2 = 13.782, df = 5, p = 0.017). 
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Figure 5.9 - Individual haplotype frequencies for the VEGF -460/+405 haplotype.  There 
was a significantly reduced frequency of the TG haplotype in paediatric astrocytoma 
patients compared to controls (χ2 = 4.292, df = 1, p = 0.038; Odds ratio = 0.602, 95% CI 
0.372 to 0.976). 
 
  
Paediatric Astrocytomas Individual Haplotype Frequency
0
10
20
30
40
50
60
70
80
90
100
CG TC TG
O
b
se
rv
e
d
 F
re
q
u
e
n
cy
 (
%
)
Controls (n=474) All Paediatric Astrocytomas (n=89)
*
206 
 
For low grade Astrocytomas there was again a difference in distribution of 
haplotype pairs together with borderline increase of TC haplotype and 
borderline decrease of TG haplotype when compared to controls (Figures 
5.10 & 5.11). 
 
Figure 5.10 - Distribution of haplotype pairs for the VEGF -460/+405 haplotype in 
paediatric low grade astrocytomas.  There was a significant difference in haplotype pair 
frequencies between cases and controls (χ2 = 18.249, df = 5, p = 0.003). 
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Figure 5.11 - Individual haplotype frequencies for the VEGF -460/+405 haplotype.  There 
was a borderline increased frequency of the TC haplotype and borderline decrease in the 
TG haplotype in paediatric low grade astrocytoma patients compared to controls (TC χ2 = 
3.811, df = 1, p = 0.051; Odds ratio = 1.632, 95% CI 0.995 to 2.677; TG χ2 = 3.753, df = 
1, p = 0.053; Odds ratio = 0.607, 95% CI 0.366 to 1.009). 
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For Medulloblastomas (n=31), there was an overall significant difference in 
distribution of haplotype pairs compared to controls (Figure 5.12) but 
otherwise no difference in genotype at either locus. 
 
Figure 5.12 - Distribution of haplotype pairs for the VEGF -460/+405 haplotype in 
paediatric medulloblastomas.  There was a significant difference in haplotype pair 
frequencies between cases and controls (χ2 = 17.773, df = 5, p = 0.007). 
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5.2.4 Survival Analysis 
5.2.4.a Low Grade Astrocytoma – Progression Free Survival 
For the group of low grade Astrocytomas there was 100% progression free 
survival in the VEGF -460 CC genotype patients (n=4) compared to 15% of 
cases recurring in the other genotype groups (n=53).  Although the Kaplan-
Meier plots appear to separate, this was not a statistically significant 
difference (Figure 5.13). 
 
Figure 5.13 - Kaplan-Meier plot of progression free survival in paediatric low grade 
astrocytomas between CC and non-CC genotype at the VEGF -460 locus.  Although the 
lines separate this was not statistically significant (Log rank = 1.457, df = 1, p = 0.227). 
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At the +405 locus there was again a trend in progression free survival 
differences with patients having the CC genotype appearing to have a 
tendency to recur (Figure 5.14). 
 
Figure 5.14 - Kaplan-Meier plot of progression free survival in paediatric low grade 
astrocytomas between CC and non-CC genotype at the VEGF +405 locus.  Although the 
lines separate indicating a tendency to recur with CC genotype this was not statistically 
significant (Log rank = 2.404, df = 1, p = 0.121). 
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5.2.4.b Medulloblastomas and Ependymomas – Overall Survival 
5.2.4.b.i VEGF Genotype and Haplotype 
For the combined group of Medulloblastomas and Ependymomas there 
appeared to be several trends in overall survival between the different 
genotypes and haplotypes.  Survival of the VEGF -460 CC genotype in this 
group was 100% with no deaths in the 11 patients with CC compared to 10 
deaths in the 34 patients (29.6%) with other (CT or TT) genotypes (Figure 
5.15). 
 
Figure 5.15 - Kaplan-Meier plot of overall survival in paediatric medulloblastomas and 
ependymomas between CC and non-CC genotype at the VEGF -460 locus.  Although the 
lines separate with a trend to improved survival with the CC genotype, this was not 
statistically significant (Log rank = 3.151, df = 1, p = 0.076). 
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At the +405 locus, there was a trend for the CC genotype to have a better 
overall survival compared to other (CG and GG) genotypes.  There were no 
deaths in the 6 CC genotype patients with 10 deaths out of 39 (25.6%) in 
the patients with other genotypes (Figure 5.16). 
 
Figure 5.16 - Kaplan-Meier plot of overall survival in paediatric medulloblastomas and 
ependymomas between CC and non-CC genotype at the VEGF +405 locus.  Although the 
lines separate with a trend to improved survival with the CC genotype, this was not 
statistically significant (Log rank = 1.915, df = 1, p = 0.166). 
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For the haplotype analysis there was a trend of worse survival with the 
presence of the TG haplotype on either chromosome (Figure 5.17). 
 
Figure 5.17 - Kaplan-Meier plot of overall survival in paediatric medulloblastomas and 
ependymomas between presence and absence of VEGF -460/+405 TG haplotype.  
Although the lines separate with a trend to worse survival with presence of the TG 
haplotype, this was not statistically significant (Log rank = 2.268, df = 1, p = 0.132). 
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5.2.4.b.ii Gender 
For this combined group of patients there was a significant survival 
advantage in male patients (Figure 5.18). Looking at the Medulloblastomas 
and Ependymomas separately there was a survival advantage in the males 
but this was not independently significant in either group (Medulloblastoma 
Log rank = 1.195, df = 1, p = 0.274 and Ependymoma Log rank = 2.718, df 
= 1, p = 0.099). 
 
Figure 5.18 - Kaplan-Meier plot of overall survival in paediatric medulloblastomas and 
ependymomas between genders.  There was a significantly better survival in males in this 
combined group (Log rank = 3.928, df = 1, p = 0.047). 
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5.2.4.b.iii Extent of Resection 
The amount of surgical resection had a significant effect on survival with 
patients where a gross total resection (GTR) or almost total resection (ATR), 
i.e. >95% resection, was achieved having a significant survival advantage 
over subtotal resection or biopsy (Figure 5.19). 
 
Figure 5.19 - Kaplan-Meier plot of overall survival in paediatric medulloblastomas and 
ependymomas between gross or almost total resection and subtotal resection or biopsy.  
There was a significant survival advantage with gross or almost total resection (Log rank 
= 5.874, df = 1, p = 0.015). 
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5.2.4.b.iv Age at Presentation 
There was a strong influence of age at presentation on survival with patients 
under 3 years of age at presentation having a significantly worse prognosis 
compared to older patients (Figure 5.20). 
 
Figure 5.20 - Kaplan-Meier plot of overall survival in paediatric medulloblastomas and 
ependymomas between age groups.  There was a strongly significant survival advantage 
for patients age 3 and over (Log rank = 21.221, df = 1, p = 0.000004). 
 
  
OS Paediatric Medulloblastomas and Ependymomas (n=45)
217 
 
5.2.5 Cox proportional hazards model 
The statistically significant variables on univariable analysis were entered 
into a Cox proportional hazards model.  Significance was maintained in the 
model for age category and gender but not extent of resection (table). 
 
P 
value 
Risk 
Ratio 
95% CI for RR 
Lower Upper 
Age under 3 (Worsened 
Survival) 
0.004 30.693 3.038 310.110 
Gender (Female 
Worsened Survival) 
0.039 4.860 1.081 21.848 
Extent of Resection 0.730 1.381 0.220 8.654 
Table 5.2 – Cox regression analysis results for age under 3, gender and extent of 
resection.  Significance is maintained for age under 3 and gender but not extent of 
resection in the model. 
 
  
218 
 
Chapter 6 Discussion 
6.1 Prognostic factors relating to sex steroid receptors in 
meningiomas 
This study like many before has identified sex steroid receptors in 
meningiomas.  Our findings of the distribution of tumour grades and 
subtypes would be consistent with the published literature.35  Our overall 
recurrence rate for such a long period of follow up is somewhat low at 9%.71  
This should be an accurate figure as the patients are from an area with 
relatively low levels of migration and they are followed up both clinically and 
radiologically in a specific meningioma clinic. 
 
6.1.1 Sex steroid receptors 
For progesterone receptors our proportion of patients who are receptor 
positive (55%) was again consistent with the published literature.58, 65 
Oestrogen receptor levels is more variable and controversial in the literature. 
The findings of low levels of nuclear, positive oestrogen receptors (1%) has 
been the finding of many studies but others have described higher results, 
up to 94%.574  This is partly a manifestation of assay type with most of the 
studies showing higher levels of oestrogen receptors having performed 
cytosol assays of receptor levels.  This study demonstrated that oestrogen 
receptors are present in the cytoplasm in 53% of tumours and obviously this 
would have given a positive result on cytosol assay, but the receptor is only 
biologically active in the nucleus.575 
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In this study there is a correlation with progesterone receptors and gender.  
Tumours were progesterone receptor negative in 60.7% of males and 37.8% 
of females.  This has been found in other studies,58, 65 but there is no known 
mechanism that explains this finding. 
This study also showed a strong association with tumour grade and 
progesterone receptor status.  All of the grade 2 and 3 tumours were 
progesterone receptor negative.  Many other studies have shown a similar 
correlation with tumour grade and progesterone receptor status, but they 
have not found an absolute relationship, describing some grade 2 and 3 
tumours as being progesterone receptor positive.58, 65 
 
6.1.2 Recurrence 
In univariable analysis tumour grade was associated with recurrence with an 
odds ratio of 11.667.  This is a consistent finding with other published 
studies.58, 65  The numbers were too small in this study to separate out the 
magnitude of effect between grade 2 and 3 tumours. 
The absolute Simpson grade was not statistically significant in relation to 
recurrence in this cohort but this was presumably due to small numbers of 
recurrences.  When the Simpson grade was dichotomised to grades 1 and 2 
vs. grades 3-5 (where there is some amount of residual nodular tumour left 
at the time of resection) then there was a clear association with recurrence 
and less extent of resection. 
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For this study, overall gender was not a prognostic factor for tumour 
recurrence.  This is, as with other studies, despite their being an increased 
incidence of higher grade tumours in males and the implication is that males 
must have other protective factors to counteract the larger proportion of 
higher risk tumours. 
In univariable analysis on this study, progesterone receptor status is 
predictive of tumour recurrence, with an odds ratio of five times higher in PR 
negative tumours.  This has been a finding in other studies, looking at both 
grade 1 tumours and all tumour types.58, 63-65 
 
6.1.3 Multivariable analysis 
Of the papers who have found an association with progesterone receptor 
status and recurrence, only one undertook multivariable analysis to control 
for other known predictive factors.58  In this study a Cox regression model 
was constructed with a combination of progesterone receptor status, number 
of mitoses and grade 3 histology as co-variables.  They found that the 
models were significant overall but there was no indication as to whether or 
not each of the individual co-variables maintained their significance in the 
model. 
In the two studies that found progesterone receptor status to be predictive 
of recurrence in grade 1 patients,63, 64 both had high rates of recurrence for 
grade 1 patients of 28% and 50% and it may be that some of these tumours 
were actually grade 2. 
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In this study, the Cox regression analysis with progesterone receptor status, 
grade 2 and 3 tumours and extent of resection using a dichotomised 
Simpson grade was a significant model overall, but progesterone receptor 
status clearly lost significance.  Extent of resection was borderline significant 
and tumour grade 2 and 3 was borderline non-significant.  This finding is 
due to the very strong association with progesterone receptor status and 
tumour grade and implies that decreased nuclear progesterone receptor 
expression is a secondary phenomenon to increasing tumour grade. 
 
6.1.4 Biological influence of progesterone receptors 
The evidence that progesterone receptors are biologically important in 
meningiomas is reasonably strong with evidence of increased growth of 
tumours at the time of high circulating progestogens,40, 41 increased 
frequency in females,36 and an association with breast cancer.42  In addition, 
a study in nude mice showed a reduction of growth of a human meningioma 
xenograft with the administration of an antiprogesterone.576  Finally there 
have been a variety of studies looking at hormonal manipulation of 
meningiomas with mixed success but no proven therapy shown in a phase 
III randomised controlled trial.577-581 
With the advent of high throughput chromosomal and genetic expression 
analysis recent studies have shown an increase in chromosomal 
abnormalities65 and changes in gene expression66 in meningiomas with loss 
of progesterone receptor expression.  The chromosomal losses are most 
222 
 
notable in chromosomes 22 and 14, particularly in the progesterone receptor 
negative tumours.  The location of the progesterone receptor gene on 
chromosome 11q22 did not appear to be involved in the chromosomal 
changes seen in more progressive tumours.65  However, there is altered 
gene expression in progesterone negative meningiomas, including the 
mitogen activated protein kinase 4 (MAP4K4) gene.66  MAP kinases have 
been shown to be important in the regulation of progesterone receptor 
activity and localisation within the nucleus.582, 583  Also, increased cell 
turnover in itself has a down regulating effect on progesterone receptor 
expression.62 
 
6.1.5 Limitations 
This study involved the retrospective analysis of the clinical findings of the 
patient cohort.  Although this is one of the biggest studies in the published 
literature, the relatively small number of recurrences meant a limited number 
of events in the survival analysis. 
 
6.1.6 Summary 
It is reasonable from this evidence to assume that progesterone receptors 
are important in the growth of meningiomas.  The recurrent finding in many 
studies of worse prognosis with loss of nuclear progesterone receptors would 
initially seem counter intuitive to this argument.  The findings of this study 
would imply that atypical and malignant grade is a more important factor in 
terms of recurrence than progesterone receptor status.  Findings from 
223 
 
genetic studies have shown evidence of altered expression of genes 
important in the biological localisation and activity of progesterone receptors.  
This study demonstrated that there were progesterone receptors present in 
the cytoplasm of 35 out of the 46 nuclear progesterone receptor negative 
patients.  It may be that alteration of MAP kinases or other co-factors 
localising the receptors to the cytoplasm with increasing atypia in 
meningiomas is the reason why there is an association with negative nuclear 
progesterone receptors and worse outcome. 
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6.2 The effect of neoadjuvant chemotherapy on operative 
blood loss and surgical resection for Choroid Plexus 
Carcinomas 
Complete surgical resection has consistently been shown to be the most 
important factor in the survival of patients with choroid plexus carcinomas81 
and this finding is evident in this study.  In addition we also demonstrated 
the previously described finding that young age at presentation was 
associated with a poor outcome. 
 
6.2.1 Neoadjuvant chemotherapy 
In this patient group, giving neoadjuvant chemotherapy as a pre-operative 
intervention does appear to facilitate surgical resection by reducing the 
vascularity of the tumours rather than their size.  It is certainly my 
experience that the tumours operatively handle more favourably following 
chemotherapy and these quantitative findings of a reduction of mean blood 
loss from 1.11 blood volumes to 0.22 of a blood volume would appear to 
support that perception. 
The process of administering the chemotherapy in the per-operative setting 
can be very difficult and requires a lot of input from a multidisciplinary team 
to maintain control of raised intracranial pressures secondary to the tumour 
mass and associated hydrocephalus. 
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6.2.2 Limitations 
Given that choroid plexus carcinomas are rare tumours the study is 
understandably limited in its size.  In addition the choice of whether a child 
received neoadjuvant chemotherapy was multifactorial and based upon 
surgeon/oncologist preference. 
6.2.3 Summary 
The striking benefits seen within the limitations of this study would support 
neoadjuvant chemotherapy for choroid plexus carcinomas as a valid 
treatment option and warrant further studies of its use in this often 
devastating condition. 
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6.3 Single nucleotide polymorphisms of the vascular 
endothelial growth factor gene and their association with the 
development and survival of adult cerebral gliomas 
This study involved the analysis of VEGF genotype and haplotype in a cohort 
of adult glioma patients 
 
6.3.1 VEGF -460 locus 
At the -460 locus there was an overall difference in the distribution of 
genotypes between gliomas patients and controls and this was most directly 
associated with an increase in the presence of the homozygous TT genotype 
in gliomas patients.  There was a non-significant trend towards an overall 
increase in the T allele frequency. 
 
6.3.2 VEGF +405 locus 
Overall at the +405 locus there was no difference in genotype frequencies 
between cases and controls but there was a trend towards the presence of 
the homozygous CC genotype in gliomas patients. 
 
6.3.3 VEGF -460/+405 haplotype analysis 
Linkage disequilibrium allows a highly predictive allocation of haplotypes for 
the locus.  Overall there was no difference in haplotype frequency but there 
was a significant decrease seen in the presence of the CG haplotype in 
gliomas patients. 
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6.3.4 Survival analysis 
For the group as a whole the VEGF polymorphisms were not predictive of 
survival.  When the subgroup of grade 2 astrocytomas was analysed a 
significant influence was found with the patients with the -460 CC genotype 
having a better outcome.  At the +405 locus there was a trend to better 
survival with the GG genotype and on haplotype analysis the patients with 
the TG haplotype on either chromosome having a significantly worse 
survival. 
Both -460 CC genotype and TG haplotype maintained their significance in a 
Cox regression analysis model. 
 
6.3.5 Limitations 
Although the cases and control group have a similar ethnic distribution, they 
are taken from geographically different areas and this may have an influence 
on genotype frequencies.  This would not impact on the survival analysis. 
The whole group is made up of a heterogeneous cohort of gliomas and 
therefore the subgroup sample size is small. 
For the group of grade 2 astrocytomas, accurate information on initial 
tumour size and extent of resection was not available.  These are factors 
that have been shown to influence survival for these tumours although this is 
not a universal finding in all studies.35 
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6.3.6 Summary 
This is the first study to show an association with a single nucleotide 
polymorphism of the VEGF gene and cerebral gliomas.  In addition, genotype 
and haplotype of the VEGF gene has been shown to have an association with 
outcome for grade 2 astrocytomas. 
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6.4 Single nucleotide polymorphisms of the vascular 
endothelial growth factor gene and their association with the 
development and survival of paediatric brain tumours 
This study utilised the Ontario molecular-epidemiological, case-control 
database of childhood brain tumours to investigate the association of VEGF 
gene polymorphisms and paediatric brain tumours. 
 
6.4.1 VEGF -460 locus 
Looking at the variety of tumour types in total there was no significant 
difference in genotype frequency compared with controls. 
For patients with low grade astrocytomas there was an increase in the 
frequency of the CT genotype and a decrease in the homozygous CC 
genotype at the -460 locus compared to controls. 
 
6.4.2 VEGF +405 locus 
There was no difference in genotype frequency between all the combined 
tumour types and controls. 
For all grades of astrocytoma there was a significant increase in the overall C 
allele frequency.  This was also seen in the low grade astrocytoma subgroup 
along with a decrease in the homozygous GG genotype. 
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6.4.3 VEGF -460/+405 haplotype analysis 
For the subgroup of all grades of astrocytoma there was an overall 
difference in the frequency of haplotype pairs compared to controls.  This 
was most evident with the TG haplotype which was decreased compared to 
controls. 
For low grade astrocytomas there was again an overall difference in the 
haplotype pairs compared to controls.  For individual haplotypes there was a 
significant increase in the TC haplotype and a decrease in the TG haplotype. 
For medulloblastomas there was an overall difference in distribution of 
haplotype pairs compared to controls. 
 
6.4.4 Survival analysis 
For low grade astrocytomas there was a non-significant progression free 
survival advantage for patients with the VEGF -460 CC genotype with no 
recurrence of tumours in the patients with this genotype.  At the VEGF +405 
locus there was also a non-significant progression free survival advantage for 
patients with the CC genotype. 
The group of medulloblastomas and ependymomas were combined for this 
analysis.  These tumour types have a similar outcome and progression 
profile overall and it is generally different to the other common paediatric 
brain tumours.35  At the VEGF -460 locus the CC genotype patients showed 
100% overall survival which was just not significant compared to other 
genotypes.  At the VEGF +405 locus the CC genotype again showed a non-
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significant overall survival advantage with 100% survival in this group.  On 
haplotype analysis the TG haplotype of VEGF -460/+405 showed a trend to 
worse overall survival compared to patients with non-TG haplotypes. 
In this combined group of medulloblastomas and ependymomas there was 
an overall survival advantage for males compared to females.  There have 
been conflicting studies as to the effect of gender in medulloblastomas and 
ependymomas.  The largest series from the Surveillance, Epidemiology, and 
End Results (SEER) database have shown for medulloblastomas, no overall 
survival difference but in the over 3 years patients a female advantage and 
in the under 3 years a trend towards a male survival advantage.9  For 
ependymomas there was an overall survival advantage for females in all age 
groups including adults.584 
Overall in the group there was a significant survival advantage for a greater 
than 95% surgical resection and age 3 or greater at presentation.  These 
associations have been shown previously in various studies for both tumour 
types.35 
A Cox proportional hazards model of the significant variables on univariable 
analysis showed an overall significant model with age greater than 3 at 
presentation and gender maintaining their significance but extent of 
resection becoming non-significant. 
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6.4.5 Limitations 
Given the rare nature of these tumours the sample sizes, particularly in the 
subgroups were small with a limited number of events in the survival 
analysis.  This is, however, one of the largest cohorts of its nature looking at 
paediatric brain tumours, collected over several years from large catchment 
population. 
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6.5 Possible influence of VEGF SNPs on development and 
progression of CNS tumours 
 
6.5.1 Tumour type 
For both the adults and paediatric CNS tumours presented in these studies 
there have been associations demonstrated with the development of certain 
tumour types.  In addition, differences in survival have also been shown 
depending upon genotype and haplotype within the gene. 
The tumours that have been shown to be most influenced are adult low 
grade astrocytomas and paediatric medulloblastomas and ependymomas.  
The other large groups of tumours; adult high grade 
astrocytomas/glioblastomas and paediatric high grade astrocytomas tend to 
be more aggressive tumours with much shorter median survivals. 
The angiogenic profile of high grade astrocytomas is different to that of low 
grade astrocytomas.585  A study from 2003 showed that angiogenic gene 
profiling, particularly VEGF was different in low grade astrocytomas 
compared to glioblastomas.  This was most marked with primary 
glioblastomas where secondary glioblastomas shared some similarities with 
the other two types.585  Another paper from 2006 confirmed this finding in 
primary and secondary glioblastomas.586 
It has been postulated for many years that for a tumour to grow and 
progress to a more malignant lesion, there is a need for the switch to an 
angiogenic phenotype.290  To have a constitutional angiogenic genotype 
would make this process more straightforward.  This is a disease modulating 
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process as angiogenic factors such as VEGF will in themselves not promote 
malignant transformation.  A study on anaplastic astrocytoma cells that were 
genetically modified to secrete four times the normal levels of VEGF found 
that the mutant cells grew more quickly but did not transform in 
glioblastomas.587 
VEGF genotype did not appear to have an influence on survival of high grade 
astrocytomas/glioblastomas in this study.  This is probably a consequence of 
loss of multiple controls of cell division and apoptosis in these malignant 
tumours together with marked autocrine expression of angiogenic factors 
that would render a background constitutional elevation of VEGF a non-
significant factor.  There is some evidence for this in the levels of VEGFR-1 
(a physiological inhibitor of VEGF) in gliomas of different grades.  Levels of 
VEGFR-1 rise from grade 2 to grade 3 tumours but then fall off again for 
grade 4 tumours.588  The authors of this study postulate that this is a sign 
that the constitutional antiangiogenic pathways have given up the battle by 
the time a lesion is grade 4. 
 
6.5.2 Mechanism of variable action of VEGF SNPs 
Within the literature there have been a variety of studies that have 
demonstrated functional differences between VEGF SNPs and haplotypes.342, 
511, 525, 528, 568  Often these studies appear to directly contradict each other.  
Lambrechts found that the -2578/-1154/-634 AAG haplotype reduced VEGF 
expression and Stevens found that the same AAG genotype increased VEGF 
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expression.342, 528  These studies both looked at this in cell cultures with 
Lambrechts using gliosarcoma and Stevens using breast cancer cell lines.  
Other studies have shown that within the same patient the VEGF -460 T 
allele and the +405 C allele were associated with lower levels of VEGF in 
normal colorectal tissue but this was not the case in adjacent colorectal 
cancer tissue.568 
Awata found an association with the VEGF +405 C allele and diabetic 
proliferative retinopathy.511  In the same study they found an increase in 
serum levels of VEGF in 11 healthy volunteers with the VEGF +405 CC 
genotype.  The measurement of serum VEGF levels can be questioned as it 
will increase from normal background plasma levels because of release of 
VEGF from platelets during clotting.571  Watson found the opposite to Awata 
with the VEGF +405 GG showing the highest levels of VEGF protein 
production in lipopolysaccharide stimulated peripheral blood mononuclear 
cells.13  Koukourakis showed a borderline decrease in vascular density with 
the +405 GG genotype, but in this study there was no correlation to 
outcome.541 
Gender has been shown to have a variable influence on VEGF SNPs with 
Lambrechts paper where subgroup analysis by gender revealed that the 
VEGF -2578 AA genotype, which lowers VEGF expression, increased the risk 
of ALS in males. 
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Race can also have an influence on the association of VEGF SNPs and 
disease.  A large meta analysis of general cancer risk for the VEGF -460 T 
allele found an association with Asian people but not with Europeans.589 
Environmental factors have also been shown to play a part in the association 
of VEGF SNPs and cancer.  In oesophageal cancer patients with the C allele 
at VEGF -460 locus had an increased risk of developing cancer if they were 
smokers and a decreased risk compared to other genotypes if they were 
non-smokers.590 
Finally angiogenesis involves a complex genetic interaction and 
polymorphisms at a variety of associated genes such as VEGFR-2 and EGFR 
have also been shown to have an influence on survival in cancer patients.591, 
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6.5.3 What are the significant VEGF genotypes and haplotypes? 
As can be seen in table 1.3, there is much variation and no consistency in 
the literature regarding the VEGF SNPs and their associations, functional 
significance and prognostic value.  One example of this is two studies in 
breast cancer.  One showed the CC genotype was associated with large 
tumours and high grade544 and the other with small tumours.554 
Overall the literature is fairly evenly split between VEGF -460 T and C alleles 
associations and VEGF +405 C and G allele associations (Table 1.3).  There 
may be many reason for these discrepancies.  As mentioned above gene-
gene and gene-environmental interactions are evident but not usually 
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identified in a large proportion of genetic association studies.  The SNPs that 
are chosen are not consistent and often not functionally (haplotypes) 
assessed.  Multiple SNPs often on multiple genes are assessed without taking 
into account corrections for multiple testing.  Finally the phenotypes are 
often not clearly defined and other proven associated factors not taken into 
account in multivariable testing. 
With this study we found a variety of associations with different tumour 
types in adults and children.  At the VEGF -460 locus there was a theme of 
increased T allele and decreased C allele.  At VEGF +405 there was a general 
trend towards increased C allele and decreased G allele.  In terms of survival 
there was significant improvement and trends towards better survival with 
VEGF -460 CC and VEGF +405 CC genotypes in both adult and paediatric 
tumours.  With regards to haplotype a significant worsening in survival is 
seen with adult low grade astrocytomas and VEGF -460/+405 TG haplotype 
and this is mirrored with a trend to worse survival with TG haplotype in 
paediatric medulloblastomas and ependymomas. 
 
6.5.4 Antiangiogenic therapy 
With the advent of multiple antiangiogenic therapies becoming available to 
treat CNS malignancies,12 the best use of VEGF SNPs would be as factors 
predictive of response to treatment.  Young was the first to describe VEGF 
SNPs as being predictive of treatment response with retinoids in patients 
with psoriasis.593  This study found an improved response to retinoids in the 
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VEGF -460 TC patients compared to other genotypes.  Subsequent to this a 
phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as 
initial chemotherapy for metastatic breast cancer showed improved response 
to the antiangiogenic treatment arm for patients with VEGF -1540 AA and 
VEGF -116 AA genotypes.594  In addition the VEGF -460 TT and the VEGF 
+405 CC genotypes were associated with less grade 3 and 4 hypertension 
compared to the other genotypes.  Overall survival in the study was 
improved for those patients who did experience grade 3-4 hypertension.  
This phenomenon has been seen in other studies.595, 596  It is also felt that a 
low background level of plasma VEGF production predicts a better outcome 
with antiangiogenic therapy.597 
 
6.6 Conclusions 
Studies examining prognostic factors have the potential to be incredibly 
helpful in the management of patients.  There are, however many ways that 
such studies can become confusing and misleading.  This is particularly true 
in the field of neuro-oncology where sample size is often necessarily small 
making the affirmation of correct conclusions often very difficult. 
A good understanding of all the various influences that have an impact on 
the prognostic factors discussed in this work is vital so that the information 
that the studies provide is utilised to bring the most benefit to patients, both 
young and old. 
 
239 
 
 
6.7 Future work from this thesis 
The findings of my research throughout all the chapters lead to many further 
questions that I wish to pursue in the future. 
For the progesterone receptors in meningiomas, I wish to further study the 
altered expression of genes associated with progesterone receptor function, 
notably the mitogen activated protein kinase 4 as postulated earlier in this 
chapter. 
In my practice I have adopted the treatment paradigm of neo-adjuvant 
chemotherapy for choroid plexus carcinomas.  I have also used this with 
great anecdotal effect in a patient with a large and vascular choroid plexus 
papilloma and further study of this patient group would be warranted.  I am 
attempting with these patients to more accurately assess the reduction of 
vascularity by undertaking serial CT perfusion scans. 
For the VEGF polymorphisms, there is a need for ongoing prospective 
validation of the findings from this thesis.  In Manchester we are enrolling 
patients into trials using the anti-VEGF Bevacizumab (Avastin) and I would 
aim to undertake a pilot study to determine the VEGF genotype of these 
patients and their response to treatment.  The long term goal would be to be 
able to predict response to anti-angiogenic therapy, based upon VEGF 
genotype and therefore provide a tailored pharmacogenomic based therapy 
to patients with brain tumours.  
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Appendix I – Meningioma receptor study data table 
 
Number 
Date of 
Birth 
Age at 
Presentation 
Sex 
Histology 
Category 
PRn 
Negative 
PRc 
Negative 
ERn 
Negative 
ERc 
Negative 
Date of 
Operation 
Simpson 
Grade 
Recurrence 
Date 
Recurrence 
Died 
Final 
Follow Up 
1 06/08/1927 68 F Transitional No No Yes No 28/06/1996 1 No 14/04/2010 No 14/04/2010 
2 24/01/1940 52 F Transitional No No Yes No 01/01/1992 4 No 21/03/2001 No 21/03/2001 
3 16/12/1953 42 M Transitional Yes No Yes Yes 04/10/1996 4 No 11/02/2004 No 11/02/2004 
4 31/07/1911 82 M Microcystic Yes No Yes No 26/03/1993 4 No 01/06/2002 No 01/06/2002 
5 27/08/1943 47 F Meningothelial Yes Yes Yes No 07/03/1991 1 No 01/06/2002 No 01/06/2002 
6 24/07/1929 65 F Transitional No No Yes Yes 16/06/1995 4 No 02/05/2007 No 02/05/2007 
7 07/11/1923 70 F Transitional Yes No Yes No 01/01/1994 
 
No 01/06/2002 No 01/06/2002 
8 13/03/1959 31 M Transitional Yes No Yes No 22/11/1990 1 No 21/02/1997 No 21/02/1997 
9 21/03/1921 73 F Angiomatous No No Yes No 24/03/1995 1 Yes 04/04/1996 No 19/04/2006 
10 21/04/1947 49 M Transitional No No Yes No 03/10/1996 4 No 23/07/2004 No 23/07/2004 
11 15/01/1965 32 F Microcystic No No Yes No 14/02/1997 2 No 14/04/2010 No 14/04/2010 
12 15/05/1937 53 F Transitional No No Yes No 28/03/1991 4 Yes 28/08/1996 Yes 14/03/1999 
13 27/09/1926 65 F Meningothelial No No Yes No 10/09/1992 4 No 09/06/2000 No 01/06/2002 
14 09/01/1924 63 M Anaplastic Yes No Yes No 15/05/1987 4 Yes 23/02/1996 No 22/10/2003 
15 12/09/1931 62 F Transitional No No Yes No 25/07/1994 4 No 31/03/1999 No 31/03/1999 
16 11/02/1934 61 F Fibroblastic Yes No Yes No 18/05/1995 2 Yes 10/02/2000 No 25/01/2006 
17 04/09/1924 67 M Transitional No No Yes No 16/04/1992 3 No 04/12/1996 No 04/12/1996 
18 18/08/1908 87 F Psammomatous Yes No Yes No 01/01/1995 4 No 24/04/1996 No 24/04/1996 
19 02/04/1941 55 F Transitional Yes Yes Yes No 19/07/1996 1 No 01/06/2002 No 01/06/2002 
20 19/04/1919 77 M Transitional Yes No Yes Yes 26/11/1996 2 No 07/10/1998 No 07/10/1998 
21 17/03/1923 71 F Atypical Yes Yes Yes Yes 18/04/1994 4 Yes 28/07/1995 Yes 14/09/1995 
22 09/01/1941 51 F Psammomatous Yes No Yes Yes 20/08/1992 4 No 31/03/1999 No 31/03/1999 
23 12/04/1938 56 F Psammomatous Yes Yes Yes Yes 29/11/1994 2 No 01/06/2002 No 01/06/2002 
24 02/11/1941 51 F Meningothelial No No Yes Yes 21/01/1993 5 No 09/03/2010 No 09/03/2010 
25 25/08/1912 79 M Fibroblastic Yes No Yes No 01/01/1992 
 
No 25/08/1995 Yes 25/08/1995 
26 15/07/1925 70 F Metaplastic No No No No 23/11/1995 2 No 01/06/2002 No 01/06/2002 
27 19/05/1927 64 F Transitional No No Yes No 04/07/1991 2 No 18/06/1997 No 18/06/1997 
28 21/08/1944 49 F Transitional No No Yes No 28/06/1994 3 No 07/12/2001 No 07/12/2001 
29 30/11/1936 59 F Transitional No No Yes No 12/09/1996 4 No 30/11/2006 Yes 30/11/2006 
30 25/04/1952 44 F Atypical Yes No Yes Yes 11/10/1996 1 No 15/11/2006 No 15/11/2006 
31 03/03/1936 54 F Meningothelial No No Yes Yes 23/10/1990 4 No 01/06/2002 No 01/06/2002 
32 05/10/1926 67 F Atypical Yes No Yes Yes 28/07/1994 2 No 01/06/2002 No 01/06/2002 
33 09/02/1962 28 F Transitional No No Yes No 28/09/1990 1 No 10/01/1997 No 10/01/1997 
34 13/03/1920 71 M Atypical Yes Yes Yes Yes 28/11/1991 4 No 01/06/2002 No 01/06/2002 
35 09/10/1924 71 M Transitional No No Yes No 25/01/1996 4 No 01/06/2002 No 01/06/2002 
36 12/10/1913 76 F Atypical Yes Yes Yes Yes 21/12/1988 4 Yes 21/05/1990 Yes 11/07/1990 
37 16/04/1947 49 F Meningothelial Yes Yes Yes Yes 06/03/1997 1 No 12/12/2001 No 12/12/2001 
38 10/04/1930 64 F Transitional No No Yes No 06/10/1994 5 No 22/10/1994 Yes 22/10/1994 
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Number 
Date of 
Birth 
Age at 
Presentation 
Sex 
Histology 
Category 
PRn 
Negative 
PRc 
Negative 
ERn 
Negative 
ERc 
Negative 
Date of 
Operation 
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Recurrence 
Date 
Recurrence 
Died 
Final 
Follow Up 
39 30/11/1937 54 F Transitional Yes No Yes No 28/02/1992 2 No 03/12/1997 No 03/12/1997 
40 28/05/1921 72 M Atypical Yes No Yes No 29/11/1993 4 No 01/10/1996 Yes 01/10/1996 
41 07/02/1933 58 F Transitional No No Yes Yes 17/07/1991 3 No 01/06/2002 No 01/06/2002 
42 09/09/1942 52 F Transitional Yes No Yes No 02/02/1995 2 No 09/09/2009 Yes 09/09/2009 
43 11/01/1940 56 F Transitional No No Yes Yes 16/02/1996 3 No 25/10/1996 Yes 25/10/1996 
44 28/04/1915 77 F Meningothelial No No Yes No 19/01/1993 1 No 01/06/2002 No 01/06/2002 
45 26/02/1927 67 F Meningothelial Yes No Yes Yes 02/08/1994 4 No 01/06/2002 No 01/06/2002 
46 12/06/1918 76 F Psammomatous Yes Yes Yes Yes 29/09/1994 1 No 15/02/1995 No 15/02/1995 
47 22/05/1935 60 M Transitional Yes No Yes No 02/11/1995 4 No 07/07/1997 Yes 07/07/1997 
48 05/10/1937 56 F Transitional No No Yes Yes 24/02/1994 3 No 12/04/1995 No 12/04/1995 
49 22/04/1936 59 F Psammomatous No No Yes No 04/08/1995 2 No 11/11/1998 No 11/11/1998 
50 19/11/1939 51 M Benign Yes No Yes No 01/01/1991 1 No 01/06/2002 No 01/06/2002 
51 27/08/1920 73 F Transitional Yes No Yes Yes 24/06/1994 4 No 17/09/1997 Yes 17/09/1997 
52 28/02/1947 48 F Transitional No No Yes Yes 15/12/1995 3 No 01/06/2002 No 01/06/2002 
53 21/06/1904 83 F Transitional No No Yes Yes 02/12/1987 2 No 01/06/2002 No 01/06/2002 
54 31/07/1922 65 F Transitional Yes No Yes Yes 09/12/1987 2 No 01/06/2002 No 01/06/2002 
55 29/11/1923 64 F Transitional No No Yes Yes 29/07/1988 2 No 01/06/2002 No 01/06/2002 
56 09/10/1945 43 F Benign Yes No Yes Yes 16/09/1988 2 No 01/06/2002 No 01/06/2002 
57 09/05/1944 45 M Atypical Yes No Yes No 20/10/1989 1 No 01/06/2002 No 01/06/2002 
58 09/01/1932 57 F Transitional No No Yes No 06/04/1989 1 No 03/06/1998 No 03/06/1998 
59 24/02/1920 69 M Transitional No No Yes No 21/12/1989 2 No 01/06/2002 No 01/06/2002 
60 06/07/1938 50 M Transitional No No Yes No 25/01/1989 1 No 01/06/2002 No 01/06/2002 
61 03/08/1921 75 F Transitional No No Yes Yes 20/05/1997 2 No 01/06/2002 No 01/06/2002 
62 31/03/1957 40 M Transitional No No Yes Yes 20/05/1997 1 No 19/04/1999 No 19/04/1999 
63 23/09/1958 39 F Transitional No No Yes Yes 06/11/1997 1 No 23/12/1998 No 23/12/1998 
64 30/08/1917 70 F Transitional Yes Yes Yes Yes 04/08/1987 2 No 30/04/1997 No 30/04/1997 
65 28/12/1926 61 M Transitional No No Yes No 10/03/1988 1 No 01/06/2002 No 01/06/2002 
66 10/06/1923 64 F Transitional No No Yes No 28/01/1988 1 No 01/06/2002 No 01/06/2002 
67 06/03/1931 66 M Psammomatous Yes No Yes No 17/10/1997 1 No 01/06/2002 No 01/06/2002 
68 18/10/1918 79 M Transitional No No Yes No 05/03/1998 2 No 17/03/1998 Yes 17/03/1998 
69 22/08/1910 87 F Transitional No No Yes Yes 07/10/1997 2 No 07/12/1997 Yes 07/12/1997 
70 28/06/1943 54 M Transitional No No Yes No 18/09/1997 1 No 26/11/1997 Yes 26/11/1997 
71 29/01/1913 76 F Transitional No No Yes No 20/07/1989 1 No 29/01/2005 Yes 29/01/2005 
72 04/08/1926 62 F Transitional No No Yes Yes 01/07/1988 2 No 01/06/2002 No 01/06/2002 
73 07/09/1928 59 F Transitional No Yes Yes Yes 11/12/1987 2 No 01/06/2002 No 01/06/2002 
74 01/01/1962 35 F Fibroblastic No No Yes Yes 25/11/1997 2 No 01/02/1998 Yes 01/02/1998 
75 11/05/1925 72 F Meningothelial Yes Yes Yes Yes 15/04/1997 2 No 11/05/2008 Yes 11/05/2008 
76 29/09/1940 55 M Transitional No No Yes No 26/07/1996 1 No 29/07/1998 No 29/07/1998 
77 05/12/1922 74 F Transitional No No Yes Yes 24/01/1997 2 No 14/12/2005 No 14/12/2005 
78 24/08/1923 70 F Psammomatous No No Yes Yes 01/01/1994 2 No 03/12/2001 Yes 03/12/2001 
79 03/09/1933 59 M Anaplastic Yes No Yes No 01/04/1993 
 
No 18/08/1993 Yes 18/08/1993 
80 02/12/1939 49 F Transitional No No Yes Yes 14/11/1990 2 No 01/06/2002 No 01/06/2002 
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Number 
Date of 
Birth 
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Histology 
Category 
PRn 
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PRc 
Negative 
ERn 
Negative 
ERc 
Negative 
Date of 
Operation 
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Recurrence 
Date 
Recurrence 
Died 
Final 
Follow Up 
81 06/03/1926 71 F Atypical Yes No Yes No 01/03/1997 3 Yes 01/11/2000 No 04/04/2001 
82 30/01/1926 67 M Atypical Yes Yes Yes Yes 01/01/1993 
 
No 05/01/1996 Yes 05/01/1996 
83 24/05/1910 82 F Benign No No Yes No 01/01/1993 
 
No 01/06/2002 No 01/06/2002 
84 30/08/1908 83 F Meningothelial Yes No Yes No 01/01/1992 
 
No 17/02/1993 No 17/02/1993 
85 29/01/1932 58 M Transitional Yes No Yes No 06/02/1992 1 No 01/06/2002 No 01/06/2002 
86 24/09/1944 48 F Transitional No No Yes No 04/02/1993 2 No 26/03/2003 No 26/03/2003 
87 08/01/1954 43 M Atypical Yes No Yes Yes 13/05/1997 1 No 18/11/2004 No 18/11/2004 
88 12/03/1932 60 F Meningothelial Yes No Yes Yes 18/03/1997 4 Yes 07/06/1999 No 06/02/2003 
89 20/06/1915 81 F Benign No No Yes Yes 22/04/1997 4 No 21/07/1999 No 21/07/1999 
90 21/11/1935 61 M Atypical Yes No Yes Yes 15/07/1997 1 No 12/03/1999 No 12/03/1999 
91 21/02/1922 75 F Fibroblastic Yes No Yes Yes 24/12/1997 4 No 14/04/2005 No 14/04/2005 
92 28/07/1958 40 F Microcystic No No Yes Yes 01/01/1989 
 
No 01/06/2002 No 01/06/2002 
93 30/04/1923 66 F Transitional No No Yes No 01/01/1989 
 
No 09/10/1996 No 09/10/1996 
94 29/01/1913 76 F Transitional No No Yes Yes 01/01/1989 
 
No 01/06/2002 No 01/06/2002 
95 15/10/1936 51 F Benign No No Yes Yes 01/01/1988 
 
No 21/09/1998 No 21/09/1998 
96 12/11/1913 75 F Transitional No No Yes Yes 05/08/1988 1 No 21/01/1999 No 21/01/1999 
97 13/12/1940 47 F Transitional Yes No Yes No 01/01/1988 
 
No 01/06/2002 No 01/06/2002 
98 09/02/1920 68 F Benign Yes No Yes Yes 01/01/1988 
 
No 09/02/1989 Yes 09/02/1989 
99 08/08/1936 62 F Fibroblastic No No Yes Yes 30/04/1998 4 No 19/08/2009 No 19/08/2009 
100 28/10/1964 34 M Transitional No No Yes No 24/04/1998 1 No 23/01/2002 No 23/01/2002 
101 13/12/1928 69 F Anaplastic Yes No Yes No 01/01/1998 4 Yes 20/04/1999 No 02/02/2000 
102 07/06/1969 27 F Psammomatous No No Yes No 19/03/1998 1 No 28/07/1999 No 28/07/1999 
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Appendix II – Choroid plexus carcinoma data table 
 
ID 
Gende
r 
DOB 
Age 
Months 
Grou
p 
GT
R 
Follow Up 
Date 
Survival 
Years 
Die
d 
Op Date 
Op 
Age 
Op 
Weight 
% 
Debulking 
Blood 
Vol 
Blood 
Loss 
1 
Femal
e 
10/04/198
6 
23 2 1 23/03/1990 1.97 Yes 
12/04/198
8 
2 13 33 1040 354.08 
1 
Femal
e 
10/04/198
6 
23 2 1 23/03/1990 1.97 Yes 
16/08/198
8 
2 16 100 1280 125.6 
1 
Femal
e 
10/04/198
6 
23 2 1 23/03/1990 1.97 Yes 
31/10/198
9 
3 18 100 1440 150.76 
2 
Femal
e 
22/01/197
4 
154 1 1 09/07/1993 6.58 No 
13/12/198
6 
12 49 95 3920 680.68 
2 
Femal
e 
22/01/197
4 
154 1 1 09/07/1993 6.58 No 
06/07/199
3 
19 50 100 4000 750 
3 Male 
12/07/198
8 
28 2 0 24/04/1992 1.45 Yes 
21/11/199
0 
2 12 5 960 356.04 
3 Male 
12/07/198
8 
28 2 0 24/04/1992 1.45 Yes 
08/05/199
1 
2 13 95 1040 217.92 
4 Male 
09/09/198
8 
0 2 1 16/07/2004 15.79 No 
14/10/198
8 
0 4 20 320 286.56 
4 Male 
09/09/198
8 
0 2 1 16/07/2004 15.79 No 
20/12/198
8 
0 5 100 400 54 
5 
Femal
e 
31/12/199
2 
6 1 1 24/07/1993 0.00 Yes 
24/07/199
4 
0 7 100 560 1500 
6 Male 
24/04/199
3 
0 1 0 20/12/1993 0.59 Yes 
25/05/199
3 
0 2.7 95 216 330.424 
7 Male 
20/07/198
4 
8 1 0 08/07/1985 0.22 Yes 
22/04/198
5 
0 8 80 640 168.64 
8 Male 
07/11/198
4 
19 1 0 17/06/1987 0.99 Yes 
03/07/198
6 
1 10.33 0 826.4 2848.965 
9 
Femal
e 
24/11/199
3 
63 3 1 28/04/2004 5.15 No 
08/03/199
9 
5 17 5 1360 247.6 
9 
Femal
e 
24/11/199
3 
63 3 1 28/04/2004 5.15 No 
17/06/199
9 
5 22.6 100 1808 244.576 
1
0 
Femal
e 
15/11/198
8 
7 2 1 13/07/1994 5.05 Yes 
02/07/198
9 
0 8.1 55 648 541.576 
1
0 
Femal
e 
15/11/198
8 
7 2 1 13/07/1994 5.05 Yes 
09/11/198
9 
0 9 95 720 215.44 
1
0 
Femal
e 
15/11/198
8 
7 2 1 13/07/1994 5.05 Yes 
02/11/199
0 
1 10.1 100 808 79.992 
1
0 
Femal
e 
15/11/198
8 
7 2 1 13/07/1994 5.05 Yes 
30/01/199
1 
2 10.2 100 816 86.496 
1
1 
Femal
e 
06/05/199
5 
4 2 1 31/08/2004 8.92 No 
04/10/199
5 
0 7 50 560 223.44 
1
1 
Femal
e 
06/05/199
5 
4 2 1 31/08/2004 8.92 No 
07/02/199
6 
0 8.7 100 696 55.68 
1
2 
Male 
16/10/199
3 
39 1 0 29/07/2003 6.47 No 
25/02/199
7 
3 14.7 95 1176 75.264 
1
3 
Male 
16/08/200
3 
2 3 1 25/08/2004 0.79 No 
03/08/200
4 
0 7.2 100 576 489.056 
1
4 
Male 
15/02/200
0 
52 1 1 22/10/2004 0.30 No 
07/07/200
4 
4 15.7 100 1256 3799.56 
1
5 
Male 
07/02/199
9 
65 3 1 22/10/2004 0.28 No 
23/07/200
4 
5 18.2 5 1456 133.952 
1
5 
Male 
07/02/199
9 
65 3 1 22/10/2004 0.28 No 
04/10/200
4 
5 22 100 1760 495.84 
1
6 
Male 
11/01/197
8 
59 1 1 20/08/2003 20.70 No 
20/12/198
2 
4 12.3 100 984 568.08 
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Appendix III – Adult glioma VEGF data table 
 
ID Cases Diagnosis Histology Died FU Date FU Years p405 gen m460 gen Hap1 Hap2 
1 study 04-Apr-93 Oligodendroglioma NO 26-Feb-04 10.90411 GC CT TC CG 
2 study 11-Mar-94 Oligodendroglioma NO 03-Sep-99 5.484932 CC TT TC TC 
3 Study 07-May-91 Neuroepithelial YES 17-Mar-95 3.863014 GG CT TG CG 
4 study 17-Sep-90 Astrocytoma YES 01-Jun-91 0.70411 GC TT TG TC 
5 study 04-Sep-93 Astrocytoma YES 21-Aug-96 2.964384 CC TT TC TC 
6 study 10-Aug-94 Glioblastoma NO 19-Aug-94 0.024658 GC CT TC CG 
7 study 21-Oct-92 Glioblastoma YES 02-Jul-93 0.69589 GG CT TG CG 
8 study 15-Jul-92 Astrocytoma YES 09-Feb-94 1.572603 GC CT TC CG 
9 study 09-Nov-95 Oligodendroglioma YES 04-Mar-00 4.320548 CC TT TC TC 
10 study 21-Oct-92 Astrocytoma YES 27-Nov-94 2.10137 GG CT TG CG 
11 study 29-Mar-93 Oligodendroglioma NO 12-Dec-03 10.71233 GG CC CG CG 
12 study 20-Sep-93 Astrocytoma YES 08-Sep-97 3.969863 GG CC CG CG 
13 study 29-Sep-92 Astrocytoma NO 01-Oct-99 7.008219 GG CC CG CG 
14 study 30-May-92 Astrocytoma YES 27-Sep-00 8.334247 GG CC CG CG 
15 study 26-Dec-90 Glioblastoma YES 10-Sep-92 1.709589 GC CT TC CG 
16 study 15-Dec-88 Astrocytoma YES 05-Mar-94 5.221918 GC CT TC CG 
17 study 16-Jan-93 Astrocytoma NO 03-Sep-96 3.632877 GC CT TC CG 
18 study 07-Jul-94 Glioblastoma YES 06-May-95 0.830137 GC CT TC CG 
19 study 25-Feb-94 Astrocytoma NO 09-Nov-01 7.709589 CC TT TC TC 
20 study 13-Mar-90 Glioblastoma YES 16-Mar-92 2.010959 GG TT TG TG 
21 study 15-Apr-95 Mixed Glioma YES 07-Jul-98 3.230137 GC CT TC CG 
22 study 11-Aug-92 Glioblastoma YES 31-Aug-93 1.054795 GG TT TG TG 
23 study 13-Mar-95 Mixed Glioma YES 28-Nov-95 0.712329 GC CT TC CG 
24 study 22-Mar-93 Glioblastoma YES 12-Feb-94 0.89589 GG CC CG CG 
25 study 16-Nov-94 Astrocytoma NO 28-Nov-00 6.038356 GG CT TG CG 
26 study 15-Mar-89 Astrocytoma YES 18-Dec-89 0.761644 CC TT TC TC 
27 study 25-Mar-92 Astrocytoma YES 04-Jan-95 2.780822 GG CC CG CG 
28 study 01-Feb-93 Astrocytoma NO 17-Jul-98 5.457534 GG CC CG CG 
29 study 23-Mar-92 Astrocytoma YES 24-Jun-94 2.254795 GC TT TG TC 
30 study 01-Sep-92 Mixed Glioma YES 10-May-95 2.687671 GC CT TC CG 
31 study 25-Aug-88 Mixed Glioma YES 21-Mar-93 4.572603 GG CT TG CG 
32 study 07-Mar-88 Oligodendroglioma YES 22-Jul-94 6.378082 CC TT TC TC 
33 study 21-Jan-94 Astrocytoma NO 28-Jan-94 0.019178 GC CT TC CG 
34 study 01-Feb-91 Glioblastoma YES 25-Sep-92 1.649315 GC CT TC CG 
35 study 25-Jun-91 Astrocytoma NO 02-Oct-03 12.27945 GG CT TG CG 
36 study 03-Aug-92 Glioblastoma YES 18-Jan-93 0.460274 GC CT TC CG 
37 study 10-Jan-92 Astrocytoma YES 15-Oct-98 6.767123 GG CC CG CG 
38 study 09-Mar-94 Astrocytoma NO 11-Mar-03 9.010959 GG CC CG CG 
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39 study 07-Sep-94 Mixed Glioma YES 14-Jul-96 1.852055 GC CT TC CG 
40 study 02-May-94 Mixed Glioma YES 08-Mar-96 1.852055 CC TT TC TC 
41 study 02-Jun-92 Mixed Glioma NO 12-Feb-99 6.70137 GG CC CG CG 
42 study 03-Apr-95 Mixed Glioma YES 20-Sep-96 1.468493 CC TT TC TC 
43 study 11-Aug-92 Glioblastoma YES 11-Feb-95 2.50411 CC TT TC TC 
44 study 25-Feb-91 Glioblastoma YES 21-Feb-93 1.991781 GG CC CG CG 
45 study 19-Jun-96 Oligodendroglioma YES 23-Jul-98 2.093151 GC CT TC CG 
46 study 08-Apr-95 Astrocytoma YES 03-Nov-95 0.572603 GG CT TG CG 
47 study 05-Mar-91 Glioblastoma YES 11-Nov-91 0.687671 GG CT TG CG 
48 study 10-Sep-96 Oligodendroglioma NO 17-Jul-03 6.852055 GC CT TC CG 
49 study 29-Jul-94 Astrocytoma NO 21-Apr-04 9.736986 GG TT TG TG 
50 study 01-Jun-94 Astrocytoma YES 17-May-95 0.958904 GC CT TC CG 
51 study 11-Jan-91 Oligodendroglioma YES 29-Dec-95 4.967123 GC TT TG TC 
52 study 26-Jan-96 Oligodendroglioma YES 05-Jun-00 4.361644 GC CT TC CG 
53 study 06-Jun-94 Glioblastoma YES 20-Dec-94 0.539726 GG CT TG CG 
54 study 05-Jul-88 Glioblastoma YES 01-Jan-89 0.493151 GG TT TG TG 
55 study 05-Nov-92 Astrocytoma NO 11-Dec-92 0.09863 GG CT TG CG 
56 study 18-Sep-89 Oligodendroglioma YES 15-Dec-01 12.24932 GG CT TG CG 
57 study 06-May-94 Glioblastoma YES 25-Oct-94 0.471233 GC TT TG TC 
58 study 18-Jul-89 Glioblastoma YES 12-May-91 1.816438 GG CT TG CG 
59 study 13-Jul-92 Astrocytoma YES 20-Jan-95 2.523288 GC TT TG TC 
60 study 31-Jul-89 Glioblastoma YES 04-Jul-91 1.926027 GC TT TG TC 
61 study 14-Jul-92 Astrocytoma NO 02-Jul-03 10.9726 GG CC CG CG 
62 study 09-Feb-95 Astrocytoma NO 20-Feb-04 9.035616 GG CC CG CG 
63 study 10-Jun-92 Mixed Glioma YES 04-Jul-97 5.068493 GG CC CG CG 
64 study 11-Oct-91 Oligodendroglioma YES 30-Aug-94 2.887671 GC CT TC CG 
65 study 01-May-92 Glioblastoma YES 27-Nov-92 0.575342 GC TT TG TC 
66 study 14-Feb-94 Neuroepithelial YES 11-Jun-96 2.323288 GG CC CG CG 
67 study 29-Sep-92 Glioblastoma YES 14-Aug-94 1.873973 GG CC CG CG 
68 study 03-Feb-93 Oligodendroglioma YES 10-Nov-94 1.767123 CC TT TC TC 
69 study 14-Dec-92 Astrocytoma NO 02-Apr-99 6.30137 CC TT TC TC 
70 study 18-Jan-91 Glioblastoma YES 15-May-91 0.320548 GG TT TG TG 
71 study 28-Dec-90 Astrocytoma YES 02-Sep-95 4.682192 GC TT TG TC 
72 study 12-Sep-94 Neuroepithelial YES 04-Apr-01 6.564384 GC CT TC CG 
73 study 04-Jan-93 Astrocytoma YES 07-Nov-95 2.841096 GC CT TC CG 
74 study 04-Dec-91 Glioblastoma YES 12-Dec-92 1.024658 GG CC CG CG 
75 study 02-Dec-94 Glioblastoma YES 24-May-95 0.473973 GG CC CG CG 
76 study 15-Jul-94 Oligodendroglioma NO 09-Sep-03 9.158904 CC TT TC TC 
77 study 20-Mar-92 Astrocytoma YES 17-Apr-02 10.08219 GC CT TC CG 
78 study 20-Nov-92 Astrocytoma NO 04-Aug-93 0.70411 GC TT TG TC 
79 study 09-May-89 Glioblastoma YES 13-Sep-93 4.350685 CC TT TC TC 
80 study 09-Aug-92 Astrocytoma YES 04-Feb-93 0.490411 GC CT TC CG 
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81 study 23-Oct-95 Astrocytoma YES 15-Aug-96 0.813699 CC TT TC TC 
82 study 28-Sep-92 Astrocytoma NO 02-Jun-95 2.676712 GG CT TG CG 
83 study 14-Nov-90 Astrocytoma YES 05-Apr-93 2.391781 GG CC CG CG 
84 study 22-May-92 Glioblastoma YES 16-Oct-92 0.40274 GC TT TG TC 
85 study 01-Feb-94 Astrocytoma NO 10-Jul-98 4.438356 GG CT TG CG 
86 study 05-Nov-91 Neuroepithelial NO 22-Nov-93 2.049315 GC CT TC CG 
87 study 09-Dec-91 Glioblastoma YES 24-Jan-93 1.128767 GG CT TG CG 
88 study 16-Oct-92 Mixed Glioma NO 17-Oct-93 1.00274 CC TT TC TC 
89 study 07-Aug-90 Mixed Glioma NO 23-Jul-03 12.96712 GG CC CG CG 
90 study 08-Feb-93 Astrocytoma NO 01-Oct-93 0.643836 GC TT TG TC 
91 study 20-Jun-91 Mixed Glioma YES 16-Jul-93 2.073973 GG CC CG CG 
92 study 23-Jun-95 Astrocytoma NO 14-Oct-03 8.315068 GG CC CG CG 
93 study 22-Jul-96 Oligodendroglioma YES 15-Oct-02 6.235616 GC CT TC CG 
94 study 25-Nov-92 Glioblastoma YES 07-Jan-94 1.117808 CC TT TC TC 
95 study 15-Nov-93 Oligodendroglioma NO 19-May-98 4.509589 GG TT TG TG 
96 study 02-Feb-94 Oligodendroglioma NO 03-Feb-94 0.00274 GC CT TC CG 
97 study 07-Jun-93 Oligodendroglioma YES 30-Apr-01 7.90137 CC TT TC TC 
98 study 13-Mar-92 Astrocytoma NO 10-Jan-04 11.83562 GC TT TG TC 
99 study 02-Apr-93 Astrocytoma NO 02-Apr-93 0.00274 GC CT TC CG 
100 study 31-Mar-95 Oligodendroglioma YES 05-Jul-97 2.265753 GG CT TG CG 
101 study 01-Jan-80 Mixed Glioma YES 12-Dec-95 15.95616 GC TT TG TC 
102 study 06-Aug-93 Glioblastoma YES 17-Nov-95 2.282192 GG CC CG CG 
103 study 03-Jul-96 Astrocytoma NO 13-Jan-00 3.531507 GC TT TG TC 
104 study 28-Jun-89 Glioblastoma YES 02-Aug-90 1.09589 GC TT TG TC 
105 study 11-Jul-96 Oligodendroglioma NO 24-Feb-04 7.627397 GC TT TG TC 
106 study 19-Sep-95 Mixed Glioma YES 12-Apr-96 0.564384 GG TT TG TG 
107 study 22-Mar-91 Glioblastoma YES 04-Dec-91 0.70411 GC CT TC CG 
108 study 28-Dec-90 Oligodendroglioma NO 16-May-04 13.39178 GG TT TG TG 
109 study 09-Dec-92 Mixed Glioma NO 18-Oct-01 8.863014 GG CC CG CG 
110 study 01-Apr-95 Mixed Glioma NO 10-Apr-01 6.030137 GC CT TC CG 
111 study 11-Jul-94 Glioblastoma YES 05-Jun-95 0.90137 GC CT TC CG 
112 study 26-Feb-94 Glioblastoma YES 24-Oct-94 0.657534 GG CC CG CG 
113 study 01-Mar-93 Astrocytoma YES 07-Apr-95 2.10137 GG CT TG CG 
114 study 23-Nov-90 Astrocytoma NO 20-Apr-04 13.41644 GC CT TC CG 
115 study 05-Jun-90 Glioblastoma NO 06-Jun-90 0.00274 GC CT TC CG 
116 study 12-Mar-88 Astrocytoma YES 05-Sep-97 9.490411 GC CT TC CG 
117 study 16-Jul-90 Mixed Glioma NO 06-Apr-94 3.726027 CC TT TC TC 
118 study 02-Aug-93 Astrocytoma YES 10-Oct-94 1.189041 GC CT TC CG 
119 study 21-May-96 Astrocytoma NO 26-Jul-96 0.180822 GG CC CG CG 
120 study 15-Oct-96 Oligodendroglioma YES 16-Feb-98 1.339726 GC TT TG TC 
121 study 11-Oct-96 Astrocytoma YES 29-Jan-99 2.30137 GC TT TG TC 
122 study 16-Nov-96 Glioblastoma YES 05-Jun-97 0.550685 GG CC CG CG 
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123 study 13-Aug-91 Mixed Glioma NO 10-Jan-97 5.416438 GG CC CG CG 
124 study 07-Apr-97 Mixed Glioma NO 25-Sep-97 0.468493 GG CT TG CG 
125 study 01-Apr-96 Astrocytoma YES 15-Sep-98 2.457534 GG CT TG CG 
126 study 05-Aug-91 Glioblastoma YES 10-Jul-98 6.934247 GC TT TG TC 
127 study 09-Sep-91 Astrocytoma YES 26-May-93 1.712329 GG CT TG CG 
128 study 18-Nov-96 Astrocytoma YES 17-Nov-97 0.99726 CC TT TC TC 
129 study 01-Mar-97 Astrocytoma YES 03-Feb-99 1.928767 GG CC CG CG 
130 control . 
  
. . GC CT TC CG 
131 control . 
  
. . GG CC CG CG 
132 control . 
  
. . GC CT TC CG 
133 control . 
  
. . GC TT TG TC 
134 control . 
  
. . GC CT TC CG 
135 control . 
  
. . GG CC CG CG 
136 control . 
  
. . GC CT TC CG 
137 control . 
  
. . GG CC CG CG 
138 control . 
  
. . GG CC CG CG 
139 control . 
  
. . GC TT TG TC 
140 control . 
  
. . GC TT TG TC 
141 control . 
  
. . GG CC CG CG 
142 control . 
  
. . GC CT TC CG 
143 control . 
  
. . GC CT TC CG 
144 control . 
  
. . GC TT TG TC 
145 control . 
  
. . GC CT TC CG 
146 control . 
  
. . GG CT TG CG 
147 control . 
  
. . GC CT TC CG 
148 control . 
  
. . GG CC CG CG 
149 control . 
  
. . GG CC CG CG 
150 control . 
  
. . GC CT TC CG 
151 control . 
  
. . GC CT TC CG 
152 control . 
  
. . GC TT TG TC 
153 control . 
  
. . GG CT TG CG 
154 control . 
  
. . GG CC CG CG 
155 control . 
  
. . GC CT TC CG 
156 control . 
  
. . GG CT TG CG 
157 control . 
  
. . GC CT TC CG 
158 control . 
  
. . GC TT TG TC 
159 control . 
  
. . GG CC CG CG 
160 control . 
  
. . GG CC CG CG 
161 control . 
  
. . GC CT TC CG 
162 control . 
  
. . GC CT TC CG 
163 control . 
  
. . GG CC CG CG 
164 control . 
  
. . GC CT TC CG 
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165 control . 
  
. . CC TT TC TC 
166 control . 
  
. . CC TT TC TC 
167 control . 
  
. . GC TT TG TC 
168 control . 
  
. . GG CT TG CG 
169 control . 
  
. . GC CT TC CG 
170 control . 
  
. . GG CC CG CG 
171 control . 
  
. . GC TT TG TC 
172 control . 
  
. . GG CC CG CG 
173 control . 
  
. . GC CT TC CG 
174 control . 
  
. . GC CT TC CG 
175 control . 
  
. . GC TT TG TC 
176 control . 
  
. . GG CC CG CG 
177 control . 
  
. . GC CT TC CG 
178 control . 
  
. . GG CT TG CG 
179 control . 
  
. . GG CT TG CG 
180 control . 
  
. . GC TT TG TC 
181 control . 
  
. . GC CT TC CG 
182 control . 
  
. . GG CT TG CG 
183 control . 
  
. . GG CT TG CG 
184 control . 
  
. . GC CT TC CG 
185 control . 
  
. . GC CT TC CG 
186 control . 
  
. . GG CT TG CG 
187 control . 
  
. . GG CT TG CG 
188 control . 
  
. . GC CT TC CG 
189 control . 
  
. . GG CC CG CG 
190 control . 
  
. . GC CT TC CG 
191 control . 
  
. . GC CT TC CG 
192 control . 
  
. . GC CT TC CG 
193 control . 
  
. . GC CT TC CG 
194 control . 
  
. . GC CT TC CG 
195 control . 
  
. . GG CT TG CG 
196 control . 
  
. . GC CT TC CG 
197 control . 
  
. . GG CT TG CG 
198 control . 
  
. . CC TT TC TC 
199 control . 
  
. . GG CC CG CG 
200 control . 
  
. . GG CT TG CG 
201 control . 
  
. . GC CT TC CG 
202 control . 
  
. . CC TT TC TC 
203 control . 
  
. . GG CT TG CG 
204 control . 
  
. . GC CT TC CG 
205 control . 
  
. . GC TT TG TC 
206 control . 
  
. . GG CT TG CG 
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207 control . 
  
. . GC CT TC CG 
208 control . 
  
. . GC CT TC CG 
209 control . 
  
. . GC CT TC CG 
210 control . 
  
. . GG TT TG TG 
211 control . 
  
. . GG CC CG CG 
212 control . 
  
. . CC TT TC TC 
213 control . 
  
. . GG CC CG CG 
214 control . 
  
. . CC TT TC TC 
215 control . 
  
. . GG CC CG CG 
216 control . 
  
. . GG CT TG CG 
217 control . 
  
. . GG CT TG CG 
218 control . 
  
. . GG CT TG CG 
219 control . 
  
. . GG CT TG CG 
220 control . 
  
. . GC CT TC CG 
221 control . 
  
. . GG CT TG CG 
222 control . 
  
. . CC TT TC TC 
223 control . 
  
. . GG CC CG CG 
224 control . 
  
. . GC CT TC CG 
225 control . 
  
. . GG CT TG CG 
226 control . 
  
. . GG CT TG CG 
227 control . 
  
. . GG CT TG CG 
228 control . 
  
. . GG TT TG TG 
229 control . 
  
. . GC CT TC CG 
230 control . 
  
. . GG CC CG CG 
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Appendix IV – Paediatric tumour VEGF data table 
 
ID dob Gend 
Date 
Diagnosis 
Diagnosis Category 
Pres 
Age 
Rec Date Rec 
Time 
Rec 
Died Date FU 
Time 
FU 
GTR grade 
m460 
Gen 
p405 
Gen 
Hap 1 Hap 2 
1 
26/09/198
4 
M 
26/06/199
8 
PITUITARY 13.76 
      
0 1 CC GG CG CG 
2 
25/03/198
5 
F 
25/08/199
8 
MEDULLOBLASTOMA 13.43 No 12/12/2005 7.30 No 12/12/2005 7.30 1 4 TT GG TG TG 
3 
28/11/198
5 
M 
04/11/199
8 
CRANIOPHARYNGIOMA 12.94 No 30/08/2004 5.82 No 30/08/2004 5.82 1 1 CC GG CG CG 
4 
01/03/198
6 
M 
07/01/200
4 
NEUROCYTOMA 17.87 Yes 07/01/2004 0.00 No 26/04/2004 0.30 0 3 CT CG CG TC 
5 
25/05/198
7 
M 
01/11/200
1 
GANGLIOGLIOMA 14.45 No 31/05/2005 3.58 No 31/05/2005 3.58 0 1 TT CC TC TC 
6 
06/12/198
7 
F 
11/09/199
8 
ASTROCYTOMA 10.77 No 06/05/2003 4.65 No 06/05/2003 4.72 1 1 TT CC TC TC 
7 
21/11/198
8 
M 
16/02/200
0 
ASTROCYTOMA 11.24 Yes 21/07/2004 4.43 No 30/05/2005 5.29 0 1 CT CG CG TC 
8 
10/11/198
4 
M 
30/05/199
8 
SARCOMA 13.56 
      
0 3 TT CC TC TC 
9 
05/05/198
8 
M 
26/06/200
0 
GERM CELL TUMOUR 12.15 No 28/10/2004 4.34 No 28/10/2004 4.34 0 3 CT CG CG TC 
10 
30/06/198
7 
F 
07/05/199
9 
ASTROCYTOMA 11.86 Yes 01/03/2004 4.82 No 04/03/2004 4.90 0 1 CT GG CG TG 
11 
27/05/199
0 
M 
25/09/200
1 
DPG 11.34 Yes 19/10/2001 0.07 Yes 30/12/2001 0.26 0 4 TT CG TC TG 
12 
17/07/199
0 
M 
22/05/199
8 
PNET 7.85 No 13/05/1999 0.98 No 13/05/1999 0.98 0 3 CT CG CG TC 
13 
01/05/199
0 
M 
19/05/199
8 
ASTROCYTOMA 8.05 No 30/06/2004 6.12 No 30/06/2004 6.21 0 1 CT CG CG TC 
14 
10/11/198
4 
M 
26/03/199
9 
GERMINOMA 14.38 No 20/06/2002 3.24 No 20/06/2002 3.24 0 1 TT GG TG TG 
15 
04/06/199
1 
M 
31/08/200
0 
GERMINOMA 9.25 No 12/09/2000 0.03 No 12/09/2000 0.03 0 1 CT CG CG TC 
16 
14/05/199
1 
M 
19/12/200
1 
ASTROCYTOMA 10.61 No 01/12/2004 2.95 No 01/12/2004 2.99 0 1 CT GG CG TG 
17 
25/04/199
1 
F 
18/03/199
8 
ASTROCYTOMA 6.90 No 12/11/2002 4.66 No 12/11/2002 4.72 1 1 CT CG CG TC 
18 
 
M 
01/01/200
1 
GERMINOMA 
 
No 21/04/2005 4.30 No 21/04/2005 4.30 0 
 
CC GG CG CG 
19 
15/02/199
2 
M 
13/04/200
0 
ASTROCYTOMA 8.16 No 29/01/2004 3.80 No 29/01/2004 3.85 0 1 TT CC TC TC 
20 
06/10/199
2 
M 
12/10/200
2 
ASTROCYTOMA 10.02 
      
0 1 TT GG TG TG 
21 
02/05/198
8 
F 
18/02/200
0 
ASTROCYTOMA 11.81 No 22/06/2004 4.35 No 22/06/2004 4.41 1 1 CT GG CG TG 
22 
18/05/199
2 
F 
18/12/199
9 
ASTROCYTOMA 7.59 
      
0 1 CT CG CG TC 
23 
05/12/198
6 
F 
25/06/200
1 
GANGLIOGLIOMA 14.56 No 07/04/2004 2.79 No 07/04/2004 2.79 0 1 TT CC TC TC 
24 
01/03/199
3 
F 
18/06/200
2 
ASTROCYTOMA 9.30 No 29/06/2004 2.03 No 29/06/2004 2.06 1 1 CT CG CG TC 
25 
 
F 
19/03/199
9           
TT CG TG TC 
26 
08/07/198
6 
M 
05/12/199
6 
DNET 10.42 Yes 18/12/1997 1.04 No 13/04/2004 7.36 0 1 TT CC TC TC 
27 
15/12/199
7 
F 
26/02/199
9 
EPENDYMOMA 1.20 Yes 30/05/2000 1.26 Yes 05/01/2001 1.86 0 3 CT GG CG TG 
28 
14/08/199
3 
F 
03/12/200
1 
ASTROCYTOMA 8.31 No 31/05/2005 3.49 No 31/05/2005 3.54 1 1 CT CG CG TC 
29 
14/07/199
2 
F 
11/12/200
0 
ASTROCYTOMA 8.42 No 05/04/2004 3.32 No 05/04/2004 3.36 0 1 CT CG CG TC 
30 
30/06/199
2  
21/11/199
7 
CRANIOPHARYNGIOMA 5.40 No 18/01/2005 7.16 No 18/01/2005 7.16 1 1 TT GG TG TG 
31 
16/12/199
3 
M 
11/02/200
0 
MEDULLOBLASTOMA 6.16 No 22/03/2005 5.11 No 22/03/2005 5.11 1 4 TT CC TC TC 
32 
19/03/199
0 
M 
19/03/200
2 
OLIGODENDROGLIOMA 12.01 No 05/08/2004 2.38 No 05/08/2004 2.38 1 2 TT CG TG TC 
33 
14/06/198
3 
F 
24/02/199
8 
GANGLIOGLIOMA 14.71 No 14/06/2001 3.30 No 14/06/2001 3.30 0 1 CT CG CG TC 
34 
20/02/198
6 
F 
28/04/199
8 
GANGLIOGLIOMA 12.19 No 04/02/2004 5.78 No 04/02/2004 5.78 1 1 CT CG CG TC 
35 
11/03/198
6 
M 
06/07/200
0 
PITUITARY 14.33 Yes 21/12/2001 1.46 No 10/03/2004 3.68 0 1 CC GG CG CG 
36 
27/02/198
9 
M 
24/12/200
2 
MEDULLOBLASTOMA 13.83 No 06/04/2005 2.28 No 06/04/2005 2.28 1 4 TT CG TG TC 
37 
01/08/199
1 
M 
08/06/200
0 
DNET 8.86 No 02/03/2005 4.73 No 02/03/2005 4.73 0 1 CT GG CG TG 
38 
01/11/198
6 
M 
10/09/199
8 
ASTROCYTOMA 11.87 No 06/12/2004 6.24 No 06/12/2004 6.33 1 1 CT GG CG TG 
39 
17/12/199
3 
M 
21/03/200
1 
MEDULLOBLASTOMA 7.26 Yes 05/03/2002 0.96 Yes 15/05/2002 1.15 0 4 CT CG CG TC 
40 
01/10/199
5 
F 
03/04/199
8 
ASTROCYTOMA 2.51 No 30/09/2003 5.50 No 30/09/2003 5.57 1 1 CT GG CG TG 
41 
01/04/199
5 
M 
11/09/200
2 
ASTROCYTOMA 7.45 No 04/10/2004 2.07 No 04/10/2004 2.09 1 1 CT CG CG TC 
42 
17/04/199
4 
M 
15/04/199
9 
MEDULLOBLASTOMA 5.00 No 31/03/2005 5.96 No 31/03/2005 5.96 1 4 CT GG CG TG 
43 
31/12/199
5 
F 
19/02/200
2 
ASTROCYTOMA 6.14 No 22/11/2004 2.76 No 22/11/2004 2.80 1 1 CT CG CG TC 
44 
24/08/199
5 
M 
22/01/200
2 
ASTROCYTOMA 6.42 No 03/05/2005 3.28 No 03/05/2005 3.33 1 1 CT CG CG TC 
45 
16/06/199
5 
M 
18/10/199
7 
MEDULLOBLASTOMA 2.34 Yes 21/05/2000 2.59 Yes 15/08/2000 2.83 0 3 CT CG CG TC 
46 
29/09/198
2 
M 
03/11/199
7 
GERMINOMA 15.11 No 21/06/2000 2.63 No 21/06/2000 2.63 0 1 CT GG CG TG 
47 
02/10/199
2 
M 
20/03/200
1 
ASTROCYTOMA 8.47 No 07/11/2003 2.64 No 07/11/2003 2.67 1 1 CT GG CG TG 
48 04/03/199 M 27/09/199 DNET 8.57 No 23/03/2004 4.49 No 23/03/2004 4.49 1 1 CC GG CG CG 
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49 
26/08/199
6 
M 
17/12/199
7 
ASTROCYTOMA 1.31 No 18/11/2004 6.93 No 18/11/2004 7.02 0 1 CT CG CG TC 
50 
10/02/199
5 
F 
16/07/200
1 
MEDULLOBLASTOMA 6.43 No 19/01/2005 3.52 No 19/01/2005 3.52 1 4 TT CG TG TC 
51 
17/09/199
6 
F 
09/01/200
2 
ASTROCYTOMA 5.32 No 21/02/2005 3.12 No 21/02/2005 3.16 1 1 TT CG TG TC 
52 
05/05/199
6 
M 
13/11/199
8 
ASTROCYTOMA 2.53 No 28/07/2004 5.71 No 28/07/2004 5.79 1 1 CT CG CG TC 
53 
18/12/199
3 
M 
04/02/199
9 
GANGLIOGLIOMA 5.13 No 17/11/2004 5.79 No 17/11/2004 5.79 0 1 CT CG CG TC 
54 
20/11/199
3 
F 
19/12/199
7 
OLIGOASTROCYTOMA 4.08 No 17/03/2005 7.25 No 17/03/2005 7.25 1 2 CC GG CG CG 
55 
13/01/198
7 
F 
17/11/199
7 
DNET 10.85 No 27/01/2005 7.20 No 27/01/2005 7.20 1 1 CT CG CG TC 
56 
19/08/198
6 
F 
03/11/199
7 
GANGLIOGLIOMA 11.22 No 15/01/2002 4.20 No 15/01/2002 4.20 1 1 TT GG TG TG 
57 
21/06/199
4 
M 
02/07/199
8 
ATRT 4.03 Yes 04/10/1998 0.26 Yes 04/10/1998 0.26 0 4 CC GG CG CG 
58 
15/05/199
0 
M 
16/10/199
7 
ASTROCYTOMA 7.43 No 04/12/1997 0.13 No 04/12/1997 0.14 1 3 CC GG CG CG 
59 
 
M 
24/02/199
8 
ASTROCYTOMA 
 
No 14/09/2004 6.56 No 14/09/2004 6.56 
 
1 CC GG CG CG 
60 
30/10/198
2 
F 
11/11/199
7 
EPENDYMOMA 15.04 No 28/06/2001 3.63 No 28/06/2001 3.63 1 2 CT CG CG TC 
61 
13/05/199
3 
M 
24/12/199
7 
ASTROCYTOMA 4.62 No 18/07/2002 4.57 No 18/07/2002 4.63 1 1 TT CC TC TC 
62 
13/05/199
3 
F 
11/09/199
8 
PINEOBLASTOMA 5.33 Yes 26/02/2001 2.46 Yes 02/04/2001 2.56 0 3 TT CC TC TC 
63 
16/01/199
4  
26/02/199
8 
ASTROCYTOMA 4.12 No 23/02/2005 7.00 No 23/02/2005 7.00 1 1 CT CG CG TC 
64 
07/04/198
7 
M 
26/02/199
8 
ASTROCYTOMA 10.90 No 23/02/2005 7.00 No 23/02/2005 7.09 1 1 CC GG CG CG 
65 
10/01/199
8 
F 
23/11/200
1 
ASTROCYTOMA 3.87 No 10/05/2005 3.46 No 10/05/2005 3.46 1 1 CC GG CG CG 
66 
04/11/198
5 
M 
28/04/199
9 
DNET 13.49 
      
0 1 CT CG CG TC 
67 
18/10/198
3 
F 
06/04/199
8 
GANGLIOGLIOMA 14.48 No 16/08/2001 3.36 No 16/08/2001 3.36 1 1 CC GG CG CG 
68 
26/07/199
6 
M 
14/04/199
8 
EPENDYMOMA 1.72 Yes 27/05/2000 2.12 Yes 27/05/2000 2.12 1 3 TT GG TG TG 
69 
21/04/199
4 
M 
14/05/199
8 
PNET 4.07 
      
1 4 CC GG CG CG 
70 
24/08/199
2 
F 
09/06/199
8 
HAMARTOMA 5.79 No 31/05/2004 5.98 No 31/05/2004 5.98 0 1 CC GG CG CG 
71 
01/05/199
7 
M 
28/07/200
0 
MEDULLOBLASTOMA 3.24 No 01/12/2004 4.35 No 01/12/2004 4.35 1 4 CT CG CG TC 
72 
12/11/198
4 
F 
16/07/199
8 
MEDULLOBLASTOMA 13.68 No 17/06/2003 4.92 No 17/06/2003 4.92 1 4 CT CG CG TC 
73 
03/03/199
7 
M 
02/06/199
8 
ASTROCYTOMA 1.25 No 25/01/2005 6.65 No 25/01/2005 6.75 1 1 TT CG TG TC 
74 
08/04/199
4 
M 
10/06/199
8 
MEDULLOBLASTOMA 4.18 No 24/03/2004 5.79 No 24/03/2004 5.79 1 4 TT CC TC TC 
75 
04/08/199
5 
M 
31/01/200
3 
MEDULLOBLASTOMA 7.50 No 21/05/2005 2.30 No 21/05/2005 2.30 0 4 CC GG CG CG 
76 
02/09/199
4 
M 
28/01/199
9 
ASTROCYTOMA 4.41 No 23/11/2004 5.82 No 23/11/2004 5.91 0 1 CT CG CG TC 
77 
20/05/199
6 
F 
10/08/199
8 
ATRT 2.22 
      
0 4 CT CG CG TC 
78 
22/11/199
4 
F 
14/08/199
8 
ASTROCYTOMA 3.73 Yes 21/02/2005 6.53 No 01/06/2005 6.90 1 1 CT CG CG TC 
79 
25/10/199
2 
F 
21/08/199
8 
LYMPHOMA 5.82 No 01/04/2005 6.62 No 01/04/2005 6.62 0 3 CT CG CG TC 
80 
 
F 
16/06/199
8 
ASTROCYTOMA 
        
3 CC GG CG CG 
81 
19/06/199
1 
F 
04/04/200
1 
CRANIOPHARYNGIOMA 9.80 Yes 04/04/2001 0.00 No 05/04/2004 3.01 0 1 CC GG CG CG 
82 
27/08/199
4 
F 
24/09/199
8 
OLIGODENDROGLIOMA 4.08 Yes 10/02/2005 6.39 No 08/06/2005 6.71 0 2 CC GG CG CG 
83 
28/06/199
6 
M 
09/09/199
8 
MEDULLOBLASTOMA 2.20 No 30/08/2004 5.98 No 30/08/2004 5.98 0 
 
TT CC TC TC 
84 
19/08/199
8 
M 
18/10/200
2 
EPENDYMOMA 4.17 No 08/05/2003 0.55 No 08/05/2003 0.55 1 3 CT CG CG TC 
85 
07/08/198
4 
M 
14/10/199
8 
SCHWANNOMA 14.19 No 20/01/2002 3.27 No 20/01/2002 3.27 1 1 TT GG TG TG 
86 
10/05/199
8 
M 
13/11/199
8 
CPP 0.51 No 10/05/2005 6.49 No 10/05/2005 6.49 1 2 CT CG CG TC 
87 
14/06/199
4 
M 
19/11/199
8 
ASTROCYTOMA 4.44 No 11/08/2004 5.73 No 11/08/2004 5.81 0 1 CT GG CG TG 
88 
21/09/199
0 
M 
03/12/199
8 
CRANIOPHARYNGIOMA 8.21 No 11/01/2005 6.11 No 11/01/2005 6.11 0 1 CT CG CG TC 
89 
26/07/199
2 
F 
15/12/199
8 
MEDULLOBLASTOMA 6.39 No 16/12/2004 6.01 No 16/12/2004 6.01 1 4 CC GG CG CG 
90 
20/05/198
8 
M 
21/12/199
8 
ASTROCYTOMA 10.59 No 26/10/2004 5.85 No 26/10/2004 5.93 1 1 CT GG CG TG 
91 
24/09/198
4 
M 
21/04/199
9  
14.58 No 30/09/2002 3.45 No 30/09/2002 3.45 
  
CC GG CG CG 
92 
07/06/198
5 
F 
12/01/199
9 
ASTROCYTOMA 13.61 No 17/10/2002 3.76 No 17/10/2002 3.82 1 1 TT CC TC TC 
93 
28/01/198
6 
M 
02/02/199
9 
MEDULLOBLASTOMA 13.02 No 11/06/2004 5.36 No 11/06/2004 5.36 1 4 TT CG TG TC 
94 
15/12/199
7 
F 
04/02/199
9 
EPENDYMOMA 1.14 
      
1 3 CC GG CG CG 
95 
01/07/199
6 
F 
08/03/199
9 
SARCOMA 2.68 Yes 22/06/1999 0.29 No 22/06/1999 0.29 0 3 CT CG CG TC 
96 
24/11/199
3 
F 
08/03/199
9 
CPC 5.29 Yes 16/10/2000 1.61 No 28/04/2004 5.15 1 3 CT CG CG TC 
97 
07/01/199
4 
F 
12/03/199
9 
ASTROCYTOMA 5.18 No 18/05/2004 5.19 No 18/05/2004 5.26 1 1 CT CG CG TC 
98 
26/02/199
0 
M 
03/08/200
0 
CRANIOPHARYNGIOMA 10.44 No 05/08/2004 4.01 No 05/08/2004 4.01 0 1 CC GG CG CG 
99 
08/01/199
8 
M 
08/04/199
9 
HAEMANGIOENDOTHELIOMA 1.25 No 18/11/2003 4.62 No 18/11/2003 4.62 0 1 CC GG CG CG 
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10
0  
F 
15/12/199
9 
ASTROCYTOMA 
 
Yes 24/05/2003 3.44 No 24/11/2004 4.95 0 1 CC GG CG CG 
10
1 
19/01/199
2 
F 
31/05/199
9 
CRANIOPHARYNGIOMA 7.37 No 08/06/2004 5.03 No 08/06/2004 5.03 0 1 CT CG CG TC 
10
2 
17/08/198
5 
F 
04/03/200
3 
ASTROBLASTOMA 17.56 No 26/05/2003 0.23 No 26/05/2003 0.23 0 2 CC GG CG CG 
10
3 
15/06/198
9 
M 
27/07/199
9 
GANGLIOGLIOMA 10.12 Yes 01/11/2000 1.27 Yes 18/01/2001 1.48 0 3 CC GG CG CG 
10
4 
25/07/199
3 
M 
31/08/199
9 
EPENDYMOMA 6.10 Yes 20/07/2004 4.89 No 12/05/2005 5.70 0 
 
CT GG CG TG 
10
5 
06/03/199
7 
F 
01/09/199
9 
EPENDYMOMA 2.49 Yes 01/02/2000 0.42 Yes 18/05/2000 0.71 0 3 CT CG CG TC 
10
6 
02/06/199
5 
M 
25/10/199
9 
MEDULLOBLASTOMA 4.40 No 05/03/2005 5.36 No 05/03/2005 5.36 1 4 CC GG CG CG 
10
7 
20/04/198
9 
F 
10/10/200
1 
OLIGOASTROCYTOMA 12.48 No 26/08/2004 2.88 No 26/08/2004 2.88 0 2 CT GG CG TG 
10
8 
01/12/199
0 
M 
02/12/199
9 
GERMINOMA 9.01 No 12/05/2005 5.45 No 12/05/2005 5.45 0 1 TT CC TC TC 
10
9 
28/01/199
7 
F 
22/12/199
9 
ASTROCYTOMA 2.90 No 07/12/2004 4.96 No 07/12/2004 5.03 1 1 CT GG CG TG 
11
0 
29/06/199
2 
M 
26/12/199
9 
CRANIOPHARYNGIOMA 7.50 Yes 04/11/2002 2.86 No 11/01/2005 5.05 0 1 CT GG CG TG 
11
1 
23/06/199
8 
F 
29/01/200
0 
ASTROCYTOMA 1.60 Yes 14/08/2000 0.54 No 01/12/2004 4.84 0 1 CT CG CG TC 
11
2 
23/06/199
8 
F 
29/01/200
0 
ASTROCYTOMA 1.60 Yes 14/08/2000 0.54 No 01/12/2004 4.91 1 1 CT CG CG TC 
11
3 
26/08/199
4 
M 
27/04/200
0 
GANGLIOGLIOMA 5.67 No 28/07/2004 4.25 No 28/07/2004 4.25 1 
 
TT CC TC TC 
11
4 
04/01/199
2 
M 
07/02/200
0 
CRANIOPHARYNGIOMA 8.10 No 04/09/2002 2.58 No 04/09/2002 2.58 1 1 TT CG TG TC 
11
5 
29/01/199
8 
F 
25/02/200
0 
MEDULLOBLASTOMA 2.07 Yes 15/06/2000 0.30 Yes 08/08/2000 0.45 0 4 CT GG CG TG 
11
6 
02/03/199
2 
M 
10/03/200
0 
EPENDYMOMA 8.03 No 17/05/2005 5.19 No 17/05/2005 5.19 1 2 CT GG CG TG 
11
7 
16/08/198
6 
F 
15/05/200
0 
PITUITARY 13.76 No 22/06/2001 1.10 No 22/06/2001 1.10 1 1 CT CG CG TC 
11
8 
07/10/199
8 
M 
06/04/200
0 
ASTROCYTOMA 1.50 No 13/05/2005 5.10 No 13/05/2005 5.18 0 1 TT CG TG TC 
11
9 
25/12/199
3 
F 
11/04/200
0 
ASTROCYTOMA 6.30 Yes 17/05/2005 5.10 No 17/05/2005 5.17 0 1 TT GG TG TG 
12
0 
08/08/199
6 
M 
27/04/200
0 
ASTROCYTOMA 3.72 Yes 05/08/2004 4.28 No 05/08/2004 4.34 1 2 TT CC TC TC 
12
1 
21/08/199
7 
M 
29/04/200
0 
ASTROCYTOMA 2.69 No 17/02/2004 3.81 No 17/02/2004 3.86 1 1 CC GG CG CG 
12
2 
12/09/199
8 
M 
30/05/200
0 
MEDULLOBLASTOMA 1.72 Yes 12/03/2002 1.78 No 17/03/2005 4.80 0 4 CC GG CG CG 
12
3 
22/09/199
1 
F 
03/06/200
0 
EPENDYMOMA 8.70 No 16/12/2004 4.54 No 16/12/2004 4.54 0 3 CC GG CG CG 
12
4 
04/02/199
7 
M 
16/06/200
0 
ASTROCYTOMA 3.36 No 02/09/2004 4.22 No 02/09/2004 4.28 1 1 TT CC TC TC 
12
5 
01/12/199
0 
M 
29/06/200
0 
ASTROCYTOMA 9.58 Yes 01/10/2003 3.26 No 16/05/2005 4.95 1 1 TT CC TC TC 
12
6 
01/12/199
5 
M 
24/05/200
2 
MEDULLOBLASTOMA 6.48 Yes 20/02/2005 2.75 No 25/04/2005 2.92 0 4 CT CG CG TC 
12
7 
20/10/199
5 
F 
20/07/200
0 
ASTROCYTOMA 4.75 No 10/06/2002 1.89 No 10/06/2002 1.92 1 1 TT GG TG TG 
12
8 
20/10/199
5 
M 
29/07/200
0 
MEDULLOBLASTOMA 4.78 No 01/12/2004 4.35 No 01/12/2004 4.35 0 4 CT CG CG TC 
12
9 
10/08/200
0 
M 
26/04/200
1 
MELANOCYTOMA 0.71 Yes 25/07/2001 0.25 Yes 25/07/2001 0.25 0 
 
TT CC TC TC 
13
0 
14/12/199
7 
M 
01/09/200
0 
GANGLIOGLIOMA 2.72 Yes 16/01/2001 0.38 Yes 12/03/2001 0.53 0 3 CT CG CG TC 
13
1 
18/05/199
2 
F 
19/01/200
5 
GERMINOMA 12.68 No 14/03/2005 0.15 No 14/03/2005 0.15 0 
 
TT CG TG TC 
13
2 
31/12/198
6 
F 
24/10/200
0 
DIG 13.82 No 12/08/2004 3.80 No 12/08/2004 3.80 0 1 CC GG CG CG 
13
3 
09/02/199
4 
F 
25/10/200
0 
MEDULLOBLASTOMA 6.71 No 16/12/2004 4.15 No 16/12/2004 4.15 0 4 CT CG CG TC 
13
4 
10/03/199
0 
F 
02/11/200
0 
CRANIOPHARYNGIOMA 10.66 No 28/06/2004 3.65 No 28/06/2004 3.65 1 1 TT CG TG TC 
13
5 
18/01/199
5 
F 
13/11/200
0 
CRANIOPHARYNGIOMA 5.82 No 01/12/2004 4.05 No 01/12/2004 4.05 0 1 TT GG TG TG 
13
6 
21/09/199
8 
F 
19/12/200
0 
MEDULLOBLASTOMA 2.25 Yes 21/02/2003 2.18 Yes 02/10/2003 2.79 0 4 CT GG CG TG 
13
7 
04/08/199
4 
M 
20/01/200
1 
MEDULLOBLASTOMA 6.47 Yes 04/02/2005 4.04 No 04/04/2005 4.21 0 4 TT CC TC TC 
13
8 
07/12/199
0 
M 
26/02/200
1 
EPENDYMOMA 10.23 No 14/10/2004 3.63 No 14/10/2004 3.63 1 3 CC GG CG CG 
13
9 
10/03/199
3 
M 
27/02/200
1 
ASTROCYTOMA 7.98 No 18/08/2004 3.47 No 18/08/2004 3.47 1 1 CT CG CG TC 
14
0 
10/03/199
3 
M 
27/02/200
1 
ASTROCYTOMA 7.98 No 18/08/2004 3.47 No 18/08/2004 3.52 1 1 CT CG CG TC 
14
1 
09/12/199
2 
F 
16/04/200
1 
ASTROCYTOMA 8.36 No 29/03/2005 3.95 No 29/03/2005 4.01 0 1 CT GG CG TG 
14
2 
07/08/199
2 
M 
09/03/200
1 
PITUITARY 8.59 No 22/02/2005 3.96 No 22/02/2005 3.96 0 1 CT CG CG TC 
14
3 
22/01/199
6 
M 
22/03/200
1 
DPG 5.17 Yes 01/06/2002 1.19 Yes 18/10/2002 1.58 0 4 CT CG CG TC 
14
4 
21/06/199
3 
M 
26/03/200
1 
CRANIOPHARYNGIOMA 7.77 No 10/05/2005 4.13 No 10/05/2005 4.13 0 1 CT GG CG TG 
14
5  
F 
14/05/200
1 
DPG 
 
Yes 12/10/2001 0.41 Yes 25/11/2001 0.53 0 4 CT GG CG TG 
14
6 
23/06/199
5 
M 
16/05/200
1 
DPG 5.90 Yes 02/05/2002 0.96 Yes 18/05/2002 1.01 0 4 TT CG TC TG 
14
7 
02/07/198
9 
M 
29/05/200
1 
ASTROCYTOMA 11.92 No 18/10/2004 3.39 No 18/10/2004 3.44 1 1 CT GG CG TG 
14
8  
M 
13/08/200
1 
ATRT 
 
Yes 23/07/2002 0.94 Yes 03/08/2002 0.97 0 4 CC GG CG CG 
14
9 
08/02/198
8 
F 
12/06/200
1 
GERM CELL TUMOUR 13.35 No 10/03/2005 3.75 No 10/03/2005 3.75 0 1 TT CG TG TC 
15
0 
31/07/198
9 
F 
26/11/200
1 
OLIGOASTROCYTOMA 12.33 Yes 05/04/2004 2.36 No 17/11/2004 2.98 0 2 CT CG CG TC 
15
1 
18/04/200
0 
M 
29/06/200
1 
EPENDYMOMA 1.20 No 07/12/2001 0.44 No 16/05/2005 3.88 1 3 TT CC TC TC 
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15
2 
04/12/199
6 
M 
20/07/200
1 
PNET 4.63 Yes 05/10/2001 0.21 Yes 28/01/2002 0.53 0 3 CC GG CG CG 
15
3 
19/03/200
1 
M 
07/08/200
1 
CPP 0.39 No 01/12/2004 3.32 No 01/12/2004 3.32 1 1 CC GG CG CG 
15
4 
26/09/199
6 
M 
18/08/200
1 
MEDULLOBLASTOMA 4.90 No 08/03/2005 3.56 No 08/03/2005 3.56 0 4 CC GG CG CG 
15
5 
12/11/198
7 
F 
11/12/200
1 
GANGLIOGLIOMA 14.09 No 20/09/2004 2.78 No 20/09/2004 2.78 0 1 TT CC TC TC 
15
6 
26/08/199
4 
M 
07/11/200
1 
PNET 7.21 Yes 03/09/2002 0.82 Yes 13/11/2002 1.02 0 
 
CT GG CG TG 
15
7 
01/10/198
9 
M 
14/09/200
1 
ASTROCYTOMA 11.96 No 22/11/2004 3.19 No 22/11/2004 3.24 1 1 CT CG CG TC 
15
8   
08/10/200
1 
DPG 
 
Yes 02/06/2002 0.65 Yes 05/08/2002 0.82 0 
 
CC GG CG CG 
15
9 
21/06/198
9 
F 
09/10/200
1 
ASTROCYTOMA 12.31 No 12/08/2004 2.84 No 12/08/2004 2.88 1 1 CT CG CG TC 
16
0 
20/07/199
0 
F 
22/10/200
1 
CRANIOPHARYNGIOMA 11.27 No 07/06/2005 3.63 No 07/06/2005 3.63 0 1 TT CC TC TC 
16
1 
13/04/200
0 
M 
21/10/200
1 
ASTROCYTOMA 1.52 No 07/11/2003 2.05 No 07/11/2003 2.08 1 1 TT CG TG TC 
16
2 
02/04/199
7 
M 
14/01/200
2 
MEDULLOBLASTOMA 4.79 No 13/04/2005 3.25 No 13/04/2005 3.25 1 4 CT GG CG TG 
16
3 
22/10/198
7 
M 
27/11/200
1 
CRANIOPHARYNGIOMA 14.11 No 25/11/2004 3.00 No 25/11/2004 3.00 0 1 TT CG TG TC 
16
4 
26/02/198
8 
F 
07/11/200
1 
CRANIOPHARYNGIOMA 13.71 No 17/05/2004 2.53 No 17/05/2004 2.53 0 1 CC GG CG CG 
16
5 
13/07/200
0 
F 
18/11/200
1 
MEDULLOBLASTOMA 1.35 Yes 04/02/2002 0.21 Yes 08/03/2002 0.30 0 4 TT CG TG TC 
16
6 
07/03/199
3 
M 
18/12/200
1 
ASTROCYTOMA 8.79 Yes 05/01/2005 3.05 No 05/01/2005 3.09 0 1 CT GG CG TG 
16
7 
05/06/199
4 
F 
28/12/200
1 
ASTROCYTOMA 7.57 No 26/05/2005 3.41 No 26/05/2005 3.46 0 1 CT CG CG TC 
16
8 
04/05/198
7 
M 
31/12/200
1 
ASTROCYTOMA 14.67 No 02/09/2003 1.67 Yes 02/09/2003 1.69 0 1 CT CG CG TC 
16
9 
23/06/199
9 
M 
09/01/200
2 
MEDULLOBLASTOMA 2.55 No 20/06/2005 3.45 No 20/06/2005 3.45 1 4 CT GG CG TG 
17
0  
M 
15/01/200
2 
PNET 
 
No 09/03/2005 3.15 
 
09/03/2005 3.15 1 
 
CT GG CG TG 
17
1 
14/03/199
5 
M 
10/01/200
2 
ASTROCYTOMA 6.83 No 31/08/2004 2.64 No 31/08/2004 2.68 1 1 CT GG CG TG 
17
2 
25/04/198
8 
M 
13/01/200
2 
ASTROCYTOMA 13.73 No 01/11/2004 2.80 No 01/11/2004 2.84 1 1 TT CC TC TC 
17
3 
17/03/200
1 
M 
22/01/200
2 
ASTROCYTOMA 0.85 No 09/05/2005 3.30 No 09/05/2005 3.34 0 1 CT CG CG TC 
17
4 
24/03/200
1 
M 
06/03/200
2 
MEDULLOEPITHELIOMA 0.95 Yes 01/07/2003 1.32 Yes 28/07/2003 1.39 1 4 TT CG TG TC 
17
5 
09/04/198
9 
F 
24/02/200
2 
ASTROCYTOMA 12.89 No 03/10/2004 2.61 No 03/10/2004 2.64 1 1 TT GG TG TG 
17
6 
26/10/199
0 
F 
11/04/200
2 
ASTROCYTOMA 11.47 No 30/03/2005 2.97 No 30/03/2005 3.01 1 1 CT CG CG TC 
17
7 
14/10/199
2 
M 
09/05/200
2 
MEDULLOBLASTOMA 9.57 Yes 14/10/2002 0.43 No 14/10/2002 0.43 0 4 CC GG CG CG 
17
8  
F 
11/07/200
2 
GERMINOMA 
 
No 21/04/2005 2.78 No 21/04/2005 2.78 0 1 TT CG TG TC 
17
9 
14/02/199
9 
F 
30/06/200
2 
CRANIOPHARYNGIOMA 3.38 No 08/04/2005 2.78 No 08/04/2005 2.78 0 
 
TT CG TG TC 
18
0 
25/11/199
9 
M 
22/06/200
2 
EPENDYMOMA 2.58 No 17/03/2005 2.74 No 17/03/2005 2.74 0 2 TT CG TG TC 
18
1 
13/09/199
8 
F 
29/06/200
2 
MEDULLOBLASTOMA 3.79 No 08/06/2005 2.95 No 08/06/2005 2.95 1 4 CC CG CC CG 
18
2 
04/05/199
2 
F 
05/07/200
2 
MEDULLOBLASTOMA 10.18 No 24/01/2005 2.56 No 24/01/2005 2.56 0 4 TT CG TG TC 
18
3   
15/07/200
2 
DPG 
 
Yes 13/12/2002 0.41 Yes 08/01/2003 0.48 0 
 
CT CG CG TC 
18
4 
11/10/199
9 
M 
29/07/200
2 
ASTROCYTOMA 2.80 No 18/11/2004 2.31 No 18/11/2004 2.34 1 1 CT GG CG TG 
18
5 
26/08/199
3 
F 
01/08/200
2 
ASTROCYTOMA 8.94 No 21/05/2005 2.81 No 21/05/2005 2.84 0 1 CT CG CG TC 
18
6 
19/03/200
2 
F 
22/08/200
2 
EPENDYMOMA 0.43 Yes 17/03/2003 0.57 Yes 21/03/2003 0.58 0 
 
CT CG CG TC 
18
7 
28/04/199
3 
F 
17/09/200
2 
ASTROCYTOMA 9.39 No 03/08/2004 1.88 No 03/08/2004 1.91 1 1 CT CG CG TC 
18
8 
03/07/200
1 
F 
30/09/200
2 
CPP 1.24 No 10/05/2005 2.61 No 10/05/2005 2.61 1 1 CC GG CG CG 
18
9 
21/06/199
7 
M 
16/10/200
2 
MEDULLOBLASTOMA 5.32 No 17/01/2005 2.26 No 17/01/2005 2.26 1 4 CC GG CG CG 
19
0 
08/10/199
5 
M 
07/11/200
2 
ASTROCYTOMA 7.09 No 17/11/2004 2.03 No 17/11/2004 2.06 1 1 CT CG CG TC 
19
1 
27/02/200
1 
M 
12/11/200
2 
CPP 1.71 No 23/03/2005 2.36 No 23/03/2005 2.36 1 1 CT CG CG TC 
19
2 
31/08/199
7 
M 
19/12/200
2 
ASTROCYTOMA 5.30 No 26/04/2005 2.35 No 26/04/2005 2.39 0 1 CT CG CG TC 
19
3 
20/08/199
0 
M 
31/12/200
2 
MEDULLOBLASTOMA 12.37 No 21/04/2005 2.31 No 21/04/2005 2.31 1 4 TT CC TC TC 
19
4    
CONTROL 
         
TT CC TC TC 
19
5    
CONTROL 
         
CT CG CG TC 
19
6    
CONTROL 
         
CT CG CG TC 
19
7    
CONTROL 
         
CT CG CG TC 
19
8    
CONTROL 
         
TT GG TG TG 
19
9    
CONTROL 
         
TT CG TC TG 
20
0    
CONTROL 
         
TT CG TC TG 
20
1    
CONTROL 
         
CT CG CG TC 
20
2    
CONTROL 
         
TT CG TC TG 
20
3    
CONTROL 
         
CC GG CG CG 
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20
4    
CONTROL 
         
CC GG CG CG 
20
5    
CONTROL 
         
CT GG TG CG 
20
6    
CONTROL 
         
TT CG TC TG 
20
7    
CONTROL 
         
CT GG TG CG 
20
8    
CONTROL 
         
CT GG TG CG 
20
9    
CONTROL 
         
TT CG TC TG 
21
0    
CONTROL 
         
CT CG CG TC 
21
1    
CONTROL 
         
TT CC TC TC 
21
2    
CONTROL 
         
TT GG TG TG 
21
3    
CONTROL 
         
CT GG TG CG 
21
4    
CONTROL 
         
CT CG CG TC 
21
5    
CONTROL 
         
CC GG CG CG 
21
6    
CONTROL 
         
CT GG TG CG 
21
7    
CONTROL 
         
TT CG TC TG 
21
8    
CONTROL 
         
CT CG CG TC 
21
9    
CONTROL 
         
CT CG CG TC 
22
0    
CONTROL 
         
CC GG CG CG 
22
1    
CONTROL 
         
TT GG TG TG 
22
2    
CONTROL 
         
CC GG CG CG 
22
3    
CONTROL 
         
TT CC TC TC 
22
4    
CONTROL 
         
CT GG TG CG 
22
5    
CONTROL 
         
CT GG TG CG 
22
6    
CONTROL 
         
CT CG CG TC 
22
7    
CONTROL 
         
TT CG TC TG 
22
8    
CONTROL 
         
CT CG CG TC 
22
9    
CONTROL 
         
CC GG CG CG 
23
0    
CONTROL 
         
CT CG CG TC 
23
1    
CONTROL 
         
CT GG TG CG 
23
2    
CONTROL 
         
CT GG TG CG 
23
3    
CONTROL 
         
TT CG TC TG 
23
4    
CONTROL 
         
CC GG CG CG 
23
5    
CONTROL 
         
CT CG CG TC 
23
6    
CONTROL 
         
CT CG CG TC 
23
7    
CONTROL 
         
CT CG CG TC 
23
8    
CONTROL 
         
CT GG TG CG 
23
9    
CONTROL 
         
TT CG TC TG 
24
0    
CONTROL 
         
CC GG CG CG 
24
1    
CONTROL 
         
CT GG TG CG 
24
2    
CONTROL 
         
CT GG TG CG 
24
3    
CONTROL 
         
CT GG TG CG 
24
4    
CONTROL 
         
CT CG CG TC 
24
5    
CONTROL 
         
TT GG TG TG 
24
6    
CONTROL 
         
CT GG TG CG 
24
7    
CONTROL 
         
TT CC TC TC 
24
8    
CONTROL 
         
TT GG TG TG 
24
9    
CONTROL 
         
CT CG CG TC 
25
0    
CONTROL 
         
TT CC TC TC 
25
1    
CONTROL 
         
CC GG CG CG 
25
2    
CONTROL 
         
CC GG CG CG 
25
3    
CONTROL 
         
TT CG TC TG 
25
4    
CONTROL 
         
CT CG CG TC 
25
5    
CONTROL 
         
CT GG TG CG 
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25
6    
CONTROL 
         
CC GG CG CG 
25
7    
CONTROL 
         
TT CC TC TC 
25
8    
CONTROL 
         
CT CG CG TC 
25
9    
CONTROL 
         
CT CG CG TC 
26
0    
CONTROL 
         
CT GG TG CG 
26
1    
CONTROL 
         
CT GG TG CG 
26
2    
CONTROL 
         
TT CG TC TG 
26
3    
CONTROL 
         
TT GG TG TG 
26
4    
CONTROL 
         
CT CG CG TC 
26
5    
CONTROL 
         
TT CG TC TG 
26
6    
CONTROL 
         
CT CG CG TC 
26
7    
CONTROL 
         
CC GG CG CG 
26
8    
CONTROL 
         
TT CG TC TG 
26
9    
CONTROL 
         
TT CG TC TG 
27
0    
CONTROL 
         
TT CG TC TG 
27
1    
CONTROL 
         
TT CC TC TC 
27
2    
CONTROL 
         
CT CG CG TC 
27
3    
CONTROL 
         
TT CG TC TG 
27
4    
CONTROL 
         
CC GG CG CG 
27
5    
CONTROL 
         
TT CG TC TG 
27
6    
CONTROL 
         
CT GG TG CG 
27
7    
CONTROL 
         
CC GG CG CG 
27
8    
CONTROL 
         
CT CG CG TC 
27
9    
CONTROL 
         
CC GG CG CG 
28
0    
CONTROL 
         
CT GG TG CG 
28
1    
CONTROL 
         
TT CG TC TG 
28
2    
CONTROL 
         
CT GG TG CG 
28
3    
CONTROL 
         
CT CG CG TC 
28
4    
CONTROL 
         
TT CG TC TG 
28
5    
CONTROL 
         
TT CC TC TC 
28
6    
CONTROL 
         
CT CG CG TC 
28
7    
CONTROL 
         
TT CG TC TG 
28
8    
CONTROL 
         
CT CG CG TC 
28
9    
CONTROL 
         
TT CG TC TG 
29
0    
CONTROL 
         
TT CC TC TC 
29
1    
CONTROL 
         
CT CG CG TC 
29
2    
CONTROL 
         
TT CC TC TC 
29
3    
CONTROL 
         
TT CG TC TG 
29
4    
CONTROL 
         
TT CG TC TG 
29
5    
CONTROL 
         
CT CG CG TC 
29
6    
CONTROL 
         
CT CG CG TC 
29
7    
CONTROL 
         
CT GG TG CG 
29
8    
CONTROL 
         
CT GG TG CG 
29
9    
CONTROL 
         
CT GG TG CG 
30
0    
CONTROL 
         
TT CC TC TC 
30
1    
CONTROL 
         
CC GG CG CG 
30
2    
CONTROL 
         
TT CC TC TC 
30
3    
CONTROL 
         
TT CG TC TG 
30
4    
CONTROL 
         
CT GG TG CG 
30
5    
CONTROL 
         
CT GG TG CG 
30
6    
CONTROL 
         
CT GG TG CG 
30
7    
CONTROL 
         
CT GG TG CG 
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30
8    
CONTROL 
         
TT GG TG TG 
30
9    
CONTROL 
         
CT GG TG CG 
31
0    
CONTROL 
         
CT CG CG TC 
31
1    
CONTROL 
         
CC GG CG CG 
31
2    
CONTROL 
         
TT CG TC TG 
31
3    
CONTROL 
         
CT GG TG CG 
31
4    
CONTROL 
         
CT CG CG TC 
31
5    
CONTROL 
         
CC GG CG CG 
31
6    
CONTROL 
         
CT GG TG CG 
31
7    
CONTROL 
         
CT GG TG CG 
31
8    
CONTROL 
         
CT CG CG TC 
31
9    
CONTROL 
         
CC GG CG CG 
32
0    
CONTROL 
         
TT CG TC TG 
32
1    
CONTROL 
         
TT CG TC TG 
32
2    
CONTROL 
         
CT CG CG TC 
32
3    
CONTROL 
         
TT CG TC TG 
32
4    
CONTROL 
         
TT CC TC TC 
32
5    
CONTROL 
         
CC GG CG CG 
32
6    
CONTROL 
         
TT CG TC TG 
32
7    
CONTROL 
         
CT CG CG TC 
32
8    
CONTROL 
         
CC GG CG CG 
32
9    
CONTROL 
         
CT GG TG CG 
33
0    
CONTROL 
         
CC GG CG CG 
33
1    
CONTROL 
         
CT GG TG CG 
33
2    
CONTROL 
         
TT CC TC TC 
33
3    
CONTROL 
         
CT GG TG CG 
33
4    
CONTROL 
         
CT CG CG TC 
33
5    
CONTROL 
         
TT CC TC TC 
33
6    
CONTROL 
         
CC GG CG CG 
33
7    
CONTROL 
         
CT GG TG CG 
33
8    
CONTROL 
         
CC GG CG CG 
33
9    
CONTROL 
         
CT CG CG TC 
34
0    
CONTROL 
         
CT GG TG CG 
34
1    
CONTROL 
         
TT CG TC TG 
34
2    
CONTROL 
         
CC GG CG CG 
34
3    
CONTROL 
         
TT GG TG TG 
34
4    
CONTROL 
         
TT CG TC TG 
34
5    
CONTROL 
         
CT CG CG TC 
34
6    
CONTROL 
         
CT CG CG TC 
34
7    
CONTROL 
         
CC GG CG CG 
34
8    
CONTROL 
         
CT GG TG CG 
34
9    
CONTROL 
         
TT CC TC TC 
35
0    
CONTROL 
         
CT GG TG CG 
35
1    
CONTROL 
         
CT CG CG TC 
35
2    
CONTROL 
         
CT CG CG TC 
35
3    
CONTROL 
         
TT GG TG TG 
35
4    
CONTROL 
         
CT CG CG TC 
35
5    
CONTROL 
         
CT CG CG TC 
35
6    
CONTROL 
         
CT GG TG CG 
35
7    
CONTROL 
         
CT GG TG CG 
35
8    
CONTROL 
         
TT CG TC TG 
35
9    
CONTROL 
         
TT CC TC TC 
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36
0    
CONTROL 
         
TT CG TC TG 
36
1    
CONTROL 
         
CC GG CG CG 
36
2    
CONTROL 
         
CC GG CG CG 
36
3    
CONTROL 
         
CC GG CG CG 
36
4    
CONTROL 
         
CT CG CG TC 
36
5    
CONTROL 
         
TT CG TC TG 
36
6    
CONTROL 
         
CT GG TG CG 
36
7    
CONTROL 
         
TT CG TC TG 
36
8    
CONTROL 
         
TT CG TC TG 
36
9    
CONTROL 
         
CT GG TG CG 
37
0    
CONTROL 
         
TT CG TC TG 
37
1    
CONTROL 
         
CC GG CG CG 
37
2    
CONTROL 
         
TT CG TC TG 
37
3    
CONTROL 
         
CC GG CG CG 
37
4    
CONTROL 
         
TT CC TC TC 
37
5    
CONTROL 
         
TT CG TC TG 
37
6    
CONTROL 
         
TT CG TC TG 
37
7    
CONTROL 
         
CT CG CG TC 
37
8    
CONTROL 
         
CT CG CG TC 
37
9    
CONTROL 
         
CT GG TG CG 
38
0    
CONTROL 
         
CT CG CG TC 
38
1    
CONTROL 
         
CT GG TG CG 
38
2    
CONTROL 
         
TT CG TC TG 
38
3    
CONTROL 
         
CT CG CG TC 
38
4    
CONTROL 
         
TT GG TG TG 
38
5    
CONTROL 
         
TT GG TG TG 
38
6    
CONTROL 
         
TT CC TC TC 
38
7    
CONTROL 
         
TT CG TC TG 
38
8    
CONTROL 
         
CC GG CG CG 
38
9    
CONTROL 
         
CT GG TG CG 
39
0    
CONTROL 
         
TT CG TC TG 
39
1    
CONTROL 
         
CT CG CG TC 
39
2    
CONTROL 
         
CT CG CG TC 
39
3    
CONTROL 
         
CC GG CG CG 
39
4    
CONTROL 
         
CT GG TG CG 
39
5    
CONTROL 
         
CC GG CG CG 
39
6    
CONTROL 
         
TT CC TC TC 
39
7    
CONTROL 
         
TT CC TC TC 
39
8    
CONTROL 
         
CT GG TG CG 
39
9    
CONTROL 
         
CC GG CG CG 
40
0    
CONTROL 
         
CC GG CG CG 
40
1    
CONTROL 
         
CT CG CG TC 
40
2    
CONTROL 
         
TT CC TC TC 
40
3    
CONTROL 
         
CC GG CG CG 
40
4    
CONTROL 
         
CT GG TG CG 
40
5    
CONTROL 
         
CT CG CG TC 
40
6    
CONTROL 
         
CT CG CG TC 
40
7    
CONTROL 
         
CT CG CG TC 
40
8    
CONTROL 
         
TT CG TC TG 
40
9    
CONTROL 
         
CC GG CG CG 
41
0    
CONTROL 
         
CT CG CG TC 
41
1    
CONTROL 
         
CT CG CG TC 
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41
2    
CONTROL 
         
TT CC TC TC 
41
3    
CONTROL 
         
CT GG TG CG 
41
4    
CONTROL 
         
CC GG CG CG 
41
5    
CONTROL 
         
CC GG CG CG 
41
6    
CONTROL 
         
CT GG TG CG 
41
7    
CONTROL 
         
TT CC TC TC 
41
8    
CONTROL 
         
CT GG TG CG 
41
9    
CONTROL 
         
TT CG TC TG 
42
0    
CONTROL 
         
CT CG CG TC 
42
1    
CONTROL 
         
TT GG TG TG 
42
2    
CONTROL 
         
CC GG CG CG 
42
3    
CONTROL 
         
CC GG CG CG 
42
4    
CONTROL 
         
CT CG CG TC 
42
5    
CONTROL 
         
TT CG TC TG 
42
6    
CONTROL 
         
TT CC TC TC 
42
7    
CONTROL 
         
CT GG TG CG 
42
8    
CONTROL 
         
CT CG CG TC 
42
9    
CONTROL 
         
TT CG TC TG 
43
0    
CONTROL 
         
CT CG CG TC 
43
1    
CONTROL 
         
CT GG TG CG 
43
2    
CONTROL 
         
CC GG CG CG 
43
3    
CONTROL 
         
TT CG TC TG 
43
4    
CONTROL 
         
CC GG CG CG 
43
5    
CONTROL 
         
CT CG CG TC 
43
6    
CONTROL 
         
TT CG TC TG 
43
7    
CONTROL 
         
CC GG CG CG 
43
8    
CONTROL 
         
CT GG TG CG 
43
9    
CONTROL 
         
CC GG CG CG 
44
0    
CONTROL 
         
CT CG CG TC 
44
1    
CONTROL 
         
CC GG CG CG 
44
2    
CONTROL 
         
CC GG CG CG 
44
3    
CONTROL 
         
TT CG TC TG 
44
4    
CONTROL 
         
TT GG TG TG 
44
5    
CONTROL 
         
TT GG TG TG 
44
6    
CONTROL 
         
CT GG TG CG 
44
7    
CONTROL 
         
CT GG TG CG 
44
8    
CONTROL 
         
TT GG TG TG 
44
9    
CONTROL 
         
CC GG CG CG 
45
0    
CONTROL 
         
CT CG CG TC 
45
1    
CONTROL 
         
CT CG CG TC 
45
2    
CONTROL 
         
CT CG CG TC 
45
3    
CONTROL 
         
CT GG TG CG 
45
4    
CONTROL 
         
TT GG TG TG 
45
5    
CONTROL 
         
CC GG CG CG 
45
6    
CONTROL 
         
CT CG CG TC 
45
7    
CONTROL 
         
TT CG TC TG 
45
8    
CONTROL 
         
CT CG CG TC 
45
9    
CONTROL 
         
CT CG CG TC 
46
0    
CONTROL 
         
CC GG CG CG 
46
1    
CONTROL 
         
TT GG TG TG 
46
2    
CONTROL 
         
TT GG TG TG 
46
3    
CONTROL 
         
CT GG TG CG 
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46
4    
CONTROL 
         
TT GG TG TG 
46
5    
CONTROL 
         
CT CG CG TC 
46
6    
CONTROL 
         
CC GG CG CG 
46
7    
CONTROL 
         
CC GG CG CG 
46
8    
CONTROL 
         
CT CG CG TC 
46
9    
CONTROL 
         
CT CG CG TC 
47
0    
CONTROL 
         
CT CG CG TC 
47
1    
CONTROL 
         
CC GG CG CG 
47
2    
CONTROL 
         
TT CC TC TC 
47
3    
CONTROL 
         
CT CG CG TC 
47
4    
CONTROL 
         
TT CC TC TC 
47
5    
CONTROL 
         
CC GG CG CG 
47
6    
CONTROL 
         
TT CG TC TG 
47
7    
CONTROL 
         
TT GG TG TG 
47
8    
CONTROL 
         
CC GG CG CG 
47
9    
CONTROL 
         
CT CG CG TC 
48
0    
CONTROL 
         
CT GG TG CG 
48
1    
CONTROL 
         
CT CG CG TC 
48
2    
CONTROL 
         
CC GG CG CG 
48
3    
CONTROL 
         
CT CG CG TC 
48
4    
CONTROL 
         
CT GG TG CG 
48
5    
CONTROL 
         
CC GG CG CG 
48
6    
CONTROL 
         
CT CG CG TC 
48
7    
CONTROL 
         
TT CG TC TG 
48
8    
CONTROL 
         
TT CG TC TG 
48
9    
CONTROL 
         
CC GG CG CG 
49
0    
CONTROL 
         
CC GG CG CG 
49
1    
CONTROL 
         
CT GG TG CG 
49
2    
CONTROL 
         
CT GG TG CG 
49
3    
CONTROL 
         
CT CG CG TC 
49
4    
CONTROL 
         
CT CG CG TC 
49
5    
CONTROL 
         
CT CG CG TC 
49
6    
CONTROL 
         
CT GG TG CG 
49
7    
CONTROL 
         
CT GG TG CG 
49
8    
CONTROL 
         
CT GG TG CG 
49
9    
CONTROL 
         
TT CC TC TC 
50
0    
CONTROL 
         
TT CG TC TG 
50
1    
CONTROL 
         
TT CC TC TC 
50
2    
CONTROL 
         
CT GG TG CG 
50
3    
CONTROL 
         
CT GG TG CG 
50
4    
CONTROL 
         
TT CC TC TC 
50
5    
CONTROL 
         
TT CG TC TG 
50
6    
CONTROL 
         
CC GG CG CG 
50
7    
CONTROL 
         
CT CG CG TC 
50
8    
CONTROL 
         
TT CG TC TG 
50
9    
CONTROL 
         
CT GG TG CG 
51
0    
CONTROL 
         
CT CG CG TC 
51
1    
CONTROL 
         
CT GG TG CG 
51
2    
CONTROL 
         
TT CG TC TG 
51
3    
CONTROL 
         
CT CG CG TC 
51
4    
CONTROL 
         
TT CG TC TG 
51
5    
CONTROL 
         
TT CG TC TG 
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